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ABSTRACT 
Recent evidence has shown that non-neuronal cells within the CNS play a role in 
motoneuron degeneration in ALS. However, while it is accepted that various 
muscles are differentially affected within the disease, it is still unclear whether 
muscle has a causal role in ALS. In this Thesis, using a mouse model of ALS 
(mutant SOD1 transgenic mice), I examined muscle and NMJ pathology in two 
different muscle types, at various stages of disease progression.  
 
Using morphological and functional markers of innervation, I found that mSOD1-
mediated pathology was present in fast-twitch muscles of mSOD1 mice prior to 
motoneuron degeneration. This occurred at a time when slow-twitch muscles 
remain innervated. This difference in the vulnerability of fast-twitch and slow-twitch 
muscles to disease was reflected in a differential heat shock response (HSR), with 
the slow-twitch soleus muscle displaying higher heat shock protein (hsp) levels 
over a longer duration of disease than the fast-twitch TA muscle.  
 
Equally, examination of the NOS response revealed a significant difference in 
nNOS expression between the fast-twitch TA and slow-twitch soleus muscles. 
Furthermore, fast-twitch muscles from mSOD1 mice also demonstrated greater 
vulnerability to cell stress such as glucose deprivation and caffeine stress in vitro. 
 
This Thesis also examined the effect of treatment with Arimoclomol, a 
pharmacological co-inducer of the HSR, on muscle and NMJ pathology. I found 
that treatment with was sufficient to decrease muscle pathology, augment the HSR 
and reduce mSOD1-meditated changes in nNOS expression. These findings 
support previous suggestions that targeting the periphery, in conjunction with the 
CNS, is an effective therapeutic strategy against ALS. Furthermore, that 
Arimoclomol’s previously reported beneficial effects are due, at least in part, to its 
effect in the periphery.  
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Abbreviations 
 
ALS   Amyotrophic lateral sclerosis 
ACh   Acetylcholine 
CNS   Central Nervous System 
DAKO   Dakocytomation 
DHPR   Dihydropyridine Receptor 
DGC   Dystrophin associated glycoprotein complex 
DMD   Duchenne muscular dystrophy 
DPX   Di-n-butylPhthalate in Xylene 
EDL   Extensor digitorum Longus 
ERK   extracellular-signal-regulated kinase 
fALS   Familial ALS 
FOXO   Fork head box transcription factor family 
GRP4   Glucose related protein-4 
hsp   Heat shock protein 
HSR   Heat shock response 
IBM   Inclusion body myostisis 
IHC    Immunohistochemistry  
JNK   c-Jun N-terminal kinase 
MAFbx  Muscle atrophy F box 
MG   Medial Gastronemius 
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MGF   Mechano-growth factor 
mIGF-1  Muscle expressed insulin-like growth factor 
MOM   Mouse on mouse kit 
mSOD1  SOD1G93A  
mSOD1mus  Muscle restricted mSOD1 transgenic mice 
mATPase  Myosin Adenosine Triphosphate 
MuF1   Muscle RING finger 1 
MyHCI  Myosin heavy chain I 
MyHCIIa  Myosin heavy chain IIa 
MyHCIIb  Myosin heavy chain IIb 
NMJ   Neuromuscular junction 
PMSF   Phenylmethylsulfonylfluride 
PNS   Peripheral Nervous System 
sALS   Sporadic ALS 
SDH   Succinate Dehydrogenase 
TA   Tibialis Anterior 
tSCh   Terminal Schwann cells 
WB   Western blot 
WT   Wild-type non-transgenic 
wtSOD1  human wild-type SOD1 transgenic 
XOR   Xanathine oxidoreductase 
SR   Sarcoplsmic reticulum 
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NMDA  N-methyl-D-aspartate 
 HOP    Hsc70-Hsp90-organizing protein 
NMDA   N-methyl-D-aspartate  
AMPA   Amino-3-hydroxy-5-methly-4-isoxazoleproprionicacid receptors  
GluR2  
TDP-43   TAR DNA-binding protein-43  
FUS    RNA-binding protein that was FUsed in Sarcoma  
OPTN   Optineurin  
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1.1 Introduction 
Amyotrophic lateral sclerosis (ALS) was first described by the French physician 
Jean-Martin Charcot, and is characterised by a progressive degeneration of 
motoneurons in the spinal cord and brainstem. For a long time, the disease was 
regarded as one that exclusively affects motoneurons, and consequently most 
research focused on motoneuron pathology. However, over the last decade, it has 
been demonstrated that non-neuronal cells such as astroglia and microglia, within 
the CNS, play an important role in the onset and progression of ALS (Clement et 
al., 2003, Boillee et al., 2006). However, very little is known about the role that 
other non-neuronal cells play in the disease or how they might contribute to 
disease progression. In particular, the role of the muscle in the periphery has not 
been extensively investigated. Thus, in this Thesis, I examine pathological events 
occurring in muscle and whether treatment with Arimoclomol, a pharmacological 
co-inducer of the heat shock response, previously shown to be beneficial in ALS 
models, acts in the periphery as well as the CNS.  
 
The neuromuscular junction (NMJ) is the point of interface between muscle and 
nerve. During the course of embryonic and early post embryonic development of 
the NMJ, the muscle and the motoneuron go through a phase of co-ordinated 
developmental steps to ensure the best arrangement for muscle innervation. There 
is a wealth of evidence that demonstrates the inter-dependent relationship of 
motoneurons and skeletal muscles throughout the formation and maturation of the 
NMJ (Vrbova and Gordon, 1994). Therefore, it is possible that not only can 
pathology within motoneurons affect muscle function, but also that events 
occurring within muscles may contribute to motoneuron function, stability and 
ultimately survival.  
 
1.2 Formation of the NMJ 
Prior to the stage when motor nerve terminals and muscle fibres first contact each 
other, each cell type is independent on the other for its development. However, 
from the point at which these two cells first make contact, they become critically 
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dependent upon each other for their continued development. As the motor nerve 
terminal reaches its target, the motoneuron growth cone makes contact and early 
synaptic transmission is initiated between axon terminals and muscle fibres, which 
have acetylcholine receptors (AChR) on their surface. Initially, transmission is 
spontaneous and evoked as well as very inefficient. Synaptic efficiency is improved 
by the differentiation of both presynaptic and postsynaptic sites. Presynaptic and 
postsynaptic differentiation is essential for improved synaptic efficiency. 
 
Following contact between the motor nerve terminal and muscle fibre, muscle 
derived factors such as fibroblast growth factor 2 and laminin β2 stimulate synaptic 
vesicle clustering within the axon terminal (Dai and Peng, 1995, Porter et al., 
1995). Subsequently, the axon terminal develops active zones: densely packed 
areas with synaptic vesicles within the nerve terminal (Ko, 1985, Buchanan et al., 
1989) 
 
During postsynaptic differentiation, AChR, which up to this point are expressed in a 
quasi-random distribution across the sarcolemma, begin to cluster at the point of 
nerve contact. This process is modulated by the motoneuron via factors such as 
agrin, acetylcholine and neuregulin (Jo et al., 1995). Agrin released from the motor 
nerve results in the production of muscle-specific tyrosine kinase at the synaptic 
site as well as the recruitment rapsyn, which promotes AChR clustering and 
stabilisation (Anderson et al., 1977, Gautam et al., 1995). As AChRs cluster at the 
synapse, the density of extrasynaptic AChR declines, resulting in a distribution of 
AChRs that resembles the distribution seen in mature adult muscle.  
 
During this period of development a number of myogenic regulatory factors such 
as MyoD, Myf-5, myogenin and Myf-6, and the paired box transcriptional factors, 
muscle cells are expressing Pax3 and Pax7. These factors regulate muscle-related 
gene expression and ensure the formation of the myogenic lineage (Duprey and 
Lesens, 1994). Further somite differentiation is due to positive signalling from Wnts 
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and Sonic hedgehog (Shh), as well as negative signalling from bone morphogenic 
factor 4 (Kobayashi et al.). 
 
During early development, individual nerve terminals establish contact with more 
than one muscle fibre. This phenomenon is termed polyneuronal innervation (PNI) 
(Korneliussen and Jansen, 1976, Dangain and Vrbova, 1983). Thus, despite the 
differentiation of both the presynaptic and postsynaptic membranes, synaptic 
transmission efficiency is still poor as PNI, characterised by large motor units that 
overlap, predominates (O'Brien et al., 1982) and results in unrefined movements. 
As the neuromuscular system matures and PNI is reduced, movement becomes 
more refined. Synaptic elimination enables the reorganisation of synaptic contacts 
and ensures that only one highly efficient motor axon innervates a muscle fibre 
(Buffelli et al., 2003, Kasthuri and Lichtman, 2003). This process, which is driven 
by neuromuscular activity, is directed by Cholineacetyltransferase (ChAT) activity 
at the presynaptic site. At a given endplate, the more active nerve terminal, as 
determined by ChAT levels, will compete with weaker terminals. In all cases, the 
more active terminal will win. This results in the retraction and elimination of the 
weaker terminal (Buffelli et al., 2003, Kasthuri and Lichtman, 2003, Deschenes et 
al., 2005). The elimination of superfluous nerve terminals does not result in 
motoneuron death, but rather a reduction in the size of the peripheral field of 
motoneurons. By the end of this process, the synapse now resembles a mature 
NMJ, where each muscle fibre has one endplate that is innervated by a single axon 
(Buffelli et al., 2003). 
 
The NMJ is plastic and can be altered by a number of factors. It can undergo 
pathological changes as a result of neuropathy or myopathy (Dastur and Razzak, 
1973, Frey et al., 2000). For example, following denervation of muscle fibres, 
Neuronal nitric oxide synthase (nNOS) expression, which is normally found in 
presynaptic nerve terminals and the adjacent postsynaptic muscle membrane, is 
down regulated (Ribera et al., 1998). This precipitates the down-regulation of 
postsynaptic proteins such as rapsyn and agrin (Blottner and Luck, 2001). NNOS is 
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concurrently up-regulated in surrounding terminal Schwann cells (tSChs), where it 
is thought to promote sprouting (Percival et al., 2008). The role of nNOS (a protein 
usually found bound to a protein called syntrophin at the sarcolemma) in 
denervation will be discussed in greater detail in Chapter Six.  
Denervation also results in tSCh activation. Once activated, tSChs from intact 
NMJs extend their processes and migrate to the site of injury guiding reinnervated 
axons (Auld & Robitalle, 2003). This results in the reinnervation of denervated 
endplates by different nerve terminals and the loss of the mosaic-like pattern of 
fibre typing seen in healthy muscle. Thus, as shown by Vrbova & Gordon (1994), 
muscle fibres re-innervated by a specific motoneuron will acquire the phenotype 
specified by that motoneuron: for example, fast firing, phasic motoneurons 
innervate fast fatigable muscle fibres. 
 
1.3 Enzymatic markers of neuromuscular transmission: AChE and ChAT  
ChAT and AChE are two critical enzymes involved in neuromuscular transmission. 
They are responsible for the metabolism and catabolism, respectively, of 
acetylcholine (ACh), the primary neurotransmitter at the NMJ. The expression and 
activity of these enzymes can be used as markers of NMJ activity (Ellman et al., 
1961, Diamond et al., 1974). 
 
ChAT is an enzyme that catalyses the synthesis of acetylcholine. It acts by 
catalysing the condensation reaction between Acetyl coenzyme A and Choline. 
The newly formed ACh is then stored in vesicles at the active zone in the 
presynaptic nerve terminal and is subsequently released into the synaptic cleft 
upon the arrival of an action potential in the presynaptic terminal. 
 
Once the NMJ is established, the level of ACh, released by the axon terminal, 
increases dramatically (Witzemann, 2006). Acetyl Cholinesterase (AChE), one of 
the key enzymes involved in the breakdown of ACh, is expressed at the new NMJ 
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shortly after synaptic transmission is established. This enzyme catalyses the 
hydrolysis of acetylcholine into acetyl coenzyme A (AcCoA) and Choline (Wilson 
and Deschenes, 2005). It is found both at the presynaptic junction and 
postsynaptic junction of the NMJ, and in the basal lamina in very high 
concentrations (Wooten and Cheng, 1980, Fernandez et al., 1986). The expression 
of AChE is tightly regulated in the muscle by neuromuscular activity (Rotundo, 
2003). AChE expression is therefore restricted to the NMJ junction where synaptic 
neuromuscular activity is localised.   
 
1.4 Muscle Fibre Types 
Muscle heterogeneity is a well-documented phenomenon in all mammals. This 
heterogeneity exists not only between muscles but also within muscles (Kernell, 
1998). The three main muscle fibre groups (see Table 1.1) are typically 
characterised by the type of myosin heavy chain that the fibres express. These 
groups are Myosin heavy chain I (MyHCI), Myosin heavy chain IIa (MyHCIIa) and 
Myosin heavy chain IIb (MyHCIIb) (Vrbova and Gordon, 1994).  
 
Table 1.1: Muscle fibre characteristics 
 Type of fibre 
Characteristic Slow oxidative (I) Fast oxidative (IIa) Fast glycolytic (IIb) 
Myosin ATPase activity LOW HIGH HIGH 
Speed of contraction SLOW FAST FAST 
Fatigue resistance HIGH Intermediate LOW 
Oxidative capacity HIGH HIGH LOW 
Anaerobic enzyme 
content 
LOW Intermediate HIGH 
Mitochondria MANY MANY FEW 
Capillaries MANY MANY FEW 
Myoglobin content HIGH HIGH LOW 
Colour of fibre RED RED WHITE 
Glycogen content LOW Intermediate HIGH 
Fibre diameter SMALL Intermediate LARGE 
Intracellular lipid levels HIGH HIGH LOW 
nNOS expression LOW LOW HIGH 
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These differences in muscle fibre type allow for the execution of a number of tasks, 
which are carried out by these various muscle groups (Vrbova and Gordon, 1994). 
These tasks range from postural actions like maintaining a standing position, to 
high-powered actions such as braking from a sprint, or finer movements such as 
writing (Vrbova and Gordon, 1994). The muscle types that give rise to these 
movements vary in a number of key features including their metabolism, blood 
supply, protein expression, as well as their activity (Aitman et al., 1979, Moruzzi 
and Bergamini, 1983, Reichmann and Nix, 1985, Wineinger et al., 1991, Muthny et 
al., 2008). This results in muscles having contractile profiles appropriate for their 
function. For instance, a high proportion of tonic motoneurons innervate a slow-
twitch postural muscle like the soleus muscle in the leg. It has a phenotype suited 
to slow and regular contraction (Vrbova and Gordon, 1994). It also has a very high 
resistance to fatigue, which is necessary to maintain posture. In contrast, fast-
twitch muscles, like the Extensor Digitorum Longus (EDL) and the Tibialis Anterior 
(TA) muscles, are innervated by a larger proportion of phasic motoneurons and 
have much faster and variable rates of contraction (Vrbova and Gordon, 1994). 
They are consequently far more fatigable - thus suited to rapid, powerful movement 
that occurs in short bursts. 
 
1.5 Plasticity of the NMJ - the effects of denervation  
During embryonic development, the motoneuron is critically dependant on nerve-
muscle interaction for survival (Chu-Wang and Oppenheim, 1978, Oppenheim, 
1987, Martinou et al., 1992, Hughes et al., 1993, Li et al., 1994, Ikeda et al., 1996). 
However, during post-natal development, the dependence of motoneuron on 
interaction with the target muscle diminishes, in rodents during early postnatal 
development (Lowrie et al., 1987, Harding et al., 1996). It is thought that this 
dependence is due, at least in part, to the release of neurotrophins from muscles 
(Oppenheim et al., 1991). 
 
Following axotomy, the distal portion of the motor nerve terminal can remain 
functional for up to 8 hours (Kernell, 2006). After this period, the extent of ACh 
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release and other functional markers declines and within 24 hours the motor nerve 
terminal and distal axon have fragmented and disintegrated (Rotundo, 2003). 
During the period of denervation the muscle fibre can undergo denervation-induced 
atrophy. In cases of chronic denervation, this can result in up to an 80% loss in 
muscle mass (Kernell, 2006).  
Following partial denervation, the proximal end of the motor nerve terminal can 
form a growth cone and grow toward the denervated empty endplates (Vrbova and 
Fisher, 1989, Keilhoff et al., 2002). This regenerative response is called sprouting 
(Brown et al., 1980, Fisher et al., 1989, Vrbova and Fisher, 1989, Rosenheimer, 
1990). The phenomenon of sprouting is a natural compensatory mechanism that 
can result in the expansion of the motor unit, up to 8-fold their original size, and 
results in the maintenance of muscle innervation and therefore muscle force (Tam 
et al., 2002, Tam and Gordon, 2003, Steele and Yi, 2006). The process of 
sprouting can result in some endplates receiving innervation by more than one 
nerve terminal, resulting in PNI (Herrera and Werle, 1990). This situation 
resembles that observed during early development. There are different types of 
sprouting, which can be categorised morphologically into three groups as 
described by Brown et al. (1981): 
 
 Ultra-terminal sprouts – where the sprout grows out of the endplate. After 
denervation of the endplate, the tSChs form a bridge between the 
innervated and denervated endplate, allowing the motoneuron terminal 
to arborise and grow along this tSCh sheath into the neighbouring 
denervated endplate (Astrow et al., 1998). 
 Pre-terminal sprouts – where the motor nerve terminal bifurcates before 
entering the endplate. 
 Nodal sprouts – where the axon sprouts at the Nodes of Ranvier, away 
from the terminal.  
Pre-terminal and ultra-terminal sprouting are most prevalent following partial 
denervation (Koirala et al., 2000).   
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Figure 1.1: A proposed pathway for denervation induced muscle atrophy 
The above schematic shows the Akt/FOXO pathway, which can initiate muscle 
atrophy (red) or muscle hypertrophy (green). Following denervation and muscle 
inactivity, nNOS dissociates from the dystrophin glycan complex (DGC) and 
initiates FOXO activity, which mediates the transcription of E3 ligases, resulting in 
muscle atrophy. (adapted from Glass et al. 2007). 
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A number of studies have revealed that the prevalence of sprouting within different 
muscles following denervation varies. For example, Rosenheimer et al. (1990) 
found that there is a differential sprouting response between fast-twitch and slow-
twitch muscles following denervation in rodents. Their findings revealed that pre-
terminal and ultra-terminal sprouting became more prevalent in the EDL muscle, in 
aged rodents and following denervation, compared to young rodents. In contrast, 
denervation did not result in any changes with age in its sprouting profile of the 
slow-twitch muscle soleus muscle. These results suggest that fast-twitch muscles, 
such as the EDL muscle are intrinsically more vulnerable to denervation with age.  
 
Muscle atrophy is a natural consequence of denervation, disuse, injury and aging 
(Bodine et al., 2001). At present the aetiology behind muscle atrophy remains 
unclear. However, one pathway known to mediate muscle atrophy is the nNOS/Akt 
pathway (Rommel et al., 2001). Upon denervation, nNOS is reported to upregulate 
the forkhead box (FOXO) transcription factor, resulting in the upregulation of a 
family of E3 ligases (Stitt et al., 2004). This in turn increases the ubiquitination and 
degradation of proteins via the proteosome (Glass et al., 2007; see Figure 1.1). 
 
1.6 NMJ in pathological conditions 
The NMJ can undergo pathological changes as a result of neuropathy or myopathy 
(Dastur and Razzak, 1973, Frey et al., 2000). NMJ insult typically results in 
denervation and the retraction of nerve terminals. Shortly after nNOS expression, 
which is normally localised to presynaptic nerve terminals and the adjacent 
postsynaptic muscle membrane, is down-regulated (Ribera et al., 1998). This 
precipitates the down-regulation of postsynaptic proteins such as rapsyn and agrin 
(Blottner and Luck, 2001) and upregulation of nNOS in surrounding tSChs, where it 
is thought to promote reactivity (Percival et al., 2008).  
 
Once activated, tSChs from intact NMJs extend their processes and migrate to the 
site of injury, guiding reinnervated axons (Auld & Robitalle, 2003). This results in 
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the random reinnervation of denervated endplates by nerve terminals and the loss 
of the mosaic-like pattern of muscle fibre types typically seen in healthy muscle so 
that grouping of muscle fibres with a similar fibre types is observed (Atkin et al., 
2005). Endplates reinnervated by a motoneuron with a different firing frequency will 
undergo re-specification and become a member of that motor unit (Vrbova and 
Gordon, 1994).  
 
1.7 Amyotrophic lateral Sclerosis 
Amyotrophic lateral sclerosis (ALS) is the most common form of adult motoneuron 
disease, affecting approximately 1-2 per 100,000 of the population (Bruijn et al., 
2004). ALS is a progressive neurodegenerative disease, with symptomatic onset 
characteristically occurring after midlife (Bruijn et al., 2004). Life expectancy is 
approximately 2-5 years from the onset of disease symptoms (Cleveland and 
Rothstein, 2001). The disease is characterised by the degeneration of large alpha 
motoneurons in the motor cortex and spinal cord (Bruijn et al., 2004). Degeneration 
of these motoneurons is reflected by a progressive decline in muscle function with 
accompanying muscle atrophy. Spasticity, hyperreflexia and extensor plantar 
reflexes are the clinical manifestations of upper motoneuron degeneration (Bento-
Abreu et al., 2008). Symptoms include muscle paresis, weight loss, muscle paresis 
and eventual paralysis. Ultimately, death occurs usually as the result of failure of 
respiratory muscles, often exacerbated by swallowing problems. 
 
ALS can also be considered as a neuromuscular disorder (NMD), and indeed 
some of the pathological characteristics of ALS muscle are shared with other non-
neurodegenerative NMDs such as Duchenne Muscular Dystrophy (DMD) and 
Inclusion Body Myositis (IBM). As illustrated in Table 1.2, these neuromuscular 
disorders have some shared pathology such as denervation, muscle atrophy, 
mitochondrial dysfunction and the preferential vulnerability of fast-twitch muscles to 
disease (Lott and Landesman, 1984). 
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Table 1.2: Myopathies that share symptoms/pathology with ALS 
Disease Shared pathology and 
symptoms 
Reference 
Duchenne 
muscular 
disease 
Reduced nNOS expression and 
NO activity, denervation & 
progressive muscle atrophy, 
Ca2+ signalling dysfunction, 
oxidative stress & increased 
fast-twitch fibre vulnerability. 
(Dastur and Razzak, 1973, 
Gissel, 2005, Whitehead et 
al., 2006, Adams et al., 
2008) 
Inclusion body 
myositis 
Muscle atrophy, weakness & 
oxidative stress & increased 
fast-twitch fibre vulnerability. 
(Amato and Barohn, 2009, 
Askanas et al., 2009, 
Parker et al., 2009) 
 
Despite intensive research, particularly over the last 20 years, there has been little 
success in the treatment of ALS.  At present, the only drug that is available is 
Riluzole, which only extends lifespan by approximately 2-4 months (Bensimon et 
al., 1994, Miller, 2003, Traynor et al., 2006).   
 
1.7.1 The genetics of ALS pathology 
The majority of cases (90%) have no clear genetic cause and are therefore usually 
defined as sporadic ALS (sALS). While approximately 10% of ALS cases have a 
clear genetic determinant and are thus termed familial ALS (fALS). Several genes 
have now been identified to cause fALS. The genes known to cause classical ALS 
as well as juvenile onset ALS and those responsible for ALS with an autosomal 
recessive genetic component are detailed in Table 1.3 and Table 1.4, respectively. 
The associated proteins and their function are summarised in Table 1.3 and 1.4, 
respectively. Despite the recent identification of new gene mutations that cause 
ALS, including TAR DNA-binding protein-43 (TDP-43) (Kuzuhara, 2008), RNA-
binding protein that was FUsed in Sarcoma (FUS) (Lagier-Tourenne and 
Cleveland, 2009) and optineurin (OPTN) (Maruyama et al., 2010). These mutations 
each account for only 1-4% and 4-5% of fALS cases for TDP-43 and FUS, 
respectively. Due to its recent identification the percentage of fALS cases due to 
OPTN remains unclear. 
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The large majority of fALS cases are due to mutations in the Copper/Zinc 
Superoxide dismutase (SOD1) gene. This mutation was first identified in 1993 by 
Rosen et al., still accounts for 15-20% of fALS cases (Shaw et al., 2001, Bento-
Abreu et al., 2008).  
 
1.8 Mutant Copper/Zinc Superoxide Dismutase 
In 1993, a mutation in the SOD1 gene, on chromosome 21q22.1, was first 
identified as causative for ALS (Rosen et al., 1993). Today, more than 150 different 
mutations have been identified in the SOD1 gene (Turner and Talbot, 2008).  
 
The SOD1 enzyme is a ubiquitously expressed, predominantly cytoplasmic 
enzyme, which acts as a cellular antioxidant by catalysing the conversion of 
superoxide radicals into hydrogen peroxide and water. 
Table 1.3 Classical ALS 
Gene Loci Protein Function Reference 
ALS1 
(SOD1) 
21q22.
1 
SOD1 Detoxifies O2- to H2O2  & 
prevents oxidative damage 
Siddique et 
al., 1991 
ALS3 18q21 - - Hand et al., 
1993 
 
ALS6 
 
 
16p11 
 
 
FUS 
Nuclear protein that is 
involved in DNA & RNA 
metabolism  
 
Ruddy et 
al., 2003 
ALS7 20p13 - - Sapp et al., 
2003 
ALS9 14q11 Angiogenin Mediates vasculature & is 
induced by hypoxia 
Wu et al., 
2007 
ALS10 1p36 
 
TDP-43 Involved in RNA biogenesis, 
apoptosis & cell division 
(Ferrari et 
al., 2011) 
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Table 1.4 ALS 
Gene 
 
Loci Protein Function Reference 
 
ALS2 
 
2q33 
 
Alsin 
Involved in vesicle transport 
& intracellular trafficking 
Kunita et al., 
2004 
ALS4 9q34 Senataxin DNA helicase involved in 
DNA repair and RNA 
production. 
Chance et 
al., 1998 
ALS5 
 
15q21 Spatacsin Possibly membrane 
associated 
Hentati et 
al., 1998 
 
ALS8 
 
20q13.
33 
Vesicle 
associated 
membrane 
protein B 
Associated with ER & Golgi 
membranes 
Sapp et al., 
2003 
 
 
ALS 12 
 
10p15 OPTN Interacts with Huntingtin & 
regulates TNF-α induced 
activation of NF-κB 
(Maruyama 
et al., 2010) 
ALS with 
frontotempo
ral dementia 
1 
9q21-
q22 
 
- 
 
- 
Hosler et al., 
2000 
ALS with 
frontotempo
ral dementia 
2 
9p21.3
-p13.2 
 
- 
 
- 
Hosler et al., 
2000 
 
The functional enzyme exists as a homodimer that requires copper and zinc 
binding for catalytic activity and stabilisation, respectively (Shaw et al., 2001), 
reducing the concentration of free superoxide radicals in the cell by catalysing the 
conversion of superoxide to oxygen and hydrogen peroxide. This is illustrated 
below: 
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 Cu2+–SOD1 + O2 → Cu2+–SOD1 + O2 
 Cu2+–SOD1 +O2 – 2H+ → Cu2+–SOD1 + H2O2 
 
Initially, mutations in the SOD1 enzyme were suggested to reduce the dismutase 
activity and enhance oxidative stress; however, genetic ablation of endogenous 
SOD1 did not induce motoneuron disease in knockout mice (Reaume et al., 1996). 
Furthermore, mutant SOD1 (mSOD1) was found to have similar catalytic activity to 
wild type (WT) (Bruijn et al., 2004).  
 
In 1994, the first genetic mouse model of ALS was generated (Gurney et al, 1994). 
These mice express the human SOD1 gene containing a Glycine to Alanine base 
pair mutation at the 93rd codon (Gurney et al., 1994). Following the initial 
generation of the G93A mutant mice, a number of additional transgenic mice 
expressing a variety of SOD1 mutations have been generated, and been found to 
exhibit a phenotype that closely resembles human ALS (Gurney et al., 1994, Bruijn 
and Cleveland, 1996). Despite intensive investigation, the precise mechanism by 
which mutations in this ubiquitously expressed gene results in motoneuron 
degeneration remains unclear. The mechanism is known to involve a toxic gain of 
function, as knockout SOD1 mice do not develop motoneuron pathology (Bruijn et 
al., 2004). This toxic gain of function is independent of SOD1 activity levels 
(Borchelt et al., 1994, Dal Canto and Gurney, 1994, Ripps et al., 1995, Wong et al., 
1995, Bruijn and Cleveland, 1996). 
 
The generation of transgenic mice expressing mutations in the human SOD1 
enzyme has provided an excellent research tool to investigate the pathogenesis of 
ALS. It has also enabled the preclinical testing of potential therapeutic agents. 
Indeed, mSOD1 mice demonstrate many of the pathological features seen in 
humans, including neurofilament inclusions, ubiquitin positive aggregates and 
selective motoneuron loss (Gurney, 1994, Ripps et al., 1995, Wong et al., 1995, 
 31 
Bruijn and Cleveland, 1996). mSOD1 transgenic mice expressing the G93A 
mutation are the most widely used animal model of ALS and have therefore been 
well characterised. There are two variants of this model: the most commonly used 
high copy number variant, which express mSOD1 approximately 25 times higher 
than the normal level and the low copy number transgenic mouse, which express 
mSOD1 approximately 8 times higher than normal levels (Henriques et al.). In this 
study, the high copy number mice have been used in all experiments and are 
referred to simply as mSOD1 mice. 
 
mSOD1 mice develop muscle fasciculation, weight loss, hindlimb paresis and 
eventual hindlimb paralysis and display selective motoneuron death (Ilieva et al., 
2009). The mSOD1 mice on the BL6/SJL background typically exhibit signs of 
hindlimb weakness at 75 days, progressing to severe muscle paralysis and atrophy 
by 120 days and endstage at around 125-130 days of age (Gurney et al., 1994, 
Kieran et al., 2004). They undergo progressive motoneuron death from 
approximately 70-80 days until endstage (Gurney et al., 1994). By this stage over 
70% of motoneurons have died (Kieran et al., 2004, Sharp et al., 2006). Using 
mSOD1 mice, it has been possible to identify a number of important cellular 
pathways that are affected in ALS.   
 
1.9   ALS Pathogenesis in the CNS 
A number of pathological mechanisms are known to contribute to the selective 
degeneration of motoneurons in ALS (Ilieva et al., 2009) and are summarised in 
Fig.1.2. Since a large number of pathological mechanisms involved in the aetiology 
of the disease, a full discussion of each mechanism is beyond the scope of this 
Thesis. Therefore, some of the mechanisms shall only be discussed briefly, whilst 
those that have greater relevance to the experiments undertaken within this Thesis 
shall be expanded upon in relevant Chapters.  
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Figure 1.2 Proposed pathological mechanisms in ALS (insert the altered text) 
(A) Excitotoxicity is the hyperactivation of motoneurons resulting from the slow 
removal of glutamate from synapses. (B) ER stress is induced by the abnormal 
interaction of mSOD1 with ER proteins. (C) Proteasome dysfunction results in 
ubiquitinated misfolded protein aggregates. (D) Mitochondrial dysfunction provokes 
the release of cytochrome-C in motoneurons. (E) Oxidative stress caused by 
microglia and astrocytes damages neighbouring motoneurons. (F) Axonal transport 
dysfunction resulting in decreased retrograde transport of proteins. Image from 
(Ilieva et al., 2009). 
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1.9.1 Motoneuron Pathology  
At an ultrastructural level, degenerating motoneurons in ALS patients display 
accumulations of intermediate filaments and ubiqutinylated intracellular aggregates 
in perikarya and proximal axons, abnormalities in mitochondrial structure and 
mitochondrial degeneration, as well as fragmentation of the Golgi apparatus 
(Gomes et al., 2008). Many of these features are also characteristic of other 
neurodegenerative conditions (Kanazawa, 2001). A number of pathological 
pathways are activated in ALS pathogenesis, including glutamate excitotoxicity, 
oxidative damage, mitochondrial dysfunction, protein aggregation, axonal transport 
deficits and neuroinflammation (Bento-Abreu et al., 2008).  
 
1.9.2 Glutamate excitotoxicity 
In non-pathological conditions, glutamate acts as an excitatory neurotransmitter in 
the CNS and is released from neurons, activating glutamate receptors on 
postsynaptic neurons. These glutamate receptors can be classified as ionotrophic, 
or metabotrophic receptors. Ionotrophic receptors largely fall into three categories: 
N-methyl-D-aspartate (NMDA) of amino-3-hydroxy-5-methly-4-isoxazoleproprionic 
acid receptors (AMPA) and kainaite receptors (Van Den Bosch and Robberecht, 
2008). In non-pathological conditions, NMDA receptors are permeable to Na+, Ca2+ 
and K+, AMPA receptors are only permeable to Na+ and K+, unless they are 
missing a functional GluR2 unit making them more permeable to Ca2+ - a feature 
commonly found in AMPA receptors on motoneurons (Van Den Bosch and 
Robberecht, 2008). 
 
In ALS patients and mSOD1 mice, NMDA and AMPA receptors become 
excessively activated causing the excessive firing of motor neurons. The receptors 
also became more permeable to Ca2+, resulting in Na+ and Ca2+ influx, resulting in 
ER stress as well as disrupted Ca2+ signalling (Takuma et al., 1999, Bruijn et al., 
2004).  
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1.9.3 Oxidative Stress 
In non-pathological conditions, anti-oxidative enzymes like SOD1 and SOD2 are 
present to reduce the levels of H2O2 and super oxide. Following the discovery of 
mSOD1 and the generation of mSOD1 mice, the role of oxidative stress in the 
disease was investigated. Studies examining ALS patients and mSOD1 mice for 
markers of oxidative stress revealed elevated protein nitrosylation, lipid 
peroxidation and protein carboxylation in the spinal cord and CNS (Ferrante et al., 
1997).  
 
1.9.4 Mitochondrial dysfunction 
Mitochondrial dysfunction is also present in motoneuron in ALS. The main function 
of mitochondria is to generate energy, in the form of ATP. In ALS, mitochondria, 
which are sensitive to damage from free radicals, are thought to become 
compromised by increased generation of reactive oxygen species (ROS) and 
reactive nitrogen species (RNS) (Heath and Shaw, 2002), which in turn results in 
alterations in the mitochondrial membrane potential and exacerbates excitotoxicity 
(Heath and Shaw, 2002). In addition, in mSOD1 mice, mSOD1 has been found to 
accumulate in the intermembrane space of mitochondria, resulting in mitochondrial 
vacuolisation (Jaarsma et al., 2000). However, mitochondrial vacuolisation is not 
observed in ALS patients (Sasaki and Iwata, 1998). Mitochondrial dysfunction 
causes metabolic dysfunction within the motoneuron (Browne et al., 1998) as well 
as potentially precipitating the release of cytochrome-C into the cytosol, initiating 
apoptosis (Higgins et al., 2003).  
 
1.9.5 Protein aggregation 
Protein aggregation is a well-characterised pathomechanism in several 
neurodegenerative disorders, including ALS. In ALS, intracellular aggregates are 
present in motoneurons from the spinal cord of ALS patients as well as mSOD1 
mice (Leigh et al., 1991, Bruijn and Cleveland, 1996, Cleveland et al., 1996, 
Watanabe et al., 2001, Jonsson et al., 2004). However, as in other 
neurodegenerative disorders, their precise role in the disease is unclear. One 
 35 
school of thought is that aggregates exert a protective effect, sequestering aberrant 
proteins away from cell organelles (Imai et al., 2003, Arrasate et al., 2004). 
However, the predominant view is that these aggregates arise from misfolded 
proteins that accumulate as a result of inadequate refolding by molecular 
chaperones, which are often sequestered (Garofalo et al., 1991, Bruijn and 
Cleveland, 1996, Jaarsma et al., 2000, Watanabe et al., 2001). Intracellular 
aggregations of misfolded proteins found in motoneurons and glial cells are 
thought to exert toxicity by the disruption of axonal transport, as well as increasing 
the likelihood of aberrant protein interactions and the sequestration of key 
organelles and essential proteins (Bruijn and Cleveland, 1996, Watanabe et al., 
2001, Cheroni et al., 2005). Ultimately, these aggregates are thought to 
overburden the proteasome within motoneurons (Johnston et al., 2000, Bruijn et 
al., 2004), further increasing their prevalence. 
 
1.9.6 The role of exosomes in ALS  
Exosomes are small membranous vesicles secreted by a number of cell types and 
can be isolated from conditioned cell media. Exosome biogenesis involves the 
inward budding of multivesicular bodies to form intraluminal vesicles. Intraluminal 
vesicles of multivesicular bodies are either sorted for degradation into lysosomes, 
or secreted as exosomes (Trajkovic et al., 2008). The mechanisms underlying the 
sorting of the membrane into the different populations of intraluminal vesicles are 
unknown. However, this occurs via one of two known pathways: either via a 
pathway that requires endosomal sorting complexes endosomal required for 
transport (ESCRT) or sphingolipid ceramides (Cutler et al., 2002). 
 
The release of the vesicles into the extracellular environment as exosomes, 
enables cell-cell signalling, as well as the transferral of pathogens as seen in 
Creutzfeldt-Jakob disease (Vella et al., 2008). Interestingly, exosome mediated 
pathology has also been proposed as a mechanism for neuron death in 
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neurodegenerative disease. Indeed, in Alzheimer's disease, recent studies have 
found that APP fragments are associated with exosomes (Vella et al., 2008).  
 
A role for the exosome mediated pathogenesis has also been found in ALS. In 
2002 Cutler et al. reported increased levels of sphingomyelin, ceramides (found in 
purified exosomes), and cholesterol esters in the spinal cords of ALS patients and 
in mSOD1 mice, which preceded symptomatic onset. They also showed that the 
pharmacological inhibition of sphingolipid synthesis prevented the accumulation of 
ceramides, sphingomyelin, and cholesterol esters and protected motoneurons from 
exosome mediate oxidative stress and cell death (Cutler et al., 2002). Furthermore, 
ESCRT dysfunction, which is present in ALS (Gomes et al., 2007), has been 
shown to facilitate the accumulation of cytoplasmic protein aggregates containing 
ubiquitin, and TDP-43 (Rusten & Simonsen, 2008).  
 
1.9.7 The role of non-neuronal cells in ALS pathogenesis 
The French physiologist Claude Bernard first established the idea that cells 
function autonomously (Reynolds, 2007). From that time until 2003, researchers 
assumed that damage within a specific cell population was sufficient to cause 
disease (Ilieva et al., 2009). Thus, for a number of years research into ALS 
pathogenesis focused primarily on motoneurons. However, Clement et al. (2003) 
with mouse chimeras elegantly demonstrated that the transplantation of 
neighbouring WT glia into the spinal cord of mSOD1 mice was sufficient to reduce 
motoneuron death and prolong survival. The converse was shown to cause the 
development of ubiquitinated inclusions and also diminished motoneuron viability. 
This study sparked extensive research into the role of glia in ALS. However, while 
non-neuronal cells have been shown to influence disease progression, the 
exclusive expression of mSOD1 in motoneurons, muscle or glia, is not sufficient to 
induce the progressive loss of motoneurons that typifies ALS (Gong et al., 2000, 
Pramatarova et al., 2001, Wong and Martin). Indeed, whether astroglia were a 
primary target of ALS was examined by Gong et al. (2000). The selective 
transgenic expression of mSOD1 in the astrocytes of mice resulted in significant 
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glial pathology, but was insufficient to alter motoneuron morphology or survival. 
Likewise, Pramatarova et al. (2001) showed that selective expression in neurons 
did not result in any motor deficits (Pramatarova et al., 2001). However, it is now 
widely agreed that astrocytes and microglia determine disease duration with 
increased mSOD1 expression in microglia and astrocytes accelerating disease 
progression (Bento-Abreu et al., 2008). While the increased expression of mSOD1 
in Schwann cells slows disease progression (Ilieva et al., 2009). 
 
1.10 Muscle pathology in ALS  
In ALS, muscle fasciculations and muscle weakness and paralysis are the main 
manifestation of the disease. Indeed, the first signs of disease appear in muscle, 
with denervation of the NMJ occurring prior to motoneuron death (Frey et al., 2000, 
Fischer et al., 2004, Pun et al., 2006, Steele and Yi, 2006).   
 
1.10.1 Selective vulnerability of fast-twitch muscle fibres in ALS 
However, studies on the muscles of ALS patients and mSOD1 mice have revealed 
that the extent and rate of denervation between different muscle types varies. 
Examination of muscle in mSOD1 mice has shown that some muscles are affected 
earlier and to a greater extent than other muscles (Frey et al., 2000; Fisher et al., 
2004; Hegedus et al., 2007). Thus, there appears to be a preferential vulnerability 
of muscles that are largely composed of fast-twitch muscle fibres, and muscles 
with a high proportion of slow-twitch fibres are affected later in the disease and 
usually to a lesser extent. Thus, in mSOD1 mice, fast-twitch muscles such as the 
tibialis anterior (TA), medial gastrocnemius (MG) and extensor digitorum longus 
(EDL) deteriorate faster and more dramatically than slow-twitch muscles such as 
the soleus muscle (Frey et al., 2000). 
 
While it is now well established that some muscles have a greater susceptibility 
disease than other groups, the underlying cause of this preferential vulnerability of 
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specific muscle fibres, or more specifically, the motoneurons that innervate them, 
remains unknown.  
The observation that fast-twitch muscles fibres are more vulnerable to disease is 
also observed in other neuromuscular diseases. This phenomenon is also seen in 
both IBM and Charcot Marie Tooth disease, which represent neuromuscular 
diseases with heterogeneous aetiology (Michael et al., 2006). This preferential 
vulnerability of fast-twitch muscle fibres to disease suggests that there may be a 
common feature within fast-twitch muscles that facilitates pathological changes. 
Conversely, there may be a feature in slow-twitch muscles that leaves them better 
equipped to resist pathological insult. There is evidence that suggests that the 
former possibility is more likely. For example, it has been shown that fast-twitch 
muscles are more susceptible to oxidative stress, as they are generally only 
equipped to handle short-lived rises in ROS, a key mediator of oxidative stress 
(Ferreira and Reid, 2008). Fast muscles also have a less robust heat shock 
response and have a lower concentration of anti-oxidative proteins (Daugaurd et 
al., 2001; Tarricone et al., 2008; Kieran et al., 2004), which may alter their 
response to systemic stress. 
 
Until recently, it was thought that changes in muscle phenotype are dependent on 
innervation characteristics and are not determined by the muscle (Kernell, 2006). 
However, studies by Santos et al (2003) and Frey et al (2000a) suggest that motor 
units of fast-fatigable nature are more likely to undergo denervation (Santos & 
Caroni, 2003). Additionally, it has been suggested that they may also have a 
decreased capacity for sprouting, both in ALS and non-ALS mice (Santos and 
Caroni, 2003). Equally, the fast-twitch glycolytic fibres are some of the first to 
atrophy with old age (Lexell, 1995). 
 
In ALS, the reason for the differential vulnerability of fast-twitch and slow-twitch 
muscle fibres to disease is still unclear. Although the differential vulnerability of 
these muscle fibres may in fact lie within the specific motoneurons that innervate 
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them, it is also possible that fast-twitch muscles are intrinsically more vulnerable to 
stress, since evidence shows that they are more vulnerable to a variety of 
pathological stresses such as ischemia and reperfusion injury (David et al., 2007). 
A small number of studies have examined muscle pathology in an aneural setting 
and some have examined the propagation of muscle phenotype in vitro (Bryla and 
Karasinski, 2001). However, to date there is little evidence examining the 
differential vulnerability of fast and slow-twitch mSOD1 muscles in an aneural 
environment. 
 
One of the consequences of the selective loss of fast-twitch muscle fibres in ALS is 
the transformation in the phenotype of fast-twitch muscles such as TA and EDL, 
into muscles with a slow-twitch phenotype composed of highly oxidative muscle 
fibres (Sharp et al., 2005). This phenotypic transformation is reflected in a change 
in the contractile characteristics of the muscle: muscles that normally contract and 
relax rapidly change into muscles with prolonged contraction and relaxation times 
(Kieran et al., 2004).  It is likely that this transformation in fast-twitch muscle 
phenotype is the result of the selective loss of fast phasic motoneurons and the 
consequent compensatory sprouting of less vulnerable, surviving motoneurons that 
normally innervate slow-twitch muscle (Amphlett et al., 1975), with a tonic pattern 
of activity that drives the expression of a slow muscle phenotype (Sharp et al., 
2005). 
 
It is known that the phenotype of a muscle fibre is largely determined by the activity 
pattern of the innervating motoneuron (Tyc and Vrbova, 1995, Slawinska et al., 
1996). Thus, a similar ‘fast-to-slow’ twitch transformation is seen experimentally 
when a fast-twitch muscle is cross-innervated by a nerve from a slow-twitch muscle 
(Ip et al., 1988). However, although a ‘fast-to-slow’ muscle transformation also 
occurs following adult nerve injury (Lowrie and Vrbova, 1984), in this case the 
transformation of the muscle is not the result of the selective death of fast 
motoneurons and subsequent sprouting of slow motoneurons, but is rather due to 
a change in the activity pattern of the reinnervating motoneurons. Following nerve 
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injury, normally fast motoneurons become hyperactive and exhibit an increase in 
the level of tonic activity, which results in a change in the muscle fibre phenotype 
(Navarrete &Vrbova, 1984).  
 
1.10.2 Mitochondrial dysfunction in ALS muscle 
It is well established that alterations in mitochondrial function are not restricted to 
motoneurons in mutant SOD1 mice, but also exist in mSOD1 muscle (Dupuis et al., 
2003). In mSOD1 muscle mitochondria display altered ATP production as well as 
calcium signalling (Dupuis et al., 2003), which is likely to result in the generation of 
ROS. Furthermore, levels of mitochondrial uncoupling proteins are elevated even 
before disease onset. This is not observed in motoneurons, despite the fact that 
mitochondrial dysfunction is considered to be a contributing factor to disease 
aetiology in the CNS (Bruijn and Cudkowicz, 2006). Dupuis et al (2009) also found 
reduced ATP levels in myogenic but not neural tissue. Furthermore, these changes 
were independent of denervation, but appear to reflect mSOD1-mediated 
pathophysiological changes that are exclusive to the muscle and may be evidence 
of an underlying systemic metabolic dysfunction (Fergani et al., 2007).  
 
A large number of cellular stresses are due to elevated oxidative species and 
aberrant protein-protein interactions affecting diverse cellular systems, such as 
energy metabolism and muscle regeneration (Dupuis et al., 2009, Dupuis and 
Loeffler, 2009). Mitochondrial dysfunction in ALS muscle is discussed in greater 
detail in Chapter 6. 
 
1.10.3 Oxidative stress in ALS muscle 
Oxidative stress arises from an imbalance between the rate of production of 
reactive oxygen species (ROS) and the rate of the elimination of ROS. Markers of 
oxidative damage include increased levels of ROS, decreased glutathione levels, 
lipid peroxidation and DNA damage (Barber et al., 2006). ALS patients display 
evidence of oxidative stress with increased protein carboxyl levels and 3-
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nitrityrosine in the CNS (Abe et al., 1997a, Abe et al., 1997b). This is also present 
in spinal cord of mSOD1 mice before disease onset (Bruijn et al., 2004). 
 
Elevated ROS levels in skeletal muscle occur frequently, even under normal 
physiological conditions such as strenuous exercise (Ferreira and Reid, 2008). 
This can result in contractile damage and raised ROS levels. Consequently, 
skeletal muscle has adaptive mechanisms that enable the fast induction of anti-
oxidative pathways within the muscle fibre, such as the upregulation of anti-
oxidative enzymes, such as superoxide dismutase and catalase as well as 
increased expression of cytoprotective heat shock proteins (hsps) (McArdle et al., 
2001). Despite these protective mechanisms, in mSOD1 mice there is evidence of 
oxidative damage in muscle, with lipid peroxidation, increased COX-1 activity and 
levels of protein carbonyls (Soraru et al., 2007, Dobrowolny et al., 2008, Wong and 
Martin, 2010). Muscle from ALS patients has been shown to display higher levels 
of lipid peroxidation (Siciliano et al., 2002), as well as increased generation of 
mitochondrial uncoupling proteins (Dupuis et al., 2009). It has been proposed that 
continued oxidative stress within mSOD1 muscle contributes to mitochondrial 
dysfunction in mSOD1 muscle and subsequently disrupted metabolic function 
within the muscle (Dupuis et al., 2003). 
 
Some muscles are better adapted to deal with oxidative stress than others. These 
muscles often have a high oxidative capacity, typically rich in slow-twitch muscle 
fibres. Currently, there is limited knowledge of how oxidative stress that arises from 
physiological activity affects mSOD1 muscle pathology. This will be discussed in 
greater depth in Chapter Six. 
 
1.10.4 Neuronal NOS expression in muscle 
Neuronal NOS (nNOS) has been implicated in muscle atrophy and reinnervation. 
nNOS has been shown to be differentially regulated in the CNS of mSOD1 mice 
(Lee et al., 2009). However, it is most abundantly expressed in skeletal muscle. 
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Notably, nNOS is preferentially expressed in fast-twitch muscle in mice (Soraru et 
al., 2007). There is some evidence that indicates that nNOS and possibly inducible 
nitric oxide synthase (iNOS) may play a role in muscle pathology in ALS and 
mSOD1 mice (Soraru et al., 2007).  
 
In the PNS, nNOS acts predominantly as a signalling protein, where it has been 
implicated in the activation of Forkhead box (FOXO) transcription factors (Suzuki et 
al., 2007b). The FOXO family of transcription factors are involved in a number of 
cellular events including the induction of muscle atrophy (Suzuki et al., 2007b). 
nNOS expression has also been implicated in nerve terminal sprouting. Indeed, 
using nNOS-deficient mice, Marques et al. (2006) have shown that nNOS plays a 
pivotal role in the regenerative effort at the NMJ following denervation. Following 
denervation, nNOS-/- mice were capable of displaying pre-terminal sprouting but 
not ultra-terminal sprouting. NNOS has also been implicated in tSCh activation 
(Marques et al., 2006), and reactive tSChs are integral to ultra-terminal sprouting. 
Thus, it is possible that nNOS may be involved in the differential regulation of 
muscles response to denervation and muscle atrophy. Changes in nNOS levels in 
muscles of mSOD1 mice are expanded upon in the Thesis in Chapter 5. 
 
1.11 The role of the Heat Shock Response in ALS 
The term ‘Heat shock response’ (HSR) was first established by Ritossa in 1962, 
after observing induction of a family of proteins in the salivary glands of Drosophila 
melanogaster larvae, following incubation at 30-32°C (Soti and Csermely, 2006). It 
is an evolutionarily conserved, ubiquitously expressed, cell defence mechanism 
that results in the induction and upregulation of cytoprotective proteins, following 
exposure to a variety of cell stresses. These proteins are called hsps and are 
responsible for the refolding of misfolded proteins and targeting irreparably 
damaged proteins to the proteosome for degradation (Bruijn et al., 2004). hsps 
therefore work to maintain normal protein-protein interactions in the cell under 
normal conditions and conditions of stress (Brown, 2007) and are essential for the 
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homeostasis of the protein pathway. However, they also have strong anti-apoptotic 
capabilities (Tonkiss and Calderwood, 2005, Voellmy and Boellmann, 2007). 
 
There are six families of heat shock proteins, defined according to their molecular 
weight. The main families of hsps are: the small hsp25; hsp40; hsp60; hsp70; 
hsp90; hsp110 and hsp170. The largest families of Hsps are the Hsp70 and Hsp90 
families (Brown, 2007). These have inducible isoforms that can be upregulated 
upon a variety of cellular insults (Wood et al., 2003). This phenomenon is 
associated with increased cellular tolerance to oxidative stress, glutamatergic 
excitotoxicity and trauma (Bento-Abreu et al., 2008). Ultimately, the induction of the 
HSR acts to increase cell survival. 
 
Two key features of all neurodegenerative disorders are protein aggregation and 
aberrant protein interactions, which suggests that elements of the heat shock 
response may be involved in the aetiology of the disease (Wood et al., 2003). The 
expression of most hsps is controlled by the transcription factor, Heat shock factor-
1 (HSF-1), which trimerises upon activation, translocating to the heat shock 
element (HSE) in the nucleus to initiate the transcription of hsp genes (Henderson 
et al., 1996) 
 
The HSR has been implicated in the pathogenesis of ALS, since motoneurons 
have a surprisingly reduced ability to upregulate hsp expression upon exposure to 
cellular stress (Batulan et al., 2003). Thus, it has been proposed that this inability 
to induce a robust HSR may contribute, at least in part, to the selective vulnerability 
of motoneurons in ALS. Furthermore, it appears that motoneurons may be 
dependent on hsps expressed and secreted by their neighbouring non-neuronal 
cells (Tonkiss and Calderwood, 2005, Brown, 2007).  
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1.11.1 Hsp90 
Hsp90, a 90kDa protein chaperone, is one of the most abundant proteins in 
mammalian cells. It is integral to cell proliferation and differentiation, signal 
transduction, protein folding and degradation as well as cell survival and adaptation 
(Sreedhar et al., 2004). Hsp90 has a number of isoforms: hsp90β: the constitutively 
expressed form, hsp90α: the inducible form, hsp90Ν: a glucose related protein-
4(GRP94) found in the endoplasmic reticulum and hsp75/TRAP, which is found in 
mitochondria. During muscle development, hsp90 plays a fundamental role where 
it is essential for myofibrillogenesis (Willis et al., 2009). 
 
Hsp90 is normally found within the sarcoplasm of muscle, where it exists as a 
homodimer or is associated with its client proteins, such as HSF1 (Ali et al., 1998). 
Hsp90 has over one hundred clients, the majority of which are involved in signal 
transduction (Richter and Buchner, 2001). Hsp90’s actions fall largely into two 
categories. When bound with its chaperones p50 & p23, hsp90 targets misfolded 
proteins, stabilising them and protecting them from degradation by the proteosome 
(Taiyab et al., 2009); alternatively, hsp90 can also facilitate protein degradation, via 
the proteosome, when bound to hsp70, Hsc70-Hsp90-organizing protein (HOP) 
and other chaperones (Adachi et al., 2007). Following cell stress, hsp90 targets 
misfolded proteins within the cytosol and results in the release of HSF1, which 
trimerises and induces the HSR (Ali et al., 1998, Bornfeldt, 2000).  
 
1.11.2 Hsp70 
Four major forms of hsp70 have been found in muscle:  
 
 The heat shock cognate, which weighs 73kDa (HSC70) and is a 
constitutively expressed form of hsp70. 
 The glucose related protein, which weighs 75kDa (GRP75) and is found in 
mitochondria. 
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 The inducible hsp70 (hsp72), which weighs 73kDa and is induced following 
the trimerisation of HSF1. 
 The glucose related protein, which weighs 78kDa (GRP78) and is found in 
the sarcoplasmic reticulum.  
 
The actions of hsp72 include the stabilization of partially folded proteins via 
interactions with HOP and hsp90, the re-folding of denatured proteins and the 
targeting of misfolded proteins to the proteosome (Asea, 2007). This is carried out 
via Carboxyl-terminus of hsp70 Interacting Protein (CHIP) interactions (Kampinga 
et al., 2003). Hsp72 also has strong anti-apoptotic properties, blocking the 
recruitment of procaspase-9 following cytochrome-C release, thereby reducing the 
likelihood of cell apoptosis (Gabai et al., 2002). Hsp72 is also known to increase 
NMJ activity (Karunanithi et al., 2002).  
 
1.11.3 Hsp60 
Hsp60 is a mitochondrial and cytosolic protein that is found in all cells and in large 
quantities in skeletal muscle (Oishi et al., 2002). Hsp60 expression in muscle is 
known to vary with mitochondrial content (Lin et al., 2001). It is therefore expressed 
at greater levels in slow-twitch muscles such as the soleus muscle (Carrier et al., 
2000, Liu and Steinacker, 2001, Oishi et al., 2002). Following exercise stress, 
hsp60 levels increase are five times greater in the slow-twitch soleus muscle than 
in the fast-twitch EDL muscle in mice (McArdle et al., 2001). Hsp60 synthesis is 
induced in skeletal muscle following a number of stresses within the muscle, 
including: exercise, ischemia reperfusion injury and mitochondrial uncoupling 
(McArdle et al., 2001).  
 
1.11.4 Hsp25 
Hsp25 is the murine orthologue of human hsp27. In the unstressed cell, it exists in 
large 400-800kDa oligomers (Adhikari et al., 2004). In this form, it facilitates the 
correct folding of proteins and carries out other essential chaperone duties 
 46 
(Abruzzo et al., 2010). In muscle, hsp25 is primarily involved in the maintenance of 
cytoskeletal integrity of the muscle fibre, both during development as well as 
throughout adulthood (Ding and Candido, 2000). Hsp25 has been shown to 
stabilise microfilaments within the muscle fibre, via its associations with Z-disks 
within fibres (Huey et al., 2004). Following cell stress, hsp25 is a key component of 
the HSR and has strong anti-apoptotic actions. Hsp25 is also involved in 
minimising oxidative stress within the muscle fibre (Lee et al., 2008). 
 
Following the induction of the HSR, hsp25 is quickly phosphorylated at a number of 
sites. This leaves it unable to bind to itself or form large oligomeric structures 
(Bryantsev et al., 2002). As a monomer, it is able to translocate to the nucleus as 
well as F-actin filaments within the cell (Ho et al., 2006). In muscle, this 
transformation is so complete that hsp25 is found almost exclusively as a monomer 
following the activation of the HSR (Ding and Candido, 2000, Adhikari et al., 2004). 
During this period, hsp25 is redistributed from the cytosol to actin filaments. As a 
monomer, hsp25 binds preferentially to misfolded proteins in the muscle fibre and 
is known to bind with mSOD1 in motoneurons where it traps aggregate prone 
folding intermediates and prevents further aggregation (Okado-Matsumoto and 
Fridovich, 2002) and targets the misfolded proteins to the proteosome. In 
motoneurons, hsp25 accumulates in the nucleus during the HSR, and directs the 
degradation of misfolded proteins within the nucleus (Lee et al., 2008). 
 
1.11.4.1 Heat shock protein expression in the muscle 
Hsps are differentially expressed in fast and slow-twitch muscles. Interestingly, the 
difference in regenerative capacity between fast and slow-twitch muscles is 
reflected in the hsp profile of these muscles (Oishi et al., 2005). Slow-twitch 
muscles have a high constitutive expression of many of the most prominent hsps, 
including the Hsp70 family (Oishi et al., 2002).  
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Following cell stress, the soleus muscle has also been shown to induce hsp72 for 
long periods (Locke et al., 1991, Oishi et al., 2002), while fast-twitch muscle 
displays a rapid but short-lived HSR, with hsp72 peaking after 1-2hrs then steadily 
declining (Kayani et al., 2008a, Kayani et al., 2008b). Therefore, it is possible that 
the differential vulnerability of fast and slow-twitch muscles to denervation (Lowrie 
and Vrbova, 1984) and degeneration (Frey et al., 2000, Fischer et al., 2004) in ALS 
is related to, or at least influenced by a difference in the hsp profile of these two 
muscle fibre types. This possibility is investigated in this Thesis in Chapter 4.  
 
1.12   Therapeutic strategies for ALS 
At present, Riluzole, a glutamate inhibitor, is the only licensed drug for treating ALS 
patients. However, Riluzole’s success is limited (Bensimon et al., 1994). In mSOD1 
mice, presymptomatic treatment with Riluzole can delay disease onset and 
extends survival (Yanagisawa and Shindo, 1996, Ludolph et al., 2010). Thus, a 
considerable research effort was focused on identifying novel therapeutic targets 
for ALS. Some of these therapeutic strategies are summarised in Table 1.5. The 
multi-factorial nature of the ALS suggests that a therapeutic strategy that can act 
on a variety of pathological mechanisms within the disease may be more 
successful (see Table 1.6). Indeed, research has shown that treatment combining 
Riluzole with Minocycline (a microglial inhibitor) plus nimodopine (a blocker of 
voltage-gated calcium channels) exerts significantly greater beneficial effects in 
mSOD1 mice on disease progression and lifespan than is achieved individually 
with these agents (Kriz et al., 2003).  
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Table 1.5: ALS therapies 
Therapy Mechanism Increase in 
lifespan 
Reference 
AR-R 17,477 nNOS 
inhibition 
13% (Facchinetti et al., 
1999) 
Riluzole Anti-
glutamate 
10.5% (Traynor et al., 
2006) 
Arimoclomol  HSP co-
induction 
22% (Kieran et al., 2004) 
Celecoxib COX2 
inhibition 
25% (Drachman et al., 
2002) 
NDGA  Inhibition of 
TNFα 
release 
32% (West et al., 2004) 
WHI-PI3I Tyrosine 
kinase 
inhibition 
49% (Trieu et al., 2000) 
ZVAD-fmk Caspase 
inhibition 
22% (Li et al., 2000) 
High energy 
diet 
Metabolic 
dysfunction 
20% (Dupuis et al., 
2004) 
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Table 1.6: Combined therapies for ALS 
Combined therapies ALS 
model 
Lifespan 
(%) 
References 
Riluzole & Minocycline & 
nimodopine 
SOD1G37R 12% (Kriz et al.,2003) 
Creatine & Celecoxib/ 
refoecoxib 
SOD1G93A 29% (Klivenyi et al., 
2004) 
Creatine & Minocycline SOD1G93A 28% (Zhang et al., 
2003) 
Exercise & insulin growth 
factor (IGF-I) 
SOD1G93A 31% (Kaspar et al., 
2005) 
 
1.12.1 Manipulation of the HSR as a disease modifying therapy for ALS 
The HSR has been targeted as a therapeutic approach in several 
neurodegenerative disorders, including ALS (Kurthy et al., 2002, Rakonczay et al., 
2002, Kalmar et al., 2003, Phukan, 2010). This pathway has been manipulated in 
NMD models both genetically with varying success; for example, Manipulation of 
the HSR in the nervous system has been shown to be neuroprotective (Kalmar and 
Greensmith, 2009). Adachi et al. 2003 shows that the overexpression of hsp70 in a 
model of SBMA ameliorated disease. However, the overexpression of hsp70 in 
mSOD1 mice by crossing transgenic hsp70 mice with transgenic mSOD1 mice did 
not result in a significant improvement in disease progression (Liu et al., 2005) as 
hsp70 became sequestered in aggregates and was therefore unable to undertake 
its cytoprotective function. Likewise, disease progression in hsp27/mSOD1 
transgenic mice remained unchanged (Krishnan et al., 2006, Krishnan et al., 2008).  
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1.12.1.1 Pharmacological manipulation of the HSR in ALS: a therapeutic 
strategy 
Pharmacological manipulation of the HSR has had some significant success in 
improving disease progression in animal models of ALS. Treatment with 
exogenous hsp70 has been shown to increase motoneuron survival, motor function 
innervation and lifespan in mSOD1 mice (Gifondorwa et al., 2007). Equally, 
pharmacological manipulation of the HSR response has increased lifespan in 
mSOD1 mice (Kieran et al., 2004, Kiaei et al., 2005).  
 
There are a small number of therapeutic compounds that induce the HSR in cells. 
Of these compounds, two drugs that can induce the HSR in mammals have been 
shown to manipulate the HSR in ALS (Traynor et al., 2006). These  are Celastrol 
and Arimoclomol. However, they have slightly different modes of action. Celastrol 
is an anti-inflammatory triterpene that induces the HSR Allison et al., 2001). 
Arimoclomol is a hydroxylamine derivative that co-induces the HSR and has 
powerful cytoprotective capabilities (Kurthy et al., 2002) 
 
HSR inducers, such as Celastrol, are able to initiate the HSR in a cell without prior 
stress, while co-inducers like Arimoclomol are only able to enhance an already-
initiated HSR. Co-inducers are likely to be a safer way of manipulating the HSR, as 
they only augment a response that is already occurring, while HSR inducers, as 
the name suggests, can induce the HSR, even in unstressed cells, causing 
potentially pathological events and may even act as cell stressors. A table detailing 
known inducers and co-inducers of the HSR can be found in Table 1.7.  
 
In vivo, both Celastrol and Arimoclomol have been reported to be cytoprotective 
within the CNS of mSOD1 mice (Kieran et al., 2004, Kiaei et al., 2005). Treatment 
of mSOD1 mice with Arimoclomol improves motoneuron survival, motor function 
and increased the lifespan of mSOD1 mice by 22% (Kieran et al., 2004). Treatment 
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with Arimoclomol has also been shown to decrease the prevalence of ubiquitin-
positive aggregations within the motoneuron (Kalmar et al. 2008). 
 
Table 1.7: Pharmacological agents that induce/co-induce the HSR 
Compound Inducer/ co-inducer 
 
Reference 
Sodium salicylate Inducer (Jurivich et al., 1992) 
Indomethacin Inducer (Locke et al., 2002) 
Geldanamycin Inducer 
(Winklhofer et al., 
2001) 
Arachidonic acid Inducer (Zeke et al., 2005) 
Geranylgeranylacetone Inducer (Endo et al., 2007) 
Carbenoxolone Inducer 
(Kawashima et al., 
2009) 
Polaprezinc Inducer (Ueda et al., 2009) 
Paeoniflorin Inducer (Yan et al., 2004) 
Glycyrrhizin Co-inducer (Yoh et al., 2002) 
Celastrol Inducer (Brown, 2007) 
Arimoclomol Co-inducer (Kieran et al., 2004) 
Curcumin Co-inducer (Chang, 2001) 
 
 
1.12.2 Muscle as a therapeutic target in ALS 
The earliest signs of pathology in ALS manifest in the periphery, at the NMJ 
(Fischer et al., 2004). A number of therapies has therefore been designed to target 
the muscle in ALS (Turner and Talbot, 2008) or as a target to administer potential 
therapies and this has had some success. Treatment with various trophic factors 
administered to the muscle has been shown to alleviate symptoms of the disease 
in mSOD1 mice (Ates et al., 2007). Recent studies have shown that trophic factors 
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such as muscle Glial cell derived neurotrophic factor (mGDNF) and insulin-like 
growth factor (IGF-I) /Mechano-growth factor (MGF) promote motoneuron survival 
and function in mSOD1 mice (Yamamoto et al., 2001, Kaspar et al., 2003, 
Dobrowolny et al., 2005, Li et al., 2007, Riddoch-Contreras et al., 2009). 
Furthermore, Li et al. (2007) have uncovered evidence that only GDNF derived 
from muscle has neuroprotective qualities. Mice that were given intramuscular 
grafts of genetically modified myoblasts that overproduced GDNF displayed 
reduced denervation and had an increased lifespan (Mohajeri et al., 1999). 
Yamamto et al. (2001) demonstrated that these trophic factors enter the 
motoneuron via retrograde transport. Despite the obvious benefits that GDNF and 
IGF have on elements of muscle function in mSOD1 they are unable to significantly 
increase the lifespan of the mice (Suzuki et al., 2007a).  
 
1.13 Aims of Thesis 
The overall aim of the Thesis is to investigate the role of muscle in disease 
progression in the SOD1 mouse model of ALS. This will be achieved by 
characterising the stress induced changes that occur in mSOD1 skeletal muscle 
during disease progression. In addition, since our group has previously established 
that upregulation of the HSR in the CNS by treatment with Arimoclomol has been 
beneficial in mSOD1 mice, I will examine whether some of these positive effects 
are due, at least in part, to an enhanced HSR in skeletal muscle. Furthermore, in 
view of the established differential vulnerability of fast and slow-twitch muscle to 
ALS pathology, I will also examine whether there is an intrinsic difference in the 
stress response of fast and slow-twitch muscles and investigate the effects of 
treatment with Arimoclomol on this response. 
   
Therefore in this thesis I will address the following questions: 
 What are the pathological effects of mSOD1 expression in muscles of 
mSOD1 mice? Do these effects differ between fast and slow-twitch 
muscles?  
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 Does pharmacological upregulation of the stress response have an effect on 
muscle pathology in the mSOD1 mouse model of ALS? 
 Is there an intrinsic difference in the vulnerability of fast and slow-twitch 
muscle fibres to cellular stress, which may increase their susceptibility to 
ALS pathology? 
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Chapter 2 : Methods 
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2.1  Introduction 
A variety of methods were utilised to investigate muscle and NMJ pathology, and 
these methods are outlined in this Chapter. Details of the specific methods 
employed in each individual results Chapter are also indicated at the start of each 
Chapter. At the beginning of each results Chapter, the specific methods employed 
will also be indicated.  
 
2.1.1 Breeding and maintenance of transgenic mouse colonies 
All experimental mice used in this study were maintained and bred in the Biological 
Services Unit at the Institute of Neurology, University College London. Every effort 
was made to ensure that reduction, refinement and replacement was considered 
during the design of these experiments, in order to minimise the number of mice 
used and maximize [maximise] their welfare. All experiments were carried out 
under license from the Home Office, in accordance with the Animals (Scientific 
procedures) Act 1986 and following approval from the Institute of Neurology Ethical 
Review Committee.  
 
Transgenic mice carrying a human SOD1 gene with a G93A mutation (TgN [SOD1-
G93A] 1Gur) were originally purchased from Jackson Laboratories (Bar Harbour, 
ME). In addition, mice overexpressing wild type human SOD1 (wtSOD1) were also 
obtained as a control for the overexpression of the SOD1 protein. These two 
colonies were maintained by breeding male heterozygous carriers with female 
B6SJLF1 hybrids. The SOD1G93A (mSOD1) mice were originally generated and 
characterised by Gurney et al., (1994) and contain 25 copies of the mSOD1 
transgene. This line is commonly referred to as the high copy number line of 
mutant SOD1 mice. The wtSOD1 mice also contain 25 copies of the WT transgene 
and therefore a good control. 
 
All mice were housed in conventional cages, with woodchip bedding and cardboard 
tubes for environmental enrichment. The temperature was maintained at 19-23°C, 
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humidity at ~40-70%, with 12-15 air changes per hour. The mice were kept in a 12 
hours light/dark cycle, with access to food and water ad libitum. The mice were fed 
a pellet diet from hoppers placed in food racks, and water was provided in bottles 
via an overhead rack. The mice were monitored and weighed regularly. In this 
colony of mice, maximum body weight was usually attained at approximately 70 
days of age. Upon the onset of symptoms, the affected mSOD1 mice and their 
littermates were weighed weekly and the cage identified as housing an affected 
mouse. This ensured appropriate monitoring of each mouse. As hindlimb muscle 
paralysis progressed, the affected mice were provided with food pellets that had 
been soaked in water. This ensured efficient nourishment and hydration.  
 
2.1.2 Characterisation of SOD1G93A mice 
High copy number mSOD1 and wtSOD1 mice were used throughout all 
experiments described in this Thesis. Disease progression in our colony of mSOD1 
mice is well-established and the different stage are classified as: 
 Presymptomatic stage – less than 70 days, represented in this study at 45 
days 
 Symptomatic onset – taken as the time that the onset of hindlimb weakness 
is first observed. This occurs around 75 days. 
 An early symptomatic stage – when mice show clear signs of hindlimb 
weakness, which occurs at 90-100 days. 
 Late symptomatic stage – when hindlimb paralysis is significant and the 
mice have difficulties moving around the cage, at approximately 120 days. 
 Endstage – defined as when the mice have lost 15% of their body weight, or 
when they are no longer able to right themselves within 30 seconds after 
being placed on their sides. This usually occurs at approximately 125 days 
in male mice and 132 in female mice (Kieran et al., 2004). 
 
The Table below summarises these different disease stages and how they relate to 
the presentation of symptoms and pathology within the mSOD1 mice.  
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Table 2.1: The presentation of symptoms and pathology in mSOD1 mice 
during disease progression 
2.1.3 Genotyping of mSOD1 mice by polymerase chain reaction 
The mice carrying a human SOD1 transgene were identified by polymerase chain 
reaction (PCR) amplification of the transgene from genomic DNA. Tail snips 
(<0.5cm) were taken days after birth or ear notches were collected just before 
weaning. This procedure was carried out using local anaesthesia. The tissue 
sample was then digested using rapid digestion buffer. 
 
Disease stage Symptoms Pathology Age Reference 
Presymptomatic 
stage 
 
None Axonal 
transport 
dysfunction, 
mitochondrial 
dysfunction 
45 ±5 
days 
(Ilieva et al., 
2009) 
Disease onset Muscle 
fasciculation, 
Muscle 
weakness,  
Motoneuron 
death, reactive 
tSCh, NMJ 
denervation 
75 ±5 
days 
(Fischer et 
al., 2004) 
Early symptomatic 
stage 
Weight loss, 
further 
weakness 
Decreased 
muscle 
fatigability and 
force 
100 ±5 
days 
Kieran et 
al., 2004, 
Atkin et al., 
2005 
Late symptomatic 
stage 
Hindlimb 
paralysis 
Severe muscle 
atrophy, muscle 
fibre type 
alterations, 
extensive 
denervation 
and 
motoneuron 
death 
120 ±5 
days 
(Atkin et al., 
2005) 
Endstage 15% loss in 
body weight 
80% 
motoneuron 
death and 
muscle atrophy 
125/132 
days 
(Frey et al., 
2000, 
Fischer et 
al., 2004) 
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For PCR, 2.5µl of each DNA sample was added to a reaction tube that contained 
17.65µl sterile water, 2.5µl PCR buffer, 0.75µl MgCl2 (50mM), 0.5µl dNTP solution, 
0.25µl of both forward and reverse primers for the endogenous SOD1 enzyme and 
human mutant SOD1 enzyme, and 0.1µl Taq polymerase to make the final volume 
of 25µl. In order to differentiate the human transgene from murine SOD1, primers 
with the following sequences were used: 
 
5’ CAT CAG CCC TAA ATC TGA 3’ 
5’ CGC GAC TAA CAA TCA AAG 3’. 
 
The samples were then temperature cycled, as summarised in Table 2.2.  
 
Table 2.2: Summary of the cycles involved in PCR analysis of mSOD1 
samples  
 
 
 
 
 
 
 
 
The PCR products were subsequently visualised by gel electrophoresis by running 
10µl of each PCR product on a 2% gel agarose gel at 60mV for 40 minutes.  
No. of cycles Temperature Duration of cycle 
1 95°C 3 minutes 
36 95°C 30 seconds 
36 60°C 30 seconds 
36 72°C 45 seconds 
1 72°C 2 minutes 
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2.2  In vivo experiments 
2.2.1 Treatment with Arimoclomol 
In some experiments, the effect of intraperitoneal (i.p.) treatment with Arimoclomol 
was examined in mSOD1 mice. The mice were randomly assigned to one of two 
treatment groups: (A) Arimoclomol (10mg/kg; i.p.) or (B) Saline (10ml/kg; i.p.). Both 
mSOD1 and WT mice were treated daily from 35 days until the tissue was 
harvested and stored as detailed below. 
 
2.2.2 Muscle dissection  
Experimental mice were terminally anaesthetised using 4% choral hydrate, 
(1ml/100g body weight i.p.). Under anaesthesia, unless stated otherwise, the right 
soleus and TA muscles of each mouse were removed and cooled in isopentane, 
then frozen and then stored at -80˚C for immunohistochemical analysis. The left 
soleus and TA muscles were removed, snap frozen in liquid nitrogen and stored so 
that they could be used for western blot analysis. In some experiments, the soleus 
and EDL muscles were removed for the analysis of muscle innervation. For these 
experiments, muscles were dissected fresh and fixed as described in Chapter 3. 
 
2.2.3 Immunohistochemistry 
Cross sections of muscle were serially cut on a cryostat at 12µm. These sections 
were collected onto polyornithine coated glass slides and were fixed with a chilled 
Methanol/Acetone (1:1) fixative solution for 1 minute. The sections were then 
rinsed with a PBS (pH 7.4) solution and incubated with a blocking solution of 5% 
milk fat and 3% normal serum for one hour at room temperature. The blocking 
solution was then removed and the sections rinsed in PBS (3x 5 minutes). The 
sections were incubated in primary antibody in PBS, overnight at 4°C. Following 
incubation, the sections were washed in PBS (3x 5 minutes) and were incubated 
with secondary antibody diluted in PBS, at the appropriate concentration, for 2 
hours at room temperature. Following this, the sections were rinsed again as 
before and incubated with the necessary fluorophore diluted in PBS for one hour at 
room temperature. The sections were then rinsed in PBS (3x 5 minutes) and 
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coverslipped using dakocytomation (DAKO) mounting medium. Detailed 
information regarding all primary and secondary antibodies used in this Thesis and 
their concentrations can be found in Tables 2.3 and 2.4, respectively. 
 
2.2.4 Mouse-on-mouse Immunohistochemistry 
When using antibodies raised in mice, on tissue sections from mice, a mouse-on-
mouse (MOM) kit was used to reduce cross reactivity (MOM kit, Vector labs, cat 
#BMK-2202). The first step involved blocking endogenous peroxidase activity by 
incubating sections in 0.3% H2O2 for 30 minutes. Sections were incubated for 1 
hour in mouse IgG blocking reagent at room temperature.  
 
Table 2.3: Primary antibodies used 
Name of 
antibody 
IHC WB Code Company 
Anti- hsp90 1:100 1:1000 SC: 7947 Santa Cruz 
Anti-hsp72 1:250 1:2000 SPA- 810 Stressgen 
Anti-hsp60 1:100 1:1000 Santa Cruz: N-
20 
Santa Ruz 
Anti-hsp25 1:200 1:2000 SPA-801 Stressgen 
Anti-nNOS 1:100 1:1000 SC- 648 Santa Cruz 
Anti CD11b 1:100 - ab53187 Abcam 
Anti- Myosin 
heavy chain I & 
II 
1:10 - NCL-MHCs 
and NCL-MHCf 
Novocastra 
Anti-iNOS 1:500 1:2000 ab3523 Abcam 
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Table 2.4: Secondary antibodies used 
Name of antibody IHC WB Code Company 
Goat anti-rabbit IgG antibody 
Alexa Fluor 488 conjugated 
1:200 - A11034 Invitrogen 
Goat anti-rabbit IgG antibody 
Alexa Fluor 569 conjugated 
1:200 - A21069 Invitrogen 
Rabbit anti –goat IgG antibody 
FITC conjugated 
1:200 - Ab5750 Abcam 
Swine anti-goat IgG HRP - 1:2000 ACI0404 Invitrogen 
Goat anti-rabbit IgG HRP - 1:2000 65-6120 Invitrogen 
Goat anti-mouse IgG HRP - 1:2000 62-6520 Invitrogen 
 
After incubation, sections were rinsed twice in PBS for two minutes each. Sections 
were then incubated in MOM diluents for 5 minutes before incubation in primary 
antibody at the appropriate concentration, for 30 minutes at room temperature. 
This was followed by two 2-minute rinses in PBS, and MOM biotinylated IgG 
reagent was then applied for 10 minutes before incubation with Alexa 488 for 1 
hour. The sections were then rinsed three times in PBS for 5 minutes and mounted 
with DAKO fluorescent mounting medium. 
 
2.2.5 Silver cholinesterase staining of nerve terminals and endplates 
Freshly removed EDL and soleus muscles were fixed in a slightly stretched 
position using buffered 4% formaldehyde fixative (40% Formaldehyde, 10% CaCl2, 
5%MgCl2, 1% CdCl2.21/2H20) in Veronal Acetate buffer for 6 hours. Muscles were 
then incubated in 10% sucrose overnight at 4°C. Longitudinal sections (40µm 
thick) were then cut on a freezing microtome and held as free floating sections in 
distilled water on ice for 10 minutes. The muscle sections were then incubated on 
ice for 20 minutes in an acetylcholine iodide solution (0.04% acetylcholine iodide, 
56% 0.1M sodium hydrogen maleate, 4% 100mM tri-sodium citrate, 8.7% 30mM 
copper sulphate, 8.7% distilled water, 8.7% 5mM potassium ferricyanide, and 13% 
sucrose). Following a brief wash in distilled water for 30 seconds, muscle sections 
were immersed in potassium ferricyanide solution (0.25% potassium ferricyanide) 
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for 9 minutes. The sections were then processed for silver in order to visualise 
axon terminals, and were then incubated in a silver solution (0.1% CaCO3, 0.06% 
CuSO4.5H2O, 10%AgNO3) for 45 minutes at 37°C. The sections were then rinsed, 
immersed in reducer solution (1%C6H4(OH)2, 10%Na2SO3) and monitored under a 
dissection microscope, in order to determine nerve terminal staining. The muscle 
sections were then washed in water, mounted on gelatinised slides and 
coverslipped Di-n-butylPhthalate in Xylene (DPX) mounting solution. The extent 
and pattern in innervation was examined and recorded under a light microscope. 
 
2.2.6 Succinate dehydrogenase staining 
Some transverse muscle sections were also stained for succinate dehydrogenase 
(SDH) activity: an indicator of the oxidative capacity of muscle fibres.   
 
A working solution was prepared, which consisted of 0.1M phosphate buffer, 
pH7.6, 1M sodium succinate, 15mM nitroblue tetrozolium, 0.1M potassium cyanide 
and 10mM phenazine methosulphate, according to the protocol described by 
Nachlas et al. (1957). The working solution was prepared and filtered; the 
photosensitive solution was subsequently stored in a brown glass bottle, away from 
light. Before sections were treated with the solution, both sections and an 
appropriate volume of working solution were heated to 37°C in an incubator for 20 
minutes. Muscle sections were then incubated in this solution at 37°C for 5 
minutes. Following incubation, sections were then rinsed on 0.9% NaCl for 1 
minute followed by dehydration in graded alcohols (70%, 90% and then two rinses 
in 100%). Sections were then cleared with histoclear for two minutes each. 
Coverslips were then mounted onto the slides with DPX mounting solution. 
 
2.2.7 Muscle homogenisation 
The snap frozen, dissected hindlimb muscles were thawed and homogenised in 
lysis buffer in a 1:3 ratio (5mM Tris, 2% SDS, 2mM EDTA, 2mM EGTA, 2mM 
phenylmethylsulfonylfluride (PMSF), 10µM leupeptin pH6.8). In each experimental 
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group, the homogenate consisted of a minimum of three muscles were pooled in 
order to provide a single sample for specific muscles (TA, EDL and soleus). Debris 
was removed by low speed centrifugation at 1000xg for 10 minutes and the 
supernatant collected. Protein levels were then established and normalised using a 
protein assay (Bio-Rad, cat# 500-01116) and protein content was determined 
using a BSA standard curve, which was read at absorbance 750nm. Samples were 
diluted with a 1:1 ratio with SDS-PAGE sample buffer (0.5M Tris-HCL, pH 6.8, 
glycerol, 10% (wt/vol) SDS, β-Mercaptoethanol and 1.0% bromophenol blue) and 
then heated to 95°C for 5 minutes before SDS-PAGE. 
 
2.2.8 Protein Assay 
Protein levels were determined using a BioRad assay and BSA standards (0.1, 
0.25, 0.5, 0.75, 1, 1.5mg/ml). Following the calculation of protein content, protein 
levels were normalised for western blotting. Western blot samples were aliquoted 
and stored in -80ºC until needed. 
 
2.2.9 Western blotting 
Hsp, nNOS and iNOS levels were examined in a fast and slow-twitch muscle in 
mSOD1 mice using western blotting. For each Western blot described in this 
Thesis, muscles from at least three different mice were pooled, providing one 
sample for each experimental group. This sample was run in duplicate in each blot 
and each western blot was repeated at least twice. Equal amounts of protein were 
loaded and electrophoresed using an acrylimide SDS gel and separated at 160mV 
for 60 minutes (Laemelli, 1970). The protein was then electrophoretically 
transferred to Hybond tm ECL TM nitrocellulose membrane in a buffer consisting of 
25mM Tris, 192mM glycine and 20% (v/v) methanol. For immunodection, non-
specific binding sites were blocked with 5% non-fat dried milk and 0.1% Tween X-
100 in PBS for 1 hour at room temperature. The blots were then incubated in 
primary antibody in 2.5% non-fat dried milk and 0.1% Tween X-100 overnight at 
4°C. After three washes in PBS containing 0.1% Tween, for 20 minutes each, the 
membranes were incubated in secondary antibody at a dilution of 1:2000 in PBS, 
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containing 0.1% Tween, for 2 hours. The membranes were then rinsed three times, 
for 20 minutes each, in PBS with 0.1% Tween and subsequently treated with a 
chemilumescent detection reagent (ECL TM, Amersham Pharmacia Biotech, cat: # 
RPN2106).   
 
The blots were then visualised using Kodak films and subsequently fixed. For each 
blot a loading control was also run. Western blot line densities of β-actin were 
established using ImageQuant software. The line densities of all bands were 
normalised against line densities of β-actin bands. Line density values were then 
represented as a percentage of the corresponding WT line densities for ease of 
comparison.  
 
2.2.10 Choline Acetyltransferase Assay 
ChAT activity was assessed using a sensitive radiochemical bioassay in which [1-
14C] acetyl-CoA and choline were used as substrates and the radioactivity of the 
reaction product was measured (Ellman et al., 1961). The TA, EDL and soleus 
muscles were dissected from WT and mSOD1 mice and stored in liquid nitrogen. 
They were then thawed and immediately processed for the assessment of ChAT 
activity. 
 
For each experimental group, muscles from at least three mice were analysed. 
Muscle homogenates (5%w/v) were prepared in 10mM eythlenediamine tetra 
acetate, pH7.4, containing 0.5% Triton X-100, to ensure the total release of 
enzyme activity. The muscle homogenate was incubated with an incubation 
medium containing (final concentration): 0.4mM [1-14C] acetyl-CoA (50.0mCi/mM 
Amersham), 300mM NaCl, 50mM sodium phosphate buffer (pH7.4) and 0.1mM 
eserine. The reaction was initiated by mixing each homogenate with 25µl of the 
incubation medium, and before transferring this solution to a 37°C water bath for 
one hour. The reaction was terminated by adding 4.5mls of 10mM sodium 
phosphate buffer (pH7.4, 4°C). All samples were assayed in duplicate, including 
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blanks. The solution was poured into a scintillation vial along with 2ml of 
acetonitrile 0.5% tetraphenylboron (Kaligonost) and 10ml of toluene scintillation 
mixture (0.5% 2,5diphenyloxazole and 0.02 1,4-bis[phenyl-2-oxazoly]-benzene;2,2-
p-phenylene-bis[phenyloxazole]). The vial was shaken gently for 1 minute in order 
to extract the acetylcholine into the toluene phase, leaving the acetyl-CoA in the 
aqueous phase. The two layers were allowed to separate for 10 minutes before 
measurement in a Beckman liquid scintillation spectrometer. Enzymatic activity 
was calculated as counts per minute (CPM) of C-14. The assay was repeated at 
least twice to ensure that a similar and reproducible pattern of ChAT activity was 
obtained from each experimental condition. 
 
2.2.11 Acetyl Cholinesterase Assay 
Acetyl cholineEsterase (AChE) activity in TA, EDL and soleus muscles was 
quantified using a colorimetric assay based on methods described in Ellman et al 
(1961) and Nostrandt (1993) with slight modifications. A 1% solution in 
homogenised medium (pH7.4, 0.4 10mM EDTA, 0.5% Triton X-100) was made. 
The homogenised tissue was incubated for 35 minutes at room temperature with 
2.5mM DNTB and 5mM acetylthiocholine iodide substrate. At the end of the 
reaction, optical density was measured at 412nm using a spectrophotometer 
(FLOUstar Omega, BMG Labtech). Optical densities were compared to a standard 
curve that was generated using the assay reaction buffer and L-Glutothione as a 
positive control dilution series. The colorimetric changes were measured and 
analysed using Omega software (BMG Labtech). Each sample was run in triplicate. 
For each sample, the results were correlated with readings obtained from a 
negative control sample containing the AChE inhibitor erserine. This enables the 
exclusion of any contribution that other esterases might make to the experimental 
results. Results were then calculated as the nmol of ACh converted per min per mg 
tissue (nmol ACh/min/mg tissue). 
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2.2.12 Imaging 
Unless otherwise stated, in this study all sections were examined under fluorescent 
microscope (Leica) and images were acquired using Leica Imaging software. On 
some occasions, images obtained using confocal microscopy were acquired using 
a Zeiss 510 Laser Scanning confocal microscope (Oberkocken, Germany).  
 
2.3   In vitro experiments 
2.3.1  Preparation of culture plates 
Glass coverslips were sterilised in the Class II microbiological safety unit, by 
passing through the flame of a Bunsen burner and then placed into a well of a 
culture plate. A solution of gelatin (2mg/ml in sterile PBS) was prepared and 500µl 
was added to each well. The plates were left overnight in an incubator. The 
following day, the gelatin was removed and the plates were left to dry for 1 hour in 
a fume hood. 
 
2.3.2  Primary mixed muscle cultures 
Primary hindlimb muscle cultures were prepared, according to a protocol described 
by Bryla et al. (2001). Following the determination of genotype, P0-P3 pups were 
decapitated, the hindlimb was skinned, and the feet removed. The hindlimb 
muscles were dissected from the bone and minced with sterile forceps. The 
minced muscles were maintained in Hank’s balanced salt solution (HBSS) with 
penicillin-streptomycin (5000 units/ml: HBSS - Invitrogen, Paisley, UK) 
supplemented with 1ml penicillin- streptomycin per 50ml HBSS, until genotyping 
was complete. A collegenase solution of penicillin-streptomycin enriched HBSS 
with 0.01% collegenase IV, and muscle media was prepared (79% Dulbecco’s 
Modified Essential Medium (DMEM; Invitrogen, Paisley, UK: supplemented with 
1% penicillin-streptomycin: 20% foetal calf serum). The minced muscle was pooled 
according to genotype, and then each muscle from genotype was cultured 
separately.  
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The pooled muscle tissue was transferred into a 0.01% collegenase IV solution 
(PBS: 5% penicillin streptomycin). The solution was incubated in a waterbath at 
37°C for 15 minutes, removed and triturated with a pipette 20 times and then 
replaced into a waterbath. This process was repeated once. The solution was 
incubated for another 15 minutes and triturated 10 times. It was removed from the 
waterbath and placed in a sterile hood and the solution was passed through a 
100µm mesh (Marathon, London, UK) into a 50ml falcon tube. The solution was 
then diluted with in muscle media to 1:2 ratio and then centrifuged at 20°C for 5 
minutes at 200xg. The supernatant was discarded and the pellet resuspended in 
1ml of DMEM supplemented with 10% FCS, 1% penicillin streptomycin. Following 
this, the cell density was determined using a haemocytometer. The cells were 
seeded at 5x105cells/cm2 for immunoflourescence and 1x106cells/cm2 for cell 
viability experiments. The cells were seeded onto the gelatin coated 9mm 
permanox chamber coverslips for imaging or 96-well-plates for assays. 
 
The cells were maintained in muscle media in a sterile 37°C, 5%CO2 humidified 
incubator for 7 days, in order to allow for maturation of myotubes. The percentage 
of muscle cells within the muscle cultures was determined by immunostaining the 
cultures for desmin and myosin, a marker for muscle cells, as well as DAPI, a 
nuclear marker (0.01% Molecular probes, Paisley, UK). The percentage of DAPI 
stained desmin/myosin positive cells was calculated. Cultures with less than 40% 
myogenicity were discarded. 
 
2.3.3 Primary fast and slow-twitch muscle cultures from neonatal mice 
In some experiments, primary muscle cultures were established from WT, mSOD1 
and wtSOD1 transgenic neonate mice using a modified protocol initially described 
by Bryla et al. (2001) and seeded at 1,000,000 cells/cm2. Neonates were 
genotyped one day before muscle dissection. The soleus and TA muscles for from 
each genotype were pooled appropriately, so that 6-8 TA and 6-8 soleus muscles 
of each genotype were used for every culture. The soleus muscle was taken as a 
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predominantly slow-twitch muscle culture, and the TA muscle as a fast-twitch 
muscle culture.  
 
2.3.4 Neuronal cell lines 
SH-SY5Y (ECACC; Catalogue number 94030304) cell lines originally derived from 
female, human neuroblastoma cells were grown in Neural Basal media that 
contained Dulbecco’s modified Eagle’s medium (DMEM-F12) containing 15% FCS, 
2mM L-glutamine, 10 IU/ml penicillin, 100µg/ml streptomycin and 1% final volume 
non-essential amino acids. Cells were maintained at 37°C in a saturated humidity 
atmosphere of 95% air and 5% CO2. Cells were then seeded onto uncoated 96-
well-plates at a cell density of 2000 cells/cm2
 
. 
 
2.3.5 Glucose deprivation (metabolic) stress 
All experimental procedures were performed on fully differentiated cells at 8-10 
days in vitro (DIV). In glucose deprivation experiments, the cells were incubated in 
glucose-free DMEM supplemented with 2% FCS and 1% penicillin-streptomycin for 
24 hours. The cultures were then processed for the assessment of cell viability 
using an LDH assay as detailed in Section 2.3.10. Control cultures were incubated 
with a high glucose DMEM (4.5g/l) supplemented with 2% FCS, 1% penicillin-
streptomycin media for 24 hours.  
 
2.3.6 Contractile/oxidative stress (caffeine) stress 
At 8 DIV, spontaneous contraction of myotubes is present, signalling the maturity 
of the contractile machinery in muscle cultures. This time point was therefore 
chosen to assess the effects of caffeine-induced stress. Application of caffeine, a 
Ryanodine receptor (RyR) agonist, initiates Ca2+ release from the sarcoplasmic 
reticulum (SR), resulting in the activation of the ECC machinery. Over time, this 
results in increased sarcoplasmic Ca2+ resulting in the production oxidative stress 
and contractile damage. At 8 DIV, muscle cultures were incubated with 150µl 
muscle media enriched with 2% FCS, 1% penicillin streptomycin 1mM, 5mM or 
 69 
10mM caffeine for 24 hours. Following this, the supernatant was collected for an 
LDH cell viability assay and the pellet used for a protein assay.  
 
2.3.7 Glucose deprivation plus caffeine stress 
All experimental procedures were performed on fully differentiated cells at 8-10 
days in vitro (DIV). Muscle cultures were incubated with 150µl glucose-free muscle 
media enriched with 2%FCS, 1% penicillin streptomycin, 1mM, 5mM or 10mM 
caffeine for 24 hours. Following this, the supernatant was collected for an LDH 
assay and the pellet used for a protein assay.  
 
2.3.8 Preparation of Muscle-conditioned media 
Muscle-conditioned medium was prepared according to a modified protocol by 
Taylor et al. (2007). Mixed muscles were cultured as described above and were 
maintained and fed every 3–4 days. At 8 DIV, cultures were incubated in basal 
media (DMEM containing 2% FCS and 1% penicillin-streptomycin) for 48 hours. 
The media was collected from cultures and centrifuged at 400xg to remove free 
cells and membrane debris. The supernatant was then centrifuged at 20,800xg for 
1 hour. The pellet was resuspended in serum free muscle media. The protein 
content was then assessed and normalised using a protein assay, (section 2.2.8). 
The solution was then filter-sterilised and frozen at -80°C until use.  
 
2.3.9 Treatment of neuronal cells with Muscle-conditioned media 
SH-SY5Y cells seeded in a 96-well-plate were treated with MCM and left for 72 
hours. In some wells, the cells were treated with 2% Triton X-100 in DMEM, in 
order to determine the maximum LDH release. After 72 hours, a cell viability assay 
was carried out by means of an LDH assay. LDH levels in unexposed DMEM were 
taken to be the baseline and the maximal LDH release was taken from SH-SY5Y 
cell incubated with 2% Triton X-100. All subsequent values were then represented 
as a percentage of that maximum, which was given the value of 100%. 
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2.3.10 Cell viability assay 
Muscle cultures were assayed for LDH release as a measure of cytotoxicity 
following treatment with the biologically relevant stressors.  
 
Two control groups were set up. Unexposed media was assayed in order to 
determine the baseline amount of LDH in the media. Untreated wells incubated 
with 2% Triton X-100 were also used to determine the maximal LDH release, the 
LDH levels of media from muscle cultures exposed to a metabolic stress, 
contractile and oxidative stress, combined metabolic and oxidative stress or SH-
SY5Y cells exposed to MCM were then examined using the LDH assay kit, which 
contained solution 1 (assay buffer preparation) and solution 2 (LDH diaphorase). 
 
The 96-well-plates were centrifuged at 250xg for 5 minutes and the supernatant 
from each well was removed, leaving a pellet. The supernatant was placed into the 
corresponding wells in an empty 96-well plate. The pellet, which contained cells, 
was kept for protein analysis. Each experiment was repeated in six wells per plate 
and each experiment was undertaken at least four times.  
 
The assay required the addition of 100µl of Diaphorase (a catalyst) and 9.6ml INT 
(the dye solution). These were mixed and 100µl added to each well. The 96-well 
plate was incubated at room temperature in the dark for 15 minutes. Absorbance 
was measured at 490nm on a spectrophotometer. Absorbance values for each well 
was expressed as a percentage of the maximum LDH release determined by the 
addition of 2% Triton X-100, and then normalised against protein values obtained 
from a protein assay on the pellet. These values were then averaged to give a 
value for each condition. 
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2.3.11 Statistical analysis 
The results were analysed and the significance was set. All quantitative data is 
presented as the mean ± standard error of the mean. In Chapters, 3, 4 and 5, data 
was statistically assessed using the one-way ANOVA test on data from a 
multivariate group. This was then followed by analysis using the student’s t-test for 
comparisons between two groups. The level of significance was set as p<0.05, 
unless otherwise stated. 
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Chapter 3 : Pathological changes in muscle during 
disease progression in mSOD1 mice and the effect of 
treatment with Arimoclomol 
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3.1 Introduction 
The earliest clinical manifestation of disease in ALS patients and mSOD1 mice is 
muscle weakness and atrophy, resulting from the denervation of muscle (Frey et 
al., 2000, Fischer et al., 2004). This has motivated a number of therapeutic 
strategies focusing on limiting denervation and protecting muscle function. 
Furthermore, as recent findings report the differential vulnerability of fast and slow-
twitch skeletal muscle fibres to disease in ALS (Frey et al., 2000), two different 
muscle types, the fast-twitch EDL muscle and the slow-twitch soleus muscle, were 
studied. In this Chapter, the pathological changes that occur in fast and slow-twitch 
muscles were characterised and compared. 
 
3.1.1 Denervation in ALS occurs before motoneuron death 
Recent studies have suggested that mSOD1-mediated pathological events in the 
PNS may not be simply secondary to motoneuron death (Pinelli et al., 1991, Frey 
et al., 2000, Fischer et al., 2004, Hegedus et al., 2007). In fact, it was 
demonstrated by Fischer et al. (2004) that in mSOD1 mice, at 47 days, well before 
motoneuron death, 40% of endplates are already denervated. Results indicated 
that denervation precedes both motoneuron death and glial activation, two major 
components of the disease aetiology. This evidence has led to the controversial 
hypothesis that ALS may in fact be a ‘distal axonopathy’, with pathology originating 
from the distal axon and working back to the soma (Fischer et al., 2004). 
Furthermore, pathological changes at the NMJ in ALS recreate many of the events 
observed during NMJ development, when muscle provides trophic support to 
vulnerable motoneurons (Oppenheim and Haverkamp, 1988). This supports the 
possibility that mSOD1 muscle may influence motoneuron viability and 
susceptibility to stress, injury or disease. 
 
3.1.2 Differential vulnerability in mSOD1 muscle 
The onset of muscle atrophy and paralysis is not homogenous across muscle 
types, with fast-twitch muscles displaying preferential vulnerability to mSOD1 
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pathology (Frey et al., 2000). A few studies have suggested factors that may 
contribute to the preferential denervation, atrophy and paralysis of fast-twitch 
muscles in the disease. For instance, it was suggested that the differential plasticity 
of synapses present in fast and slow-twitch muscle contributes to the early and 
more aggressive denervation in mSOD1 mice (Santos and Caroni, 2003). 
Furthermore, a study by Frey et al., (2000) established that these endplates are not 
just simply more susceptible to mSOD1 pathology. They demonstrated that the 
application of Botulinum toxin-A to the mSOD1 muscle resulted in the early and 
preferential loss of innervation in fast-twitch muscle fibres in the gastrocnemius 
muscle, while slow synapses, in the medial region of the gastrocnemius muscle 
remained innervated. Their study revealed that this difference in vulnerability was 
the result of the increased ability of NMJs on slow fibres to sprout, following partial 
denervation of the muscle. However, as fast-twitch muscle remains vulnerable to 
pathology in a number of neuromuscular diseases and myopathies, it is likely that a 
number of factors contribute to the consistent preferential vulnerability of fast-twitch 
muscle to disease. 
 
3.1.3 Synaptic transmission in ALS 
Pathogenesis in ALS is characterised by the selective loss of motoneurons (Bruijn 
et al., 2004). At a late stage of disease, when motoneuron death is substantial 
there is a significant reduction in the synaptic transmission enzymes ChAT and 
AChE in the CNS and muscles of ALS patients and mSOD1 mice (Fernandez et 
al., 1986, Pinelli et al., 1991, Gurney, 1994, Yoshihara et al., 1998). Studies 
examining the expression of enzymes involved in synaptic transmission within the 
CNS indicate the involvement of AChE and ChAT during disease progression (Oda 
et al., 1995, Niebroj-Dobosz and Janik, 1999). However, it is not clear when 
synaptic enzyme activity is altered in the periphery and muscle, or how enzyme 
activity changes over the course of the disease.  
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3.1.4 Therapeutic targeting of muscle function in mSOD1 mice 
A number of therapies has been shown to improve mSOD1 motoneuron survival in 
vitro and in vivo; however, those that solely target the CNS have rarely translated 
into improved muscle function (Suzuki et al., 2007). However, skeletal muscle may 
also be a good therapeutic target as well as a delivery route for  potential 
neuroprotective treatment. Indeed, targeting of the muscle has proven more 
effective in improving muscle function, even when first used as a conduit to deliver 
neuroprotective agents to motoneurons. For example, with retrograde viral delivery 
of insulin-growth factor 1 (IGF-1), results in muscle hypertrophy, increased 
motoneuron survival and the preservation of muscle function in mSOD1 mice 
(Kaspar et al., 2003). Similarly, treatment with the IGF-1 splice variant, Mechano-
growth factor (MGF), which is expressed locally within the muscle, has been shown 
to induce muscle hypertrophy, as well as increase motoneuron survival (Riddoch-
Contreras et al., 2009). As such, it is possible that a therapy that targets events in 
the CNS as well as the periphery may be the most effective approach to modify 
disease progress in ALS. 
 
3.1.5 Upregulation of the Heat shock response as a therapeutic strategy for 
ALS 
In 2004, Kieran et al. demonstrated that the systemic delivery of Arimoclomol, a co-
inducer of the HSR, was sufficient to increase lifespan in mSOD1 mice by over 
20%, improve muscle function and increase motoneuron survival. Kalmar et al. 
(2008) showed that Arimoclomol reduced protein aggregation in motoneurons. 
Both papers successfully demonstrated Arimoclomol’s central effects, but it is not 
clear from these studies whether the improvement in muscle function was due 
wholly to Arimoclomol’s actions in the CNS or whether some of its effects may be 
solely within skeletal muscles of mSOD1 mice. 
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3.1.6 Aim 
The aim of this Chapter is to characterise the time course of muscle pathology in 
fast and slow-twitch muscle of mSOD1 mice, studying muscle innervation and 
changes in enzymatic markers of neuromuscular activity. In addition, this Chapter 
will investigate whether treatment with Arimoclomol can delay the early 
pathological changes occurring at the NMJ and in the muscle of mSOD1 mice. 
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3.2 Methods 
3.2.1 Animals 
The mice were housed and fed ad libitum as detailed in Chapter Two, Section 
2.1.1. mSOD1 transgenic mice were identified from an ear notch, using human 
SOD1 PCR as detailed in Chapter 2, Section 2.1.3.  In these experiments, male 
and female, age-matched mSOD1 mice and their WT littermates were examined at 
different stages of disease. These stages were detailed in Table 3.1. In some 
experiments, mice were treated as detailed in Chapter Two, Section 2.2.1. 
 
3.2.2 Muscle dissection  
The animals were terminally anaesthetised using 4% choral hydrate, 1ml/100g 
body weight administered intraperitoneally. Under anaesthesia, the soleus and 
EDL muscles from one side of one set of mice were taken and processed for 
analysis of muscle innervation (see Chapter 2, Section 2.5). The soleus, TA and 
EDL from the other side were removed for biochemical analysis of cholinergic 
enzymes (Chapter 2, Section 2.10 & 2.11). 
 
The TA, EDL and soleus muscle from a different set of mice were dissected, snap 
frozen in melting isopentane and stored at -80°C until processed for histochemical 
analysis.  
 
3.2.3 Morphological assessment of Muscle Innervation 
The silver cholinesterase stain is a combined stain, used for the simultaneous 
visualisation of both the motor nerve terminal and Acetyl Cholinesterase at the 
endplate. The stain employs potassium ferricyanide for the staining of 
cholinesterase, which labels the endplate, while silver impregnation allows for the 
detection of the nerve terminals (Namba et al., 1967). The detailed staining 
procedure is described in Chapter 2, Section 2.5. The stained muscle sections 
were analysed using a light microscope. For each muscle a minimum of 100 
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endplates from at least three animals per experimental group were examined and 
the following features assessed: 
 The level of innervation of each muscle. 
 The extent of polyneuronal innervation (PNI). 
 The extent of nerve terminal sprouting in the muscles. 
 Endplate size. 
An endplate was classified as denervated if the whole endplate surface was void of 
nerve terminal contact. Nerve terminal sprouts were identified the total number 
established for each muscle and the number of sprouts expressed as a ratio to the 
number of endplates examined. The extent of PNI was determined by counting the 
number of endplates that were innervated by more than one nerve terminal. This 
data was expressed as a percentage of the total number of endplates investigated 
for each muscle.  
 
3.2.4 Endplate size 
Endplate size in each muscle was examined at 45 days and 120 days of age, in 
sections of EDL and soleus muscle that had been stained with Silver 
Cholinesterase staining. The sections were examined under a light microscope and 
an image of each endplate taken at x20 magnification using a Leica camera. The 
circumference of each endplate was measured. A minimum of 150 endplates was 
assessed in each muscle examined, and a minimum of three muscles was 
examined for each experimental group (for details see Chapter 2, Section 2.5) 
 
3.2.5 Assessment of Cholinergic enzyme activity 
The activity levels of ChAT and AChE, two key enzymes involved in neuromuscular 
transmission, were examined as a measure of neuromuscular activity. This was 
carried out as detailed in Chapter 2, Section 2.10 & 2.11 (Ellman et al., 1961).  
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3.2.6 Succinate Dehydrogenase Stain 
A SDH stain was used in order to examine the oxidative profile of the muscles 
examined at 45 and 120 days of age. Muscle sections, cut on a cryostat 
transversely at 12µm were stained according to the protocol described by Nachlas 
et al. (1957).  
 
3.2.7 Statistics 
All data is presented as the mean ± standard error of the mean. Data were 
statistically assessed using the one-way ANOVA test on data from a multivariate 
group. This was then followed by the student’s t-test for comparisons between two 
groups. The level of significance was set as p<0.05, unless otherwise stated. 
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3.3 Results 
3.3.1 Denervation in fast and slow-twitch muscles of mSOD1 mice  
The changes in muscle innervation in the EDL and soleus muscles of mSOD1 mice 
was determined by the assessment of the following features: 
 The number of denervated endplates. 
 The number of polyneuronally innervated endplates. 
 The extent of nerve terminal sprouting. 
3.3.1.1 Denervation in EDL muscle of mSOD1 mice 
In the first instance, the extent of muscle denervation in WT mice was compared to 
that in mice that overexpressed wtSOD1. The results showed that in WT mice, at 
all ages studied, the number of muscle fibres that were denervated was minimal 
and an average of 3.2% (±0.3 SEM; n=5) of endplates were denervated.  In the WT 
EDL muscle, this was not significantly different from level of denervation in the EDL 
muscles of wtSOD1 mice, where 4.4% (±0.4 SEM; n=3; p=0.06) of endplates were 
denervated (Appendix 1). As wtSOD1 EDL muscle showed no signs of denervation 
in this study the changes in muscle innervation in mSOD1 mice were compared to 
muscles from WT mice only.  
 
During disease progression in mSOD1 mice, there was a steady increase in the 
proportion of denervated endplates. As shown in Fig.3.1, at 45 days of age, before 
the onset of symptoms, there was a small but significant percentage of denervated 
endplates, 8.0% (±0.4 SEM; n=5; p<0.05), compared to WT mice. By 75 days, 
24.2% (±1.0 SEM; n=4; p<0.05) of the endplates examined were denervated.  
Denervation in EDL muscle continued to increase as disease progressed, so that 
by 90 days, 31.3% (±3.2 SEM; n=4; p<0.01) of the endplates were denervated and 
by 120 days, 55.4% (±2.0 SEM; n=4; p<0.01) of the endplates in the EDL muscle 
were denervated. Treatment with Arimoclomol significantly reduced the extent of 
denervation from 75 days onwards (see Fig.3.1). At 45 days, 7.8% (±0.3 SEM; 
n=3; p=0.741) of the endplates were denervated in Arimoclomol treated mSOD1 
mice 
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Figure 3.1: Denervation in the EDL & soleus muscles of WT, mSOD1 and 
Arimoclomol treated mSOD1 mice  
The extent of denervation of EDL muscles in WT, mSOD1 and Arimoclomol treated 
mSOD1 mice was observed at 45, 75, 90 and 120 days of age stained by silver 
cholinesterase. The black arrow shows an example of a normally innervated endplate (A) 
and the white arrows shows a denervated endplate (B) in the photomicrographs. The 
extent of denervation in the EDL and soleus muscle at each stage of disease progression 
is summarised in the bar charts (C & D), respectively.  
n=4; *=p<0.05;**=p<0.01 ***=p<0.001; error bars=SEM; Scale bar=25µm  
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At 75 days, EDL from Arimoclomol treated mSOD1 mice was significantly less 
denervated than EDL from untreated mSOD1 mice, with 19.2% (±4.6 SEM; n=3; 
p<0.05). This preservation of innervation in Arimoclomol treated mSOD1 EDL 
muscle was maintained as disease progressed, so that at 90 days only 14.1% 
(±2.1 SEM; n=3; p=0.009) of the endplates were denervated in Arimoclomol 
treated EDL compared to untreated muscles. Even at 120 days only 20.5% (±2.0 
SEM; n=3; p=0.001) of endplates were denervated compared to 55% in untreated 
mSOD1 mice.  
 
3.3.1.2 Denervation in the soleus muscle of mSOD1 mice 
The extent of denervation in the soleus muscles was also examined (see Fig.3.1). 
In the soleus muscle of WT mice, from 45 to 120 days: an average of only 4.9% 
(±1.4 SEM; n=5) endplates. This was similar to that seen in wtSOD1 soleus muscle 
where 4.9% (±0.3 SEM; n=3; p=1.00) were denervated. Thus, the soleus muscle 
from WT mice was used as control.  
 
In mSOD1 soleus muscle, 9.4% (±3.2 SEM; n=4; p=0.245) of the endplates were 
denervated at 45 days, which was not significantly different from the normal levels 
of denervation observed in WT soleus muscle. Surprisingly, the extent of 
denervation increased only slightly with disease in mSOD1 mice and even at 75 
days, only 12.0% (±2.4 SEM; n=4; p=0.003) of the endplates were denervated and 
at 90 days only 14.7% (±1.7 SEM; n=4; p=0.004) of endplates were denervated. 
However, by 120 days, denervation was more extensive with 40.5% (±2.3 SEM; 
n=4; p=0.003) denervated endplates (see Fig.3.1). However, even at 120 days of 
age, the extent of denervation in soleus muscle of mSOD1 mice was not as great 
as that observed in EDL muscle, where 55.5% of endplates were denervated at 
120 days of age.  
 
Treatment with Arimoclomol had very little effect on denervation in the mSOD1 
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soleus muscle during the early stages of disease. However, at 120 days, although 
there was a significant level of denervation in untreated mSOD1 soleus, treatment 
with Arimoclomol only displayed 10.9% (±2.3 SEM; n=3; p=0.0003) denervation. 
 
3.3.2 Sprouting in mSOD1 mice 
Nerve terminal sprouting is a characteristic response of denervation and muscle 
paralysis and can be used as a marker of regeneration (Brown et al., 1981). Thus, 
sprouting was assessed in the EDL and soleus muscles of WT, mSOD1 and 
Arimoclomol treated mSOD1 mice at various disease stages. 
 
3.3.2.1 Sprouting in mSOD1 EDL muscle  
In WT EDL, only 1.1% (±0.5 SEM; n=3) of the endplates examined were innervated 
by sprouts, at all ages, therefore, the data from all ages studied was pooled in 
order to obtain a mean value (see Fig.3.2). The level of sprouting in the EDL 
muscle of mSOD1 mice differed considerably from WT mice. Even as early as 45 
days of age, EDL muscles in mSOD1 mice displayed a significant level of sprouting 
at the NMJ, with 6.4% (±2.0 SEM; n=3) of endplates innervated by sprouts, 
compared to WT EDL muscle (p=0.0239). As disease progressed, the level of 
sprouting increased, so that by 75 days, 24.3% (±5.6 SEM; n=4; p=0.0022) of 
endplates were contacted by sprouts. The extent of sprouting then began to 
decline and at 90 days 18.0% (±1.1 SEM; n=4; p=0.0001) of endplates were 
innervated by sprouts. At 120 days sprouting declined to only 7.3% (±1.4 SEM; 
n=4; p=0.0025). As can be seen in Fig.3.2, treatment with Arimoclomol increased 
sprouting at all ages studied. At 45 days, 9.2% (±3.5 SEM; n=3; p=0.4905) 
endplates were innervated by sprouts in Arimoclomol treated mSOD1 EDL muscle. 
By 75 days, sprouting had reached 30.7% (±6.0 SEM; n=3; p=0.4761) and by 90 
days, 25.3% (±3.1 SEM; n=3; p=0.0535). By 120 days, sprouting was significantly 
higher in Arimoclomol treated EDL muscle compared to untreated mSOD1 EDL 
muscle, with 25.4% (±1.4 SEM; n=3; p=0.003). 
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Figure 3.2:  Nerve terminal sprouting in the EDL and soleus muscle of WT, 
mSOD1 and Arimoclomol treated mSOD1 mice  
The extent of nerve terminal sprouting in the EDL and soleus muscles of WT, mSOD1 and 
Arimoclomol treated mSOD1 mice were established at 45, 75, 90 and 120 days of age. (A) 
An example of an EDL muscle stained with silver-cholinesterase, in which a nerve terminal 
sprout can be seen (arrow). The extent of sprouting in EDL and soleus muscles at all ages 
is summarised in the bar charts (B & C), respectively. 
n=4; *=p≤0.05; **=p≤0.01; ***=p≤0.001; error bars= SEM; Scale bar=50µm  
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3.3.2.2 Sprouting in the soleus muscle mSOD1 mice 
As seen in Fig.3.2, sprouting in the soleus muscle of WT mice did not change with 
age, and at all ages studied an average of 2.2% (±1.1 SEM; n=4) of endplates 
were innervated by sprouts. In the soleus muscle of mSOD1 mice, a significant 
increase in the extent of sprouting was only observed from 75 days onwards. At 75 
days, sprouting was 7.5% (±1.3 SEM; n=4; p=0.032). By 90 days, it had increased 
to 12.7% (±5.6 SEM; n=4; p=0.115). This level of sprouting was maintained, so that 
by 120 days of age 12.0% (±4.4 SEM; n=3; p=0.054) of endplates were innervated 
by a sprout, compared to WT.  
 
Treatment with Arimoclomol resulted in a marked increase in sprouting in soleus 
muscle, compared to untreated soleus muscle of mSOD1 mice (see Fig.3.2). At 75 
days, 11.5% (±4.4 SEM; n=3; p=0.362) of endplates investigated. At 90 days, this 
increase in sprouting was maintained, so that 19.3% (±4.5 SEM; n=3; p=0.4228) of 
endplates were innervated by sprouts, compared to untreated mSOD1 soleus 
muscle. By 120 days, 22.8% (±4.4 SEM; n=3; p=0.0142) of endplates were 
innervated by sprouts, compared untreated soleus muscle from mSOD1 mice.  
 
3.3.3 Polyneuronal innervation in mSOD1 mice 
Following denervation and the ensuing sprouting, some endplates can become 
polyneuronally innervated. Therefore, the extent of PNI in the EDL and the soleus 
muscles of WT, mSOD1 and Arimoclomol treated mSOD1 mice at different stages 
of disease were examined. 
 
3.3.3.1 Polyneuronal innervation in the EDL muscle of mSOD1 mice 
In WT EDL muscle at all stages examined, the level of polyneuronal innervation 
(PNI) was very low, and an average of 1.0% (±0.4 SEM; n=4) of endplates (Fig.3.3) 
was innervated by more than one nerve terminal. In the EDL muscles of mSOD1 
mice, as can be seen in Fig.3.3, PNI was minimal during all stages of disease.  
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Thus, at 45, 75, 90 and 120 days of age, the level of PNI in mSOD1 EDL muscles 
was 4.4% (±1.8 SEM; n=6; p=0.71), 3.9% (±0.7 SEM; n=5), 6.6% (±3.2 SEM; n=3) 
and 2.5% (±1.1 SEM; n=4; p=0.768), respectively. Statistical comparison with WT 
levels revealed that this slight increase in PNI in mSOD1 EDL muscles is not 
significant at any of the ages studied, except for 75 days of age, where the very 
low standard error in the data indicates that PNI at this age was statistically greater 
than in WT EDL (p=0.71; p=0.01; p=0.64 and p=0.77) for 45, 75, 90 and 120 days 
of age, respectively. However, despite this apparent increase in PNI at 75 days of 
age, it is clear that there is a very minimal increase the number of endplates 
contacted by more than one nerve terminal in EDL muscles of mSOD1 mice. 
 
Treatment with Arimoclomol increased PNI in the EDL muscles of mSOD1 mice at 
all ages studied, but this did not reach significance until 120 days of age. Thus, at 
45 days PNI was 5.1% (±1.9 SEM; n=3; p=0.84); at 75 days it was 7.2% (±1.5 
SEM; n=3; p=0.75), and at 90 days it was, 6.0% (± 0.8 SEM; n=4; p=0.95) 
compared to untreated mSOD1 EDL muscle. By 120 days, PNI had dramatically 
increased so that 14.9% (±1.1 SEM; n=3; p=0.0006) of the endplates in the EDL 
were polyneuronally innervated, compared to untreated mSOD1 EDL muscle. 
 
3.3.3.2 Polyneuronal innervation in the soleus of mSOD1 mice 
At all stages studied, the level of PNI in WT soleus muscle did not vary, and so all 
data from all ages studied was pooled. A total of 1.8% (±1.1 SEM; n=3) of the 
endplates were polyneuronally innervated. In mSOD1 mice, the extent of PNI at 
the NMJ of soleus muscle did not alter significantly over the course of the disease 
and was between 4.0-6.0% at all ages studied. As seen in Fig.3.3, following 
treatment with Arimoclomol, there was a slight increase in PNI after 75 days, but 
this only reached significance at 120 days, when 14.7% (±3.5 SEM; n=3; p=0.034) 
of all endplates were polyneuronally innervated compared to untreated mSOD1 
soleus muscle at the same stage of disease. 
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Figure 3.3: Polyneuronal innervation in the muscle of WT, mSOD1 and 
Arimoclomol treated mice 
The number of endplates contacted by more than one nerve terminal was established and 
expressed as a percentage of the total number of endplates examined. An example of an 
EDL muscle stained with a silver cholinesterase stain is shown in (A), in which a PNI 
endplate can be seen (arrowhead). The mean number of PNI endplates in the EDL and 
soleus muscles at each stage of disease is summarised in the bar charts (B &C), 
respectively.  
n=4; *=p<0.05; ***=p<0.001; error bars = SEM; Scale bar=25µm  
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3.3.4 Endplate size in mSOD1 mouse muscle 
Alterations in endplate size are a known to occur in circumstances of NMJ 
pathology. As mSOD1 mice exhibit significant NMJ pathology, it is possible that 
endplate size is altered.  Thus, the size of endplates in the EDL and soleus 
muscles was assessed in WT, mSOD1 and Arimoclomol treated mSOD1 mice at a 
presymptomatic stage (45 days of age), when denervation is low and then at late 
symptomatic stage (120 days of age), when denervation is high. 
  
3.3.4.1 Changes in endplate size in mSOD1 EDL muscle  
As can be seen in Fig.3.4, in WT mice, endplate size in the EDL muscle did not 
change significantly with age, so the data from all age groups was combined. The 
mean endplate size in WT mice was 787.54µm2 (±30.29 SEM; n=3). In mSOD1 
mice, the mean endplate size at 45 days, when fewer than 10% of endplates were 
denervated in the EDL muscle, was 613.27µm2 (±20.12 SEM; n=3). This was 
already 20% smaller than the mean endplate size in WT EDL muscle (p=0.0087). 
However, there was no further decrease in the mean endplate size in the EDL 
muscle of mSOD1 mice, so that at 120 days, the mean endplate size was 628µm2 
(±19.98 SEM; n=3; p=0.0117), compared to WT endplates. Treatment with 
Arimoclomol prevented this decrease in endplate size in mSOD1 EDL muscle. 
Thus, at 120 days, in mSOD1 EDL muscles, the average endplate size was 
725.05µm2 (±34.85 SEM; n=4; p=0.049), which was significantly larger than 
endplate size in untreated mSOD1 EDL muscle.  
 
3.3.4.2 Changes in endplate size in mSOD1 soleus muscle  
The average size of endplates in the soleus muscle was also examined. As the 
size of endplates in the soleus muscle of WT mice did not change significantly with 
age, so data from 45 days and 120 days of age was pooled together, averaged, 
and found to be 598.03µm2 (±50.17 SEM; n=3). This was ~20% smaller than the 
mean endplate size in the EDL muscle of WT mice (p=0.0319). 
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Figure 3.4: The mean endplate size in the EDL and soleus muscles of WT, 
mSOD1 and Arimoclomol treated mSOD1 mice 
The mean endplate size in the (A) EDL and (B) soleus muscles of WT, mSOD1 mice at 45 
and 120 days of age is summarised in the bar chart. In the EDL muscle, the effect of 
treatment with Arimoclomol was also examined (A). 
n=4; *=p<0.05; error bars = SEM 
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The average endplate size in mSOD1 soleus muscle was measured (see Fig.3.4) 
and surprisingly, the mean size of endplates in mSOD1 soleus did not change 
significantly over the course of the disease. At 45 days the mean endplate size was 
625µm2 (±89.07 SEM; n=3; p=0.805) and at 120 days of age, it was 572.89µm2 
(±33.30SEM; n=3; p=0.698), which is not significantly different. As there was no 
change in endplate size in the soleus muscle during disease, the effect of 
treatment with Arimoclomol was not examined. 
 
3.3.5 Changes in the oxidative capacity of hindlimb muscles of mSOD1 mice  
A change in the oxidative capacity of fast-twitch muscle fibres is a characteristic of 
muscle pathology in mSOD1 mice (Atkin et al., 2005). In view of the improvement 
in muscle innervation in Arimoclomol treated mSOD1 mice, the effect of 
Arimoclomol on the oxidative capacity of the TA, EDL and soleus muscles were 
examined. Muscles were stained for SDH in order to distinguish between darkly 
stained, highly oxidative fibres, intermediately stained, moderately oxidative fibres 
and lightly stained, highly glycolytic muscle fibres. The number of darkly stained 
muscle fibres, intermediately stained muscle fibres and pale fibres was counted in 
the TA, EDL and soleus muscles of WT, mSOD1 and Arimoclomol treated mSOD1 
mice at 45 and 120 days of age. Examples of SDH stained muscle can be seen in 
Fig.3.5. 
 
3.3.5.1 The effect of Arimoclomol on the oxidative capacity of mSOD1 TA 
muscle 
The pattern of SDH staining in WT TA muscle was assessed at 45 and 120 days 
and was found to be similar at each age. Therefore, data from WT muscle at these 
ages was pooled and averaged. Thus, 29.46% (±0.85 SEM; n=3) of fibres were 
stained darkly for SDH. 33.58% (±4.02 SEM; n=3) of WT TA muscle fibres had an 
intermediate level of staining, and 37% (±4.87 SEM; n=3) of fibres stained faintly 
for SDH (see Fig.3.6). 
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As can be seen in Fig.3.6, in the TA muscle of 45-day-old mSOD1 mice, 27.45% 
(±3.53 SEM; n=3; p=0.6093) of fibres were darkly stained, 46.47% (±3.55 SEM; 
n=3; p=0.0760) of the fibres were intermediately stained and only 26.08% (±1.20 
SEM; n=3; p=0.0959) of the fibres stained lightly for the SDH stain. By 120 days of 
age, the oxidative profile of the mSOD1 TA was significantly different from that 
seen in WT TA muscle. 75.28% (±4.25 SEM; n=3; p=0.001) of fibres were darkly 
stained compared to WT. This represented an increase of 170%, compared to 45-
day-old mSOD1 mice (p=0.001). The percentage of intermediately stained fibres 
was significantly lower in 120-day-old mSOD1 TA muscle, with only 23.57% (±3.63 
SEM; n=3; p=0.009) of fibres stained compared to WT. There were also 
significantly fewer lightly stained muscle fibres, with only 1.15% (±0.62 SEM; n=3; 
p=0.0001), compared to WT. 
 
As can be seen in Fig.3.6, treatment with Arimoclomol prevented this change in the 
pattern of SDH staining, in the TA muscle of mSOD1 mice. In 120-day-old 
Arimoclomol treated mSOD1 TA muscle, significantly fewer fibres were darkly 
stained, with 56.45% (±3.38 SEM; n=3; p=0.026) of muscle fibres staining darkly 
for SDH, compared to untreated mSOD1 TA muscle. Significantly more fibres were 
moderately stained, so that 40.95% (±3.36 SEM; n=3; p=0.035) of fibres were 
stained, compared to 23.57% in untreated mSOD1 TA muscle. Only 2.60% (±0.02 
SEM; n=3; p=0.038) of muscle fibres were lightly stained, which was significantly 
more than in untreated mSOD1 TA muscle, but still significantly less than in WT TA 
muscle. 
 
3.3.5.2 The effect of Arimoclomol on the oxidative capacity of mSOD1 EDL 
muscle  
The oxidative profile of the EDL muscle in WT, untreated and Arimoclomol treated 
mSOD1 mice was also examined. As there was no change in the pattern of SDH 
staining in WT EDL muscle with age, the data from the two ages was pooled and 
averaged. Thus, in WT EDL muscle, 23.72% (±2.60 SEM; n=3) of the muscle fibres  
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Figure 3.5: The pattern of SDH staining in hindlimb muscles of WT, untreated 
and Arimoclomol treated mSOD1 mice 
Sections of TA, EDL and soleus muscles of WT mice as well as 120-day-old mSOD1 and 
Arimoclomol treated mSOD1 mice. Typical examples of each muscle from WT, mSOD1 
and Arimoclomol treated mSOD1 are shown. An example of the TA (A-C), the EDL (D-F) 
and the soleus muscle (G-I) from each experimental group is shown in high power images 
are shown. 
 
Scale bar = 50µm; n=4 
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Figure 3.6: The pattern of SDH staining in the hindlimb muscle of WT, 
untreated and Arimoclomol treated mSOD1 mice 
The staining intensity of muscle stained for SDH was quantified in the TA, EDL and soleus 
muscles of WT mice and untreated mSOD1 mice at 45 and 120 days of age, as well as 
Arimoclomol treated mice at 120 days of age is shown. The bar charts (A-C) summarise 
the proportion of these fibres in the TA, EDL and soleus muscles respectively. n=4 
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were darkly stained. The proportion of muscle fibres that were intermediately 
stained was 39.38% (±7.36 SEM; n=3), and the percentage of lightly stained 
muscle fibres was 36.90% (±9.96 SEM; n=3). 
 
As can be seen in Fig.3.6, in mSOD1 EDL muscle, at 45 days of age, there was a 
significant increase in darkly stained fibres with 41.42% (±2.53 SEM; n=3; 
p=0.0082), of fibres staining intensely for SDH. The level of intermediately stained 
fibres was similar to WT with 31.58% (±7.81 SEM; n=3; p=0.5076) of fibres 
intermediately stained. However, the proportion of pale muscle fibres at 45 days of 
age was a significantly fewer fibres stained lightly for SDH, with only 22.91% 
(±3.50SEM; n=3; p=0.02557), compared to WT EDL muscle. These changes in the 
oxidative profile of the EDL muscle of mSOD1 mice did not change further as 
disease progresses, so that at 120 days of age, 37.87% (±4.22 SEM; n=3; 
p=0.046), 32.97% (±6.94 SEM; n=3; p=0.56) and 29.19% (±2.86 SEM; n=3; 
p=0.49) of fibres stained darkly, intermediately and faintly for SDH, respectively 
(see Fig. 3.6).  
 
Treatment with Arimoclomol prevented the change in SDH staining pattern in the 
EDL muscles of mSOD1 mice, so that at 120 days of age, only 23.79% (±9.13 
SEM; n=3; p=0.034) of the fibres examined were dark, compared to ~38% in 
untreated mSOD1 EDL muscle. However, treatment with Arimoclomol did not alter 
the proportion of intermediately stained fibres, thus, 42.79% (±8.76 SEM; n=3; 
p=0.4292) of fibres were intermediately stained compared to untreated mSOD1 
EDL muscle. Arimoclomol also had a limited effect on the proportion of the palest 
muscle fibres, 33.07% (±6.08 SEM; n=3; p=0.992) of the fibres were pale. 
 
3.3.5.3 The effect of Arimoclomol on the oxidative capacity of soleus muscle 
The oxidative capacity of muscle fibres in the soleus muscle was also assessed. 
As pattern of staining in the soleus from WT mice did not alter with age, data from 
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all ages was pooled and averaged. As shown in Fig.3.6, 53.77% (±4.99 SEM; n=3) 
of muscle fibres were darkly stained; 35.87% (±4.81 SEM; n=3) of fibres were 
intermediately stained and a small population of fibres, 10.35% (±6.56 SEM; n=3) 
were lightly stained. 
 
In the soleus muscle of mSOD1 mice, at 45 days of age, the pattern of SDH 
staining was similar to WT. Thus, 65.38% (±5.38 SEM; n=3; p=0.189) of muscle 
fibres were darkly stained; 31.58% (±5.48 SEM; n=3; p=0.588) were intermediately 
stained and only 3.71% (±2.03 SEM; n=3; p=0.388) of muscle fibres were lightly 
stained. By 120 days, 73.81% (±4.91 SEM; n=3; p=0.046) of all muscle fibres were 
darkly stained, which was significant more than WT. The proportion of 
intermediately stained, moderately oxidative muscle fibres had decreased to 
26.19% (±4.93 SEM; n=3; p=0.233), and there were no pale fibres (0.00% 
(±0.00SEM; n=3; p=0.19)).  
 
As can be seen in Fig.3.6, treatment with Arimoclomol prevented this change in the 
oxidative capacity of the soleus muscle in mSOD1 mice. In soleus muscles of 120-
day-old Arimoclomol treated mSOD1 mice, only 55.92% (±13.63 SEM; n=3; 
p=0.285) of fibres were darkly stained, compared to untreated mSOD1 soleus 
muscle. There was a modest increase in the number of intermediately stained 
fibres, so that 35.43% (±10.03 SEM; n=3; p=0.455) of fibres were intermediately 
stained compared to untreated mSOD1 soleus muscle. Treatment also significantly 
increased the proportion of lightly stained fibres, which was 8.65% (±3.06 SEM; 
n=3; p=0.048) of the soleus, compared to untreated mSOD1 mice. 
 
3.3.6 Biochemical assessment of neuromuscular activity in the muscles of 
mSOD1 mice 
As a measure of neuromuscular transmission, the activity of the cholinergic 
enzymes ChAT and AChE were determined in the TA, EDL and soleus muscles of 
WT, mSOD1 and Arimoclomol treated mSOD1 mice. 
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3.3.6.1 The effect of Arimoclomol on ChAT activity in the TA muscle  
ChAT activity in the TA muscles from WT mice did not change over time and so 
data from all ages was pooled. In WT TA muscle, the mean ChAT activity was 
13098.53cpm (±643.32 SEM; n=10). 
 
As can be seen in Fig.3.7a, at 45 days, ChAT activity in the TA muscle of mSOD1 
mice was 10745.67cpm (±384.85 SEM; n=6; p=0.019), compared to WT TA 
muscle. By 75 days, activity had declined further to 9105.67cpm (±419.11 SEM; 
n=6; p<0.001), and by 90 days, ChAT activity in the TA muscle had fallen even 
further to 7495.00cpm (±102.00SEM; n=4; p<0.001). This was more than 50% less 
than in WT TA muscle (p<0.001). After 90 days ChAT activity remained stable so 
that at 120 days ChAT activity was 9455.25cpm (±273.76 SEM; n=3; p=0.012). 
Treatment with Arimoclomol increased ChAT activity at all ages studied. However, 
this did not reach significance until 120 days, when it was 10609.00cpm (±195.02 
SEM; n=6; p=0.011), compared to untreated mSOD1 mice.  
 
3.3.6.2 ChAT activity in the EDL muscle of mSOD1 mice and the effect of 
Arimoclomol 
ChAT activity in the EDL muscle of WT mice was examined and found to be stable 
with age, so data from all ages was grouped together and the mean ChAT activity 
in WT EDL was 16248.08cpm (±712.68 SEM; n=12).  
 
As seen in Fig.3.7b, at 45 days of age, in mSOD1 mice, there was no difference in 
the level of ChAT activity compared to WT EDL muscle. At 75 days, the level of 
ChAT activity had decreased and was 12845.67cpm (±838.78 SEM; n=3; p=0.042) 
at 90 days, declined further to 9120.67cpm (±1754.91 SEM; n=4; p<0.001), 
compared to WT. At 120 days, ChAT activity stabilised and was 10607.38cpm 
(±455.36 SEM; n=8; p<0.001) compared to WT.  
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Figure 3.7: ChAT activity in the muscle of WT, mSOD1 and Arimoclomol 
treated mSOD1 mice 
ChAT activity was assessed in hindlimb muscles of WT, mSOD1 and Arimoclomol treated 
mSOD1 muscles at 45, 75, 90 and 120 days. The mean ChAT activity in the (A) TA, (B), 
EDL and (C) soleus muscles is summarised in the bar charts. The dotted line represents 
the mean ChAT activity in corresponding muscles of WT mice.  
n=4; *=p<0.05; error bars = SEM  
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The results in Fig.3.7b shows that treatment with Arimoclomol slightly increased 
ChAT activity in the EDL muscles of mSOD1 mice, although, this did not reach 
significance. Thus, ChAT activity in Arimoclomol treated mSOD1 EDL muscle was 
13778.33cpm (±1888.79 SEM; n=3; p=0.675) and at 90 days, ChAT activity was 
13686.3cpm (±321.51 SEM; n=4; p=0.0627), and at 120 days, ChAT activity was 
13509.20cpm (±1905.41 SEM; n=5; p=0.093). 
 
3.3.6.3 The effect of Arimoclomol on ChAT activity in the soleus muscle of 
mSOD1 mice 
The examination of ChAT levels in the soleus muscles of WT mice revealed that 
ChAT activity did not change with age, so data from all ages was pooled, averaged 
and found to be 19793.59cpm (±1051.63 SEM; n=14). As can be seen in Fig.3.7c, 
in mSOD1 mice, ChAT activity declined moderately with disease progression. 
While ChAT activity at 45 days of age was similar to WT. However, by 75 days, the 
level of ChAT activity was 14372.75cpm (±907.70SEM; n=4; p=0.0175), compared 
to WT. By 90 days, ChAT activity in mSOD1 soleus had fallen further to 
12863.50cpm (±1214.46 SEM; n=4; p=0.0125) compared to WT. At 120 days, 
ChAT activity in the mSOD1 soleus was 12562.50cpm  (±758.10 SEM; n=3; 
p=0.008) compared to WT. However, treatment with Arimoclomol had little effect 
on ChAT activity in the soleus muscle of mSOD1 soleus muscle at any age 
examined (see Fig. 3.7c). 
 
3.3.7 AChE activity in the hindlimb muscles of mSOD1 mice 
The level of AChE activity in the TA, EDL and soleus muscles of mSOD1 mice and 
the effect of treatment with Arimoclomol was examined. 
 
3.3.7.1 The effect of Arimoclomol on AChE activity in the TA muscle  
The level of AChE in the TA muscle from WT mice was examined and did not 
change over time. Therefore, data from WT mice was pooled and the mean AChE  
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Figure 3.8: AChE activity in the muscle of WT, mSOD1 and Arimoclomol 
treated mSOD1 mice 
AChE activity was assessed in hindlimb muscles of WT, mSOD1 and Arimoclomol treated 
mSOD1 muscles at 45, 75, 90 and 120 days. The mean AChE activity in the (A) TA, (B) 
EDL and (C) soleus are summarised in the bar charts. The dotted line represents AChE 
activity in WT mice for the corresponding muscle. 
*=p<0.05; n=12; error bars = SEM 
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activity was taken as 1.36 nmol/min/mg (±0.06 SEM; n=12) of tissue. 
 
As can be seen in Fig.3.8a, the level of AChE activity was significantly decreased 
in mSOD1 TA muscle compared to WT TA, at all ages studied. Even at 45 days, 
there was significantly less AChE activity in the mSOD1 TA muscle and AChE 
activity was 1.05nmol/min/mg (±0.07 SEM; n=12; p<0.001). AChE activity 
continued to decrease with disease, and by75 days AChE activity had fallen to 
0.98nmol/min/mg (±0.11 SEM; n=12; p=0.002). By 90 days, AChE levels in the 
mSOD1 TA muscle had declined further, to only 0.82nmol/min/mg (±0.10SEM; 
n=8; p<0.001). AChE levels decreased even further so that by 120 days, levels 
were only 0.56nmol/min/mg (±0.03 SEM; n=9; p<0.001).  
 
Treatment with Arimoclomol resulted in an increase in AChE activity in the TA 
muscle, particularly during the earlier stages of disease. At 45 days, AChE activity 
was 1.82nmol/min/mg (±0.08 SEM; n=12; p<0.001) compared to untreated mSOD1 
littermates. By 75 days, AChE activity was 1.53nmol/min/mg (±0.10SEM; n=12; 
p<0.001), compared to untreated mSOD1 TA and by 90 days, the level of activity 
in the Arimoclomol treated TA had declined to 0.90nmol/min/mg (±0.10SEM; n=7; 
p=0.001). By 120 days, it was only 0.75nmol/min/mg (±0.07 SEM; n=9; p=0.24), 
compared to untreated mSOD1 TA muscle. 
 
3.3.7.2 AChE activity in the EDL muscle of mSOD1 mice and the effect of 
treatment with Arimoclomol 
In WT EDL muscle, the level of AChE activity did not alter with the age of the mice, 
so data from all ages was pooled, averaged and AChE activity was taken as 1.32 
nmol/min/mg (±0.10SEM; n=20).  
 
As can be seen in Fig.3.8b, AChE activity in the EDL muscle of mSOD1 mice was 
relatively stable over the course of disease, and no significant change was 
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observed until 120 days, when, AChE activity was 0.85nmol/min/mg (±0.08 SEM; 
n=10), compared to WT EDL muscle (p=0.005).  
 
Treatment with Arimoclomol increased AChE activity in mSOD1 EDL muscle, so 
that at 120 days activity was 1.36nmol/min/mg (±0.08 SEM; n=7; p<0.001), 
compared to untreated mSOD1 EDL muscle. 
 
3.3.7.3 The effect of Arimoclomol on AChE activity in the soleus muscle  
AChE activity in the soleus muscle was also assessed in WT mice. This did not 
change over time, so data from all ages was pooled and the mean was taken as 
0.50nmol/min/mg (±0.06 SEM; n=20; p<0.001).  
 
AChE activity in the soleus of mSOD1 mice was then examined. As seen in 
Fig.3.9c, AChE activity was 0.28nmol/min/mg (±0.04 SEM; n=7; p=0.047) in 
mSOD1 soleus at 45 days, compared to WT. As disease progressed, AChE activity 
declined further, so that at 75 days activity was 0.22nmol/min/mg (±0.03 SEM; n=7; 
p=0.013). At 90 days of age, AChE activity was 0.19nmol/min/mg (0.03 SEM; n=7; 
p=0.0003). By 120 days, AChE activity had slightly increased to 0.32nmol/min/mg 
(±0.01 SEM; n=7; p=0.092).  
 
Treatment with Arimoclomol did not significantly alter AChE activity in soleus 
muscles over the course of the disease until 120 days. Surprisingly, in Arimoclomol 
treated soleus muscle, AChE activity fell to 0.24nmol/min/mg (±0.02 SEM; n=7; 
p=0.004) compared to untreated mSOD1 soleus muscle. 
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3.4 Discussion 
In this Chapter, the disease progression in hindlimb muscles was investigated in 
mSOD1 mice. The pattern of innervation in WT, and mSOD1 at 45, 75, 90 and 120 
days of age was assessed as well as endplate size, and ChAT and AChE activity. 
In addition, the oxidative capacity of these muscles was also assessed. Since our 
lab has previously shown the beneficial effects of Arimoclomol in this ALS model. 
The effect of Arimoclomol on these disease characteristics was also investigated.  
 
The results presented in this Chapter revealed significant, early denervation in the 
hindlimb muscles of mSOD1 mice, which was apparent from as early as 45 days in 
the EDL muscle and 120 days of age in the soleus muscle. In the EDL muscle, 
compensatory mechanisms such as sprouting and polyneuronal innervation 
occurred at symptomatic onset, but were of a short duration. mSOD1 pathology 
also resulted in the presymptomatic reduction in endplate size in the more 
vulnerable EDL muscle. In the more resistant soleus muscle sprouting and PNI 
were minimal and endplate size was not altered by disease. mSOD1 mice also 
demonstrated moderately decreased ChAT activity and dramatically decreased 
AChE activity in both fast and slow-twitch muscles.  
 
3.4.1 Differential pathology in fast and slow-twitch muscles in mSOD1 mice 
This study showed that there is a greater loss of innervation in the fast-twitch EDL 
muscle compared to the slow-twitch soleus muscle in mSOD1 mice at each 
disease time point examined. Similar findings have also been observed in nerve 
injury models (Albuquerque and McIsaac, 1970), suggesting an intrinsic 
vulnerability of fast-twitch muscles to denervation. Indeed, following partial 
denervation caused by nerve crush, fast-twitch muscles such as the EDL have 
been shown to undergo more extensive denervation than slow-twitch muscles like 
the soleus muscle (Raffaello et al., 2006). Frey et al., (2000a) who also 
demonstrated differential denervation in fast and slow-twitch muscles in mSOD1 
mice.  
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In response to denervation, it is well established that motor axons attempt to 
compensate for the loss of innervation by sprouting to occupy the denervated 
fibres. The extent of such compensatory mechanisms can be quantified by 
counting the extent of sprouting and PNI. In this study these compensatory 
mechanisms were found to also vary between fast and slow-twitch muscles of 
mSOD1 mice. While sprouting and PNI in both muscles were low, an early and 
strong regenerative response was present in the EDL muscle at disease onset, but 
this quickly declined. Interestingly, PNI is a common consequence of reinnervation 
was minimal in both muscles examined.  
 
Denervation in the EDL muscle was accompanied by a reduction in the average 
size of endplates. Moreover, this decrease was present before disease onset. 
However, the mean endplate size did not decline further, despite the progressive 
decline in innervation. Interestingly, while denervation was also present in mSOD1 
soleus muscle, this was not accompanied by a reduction in endplate size. It is of 
interest to note that while models of nerve injury, demonstrate a reduction in the 
mean size of endplates as a consequence of denervation (Suzuki et al., 2009), 
Murray et al., (2008) found no such correlation between endplate occupancy and 
endplate size. Likewise, my results indicate that changes in mean endplate size in 
mSOD1 mice does not correlate with innervation and thus, may be dependant on 
additional unknown factors in the disease.  
 
A change in the oxidative profile of a muscle is a common consequence of 
denervation (Somasekhar et al., 1996) or age (Nishizaka et al., 2010). Following 
long-term denervation and with age, the oxidative profile of a muscle declines 
significantly (Adami et al., 1985; Nishizaka et al., 2010). While partial denervation, 
followed by reinnervation, results in the lost of the mosaic-like pattern of SDH 
staining, with fibres that stained a similar intensity for SDH grouped together. 
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Unlike, aged muscles, or muscle that had undergone long-term denervation, all of 
the muscles examined in mSOD1 mice exhibited an increase in SDH staining; 
indicative of their oxidative capacity during disease progression, with the 
preferential loss of pale glycolytic fibres. This change was greatest in the fast-
twitch TA and EDL muscles. Increases in oxidative capacity in the muscles are 
usually indicative of an increased oxidative metabolism (Jeppesen et al., 2003) and 
increased mitochondrial activity. As both oxidative stress and mitochondrial 
damage have been implicated in ALS pathogenesis, it is possible that changes in 
muscle metabolism may also play a part in muscle pathology in mSOD1 mice. 
 
3.4.2 The ratio between ACh production and breakdown differs between fast 
and slow-twitch muscle 
Previous authors have reported that ChAT activity is significantly greater in the 
slow more resilient soleus muscle compared to the vulnerable fast-twitch muscles 
such as the TA and EDL muscles of rodents (Diamond et al., 1974, Wooten and 
Cheng, 1980). Furthermore, the while the amount if ChAT increases with age in the 
soleus, this is not the case with fast muscles such as the EDL. Rather, aged EDL 
muscle has been shown to display increased AChE levels (Washio et al., 1987). It 
is thought that such differences between the age-related changes in ChAT and 
AChE contribute to the degree to which muscle activity is maintained with age. 
 
With this in mind, it is interesting to note that in the present study when the ratio 
ChAT to AChE (two enzymes with opposing effects) is compared an interesting 
pattern emerges. Thus, as is shown in Fig.3.9, the ratio of ChAT: AChE for the 
soleus muscle is very high: 45449.75 (±564.63 SEM: n=14) to 1, compared to only 
12991.68 (±877.46 SEM; n=12; p<0.001): to 1, in the EDL and 9990.39 (±564.63 
SEM; n=10; p<0.001) to 1, in the TA muscle Thus, the ChAT: AChE ratio was 
significantly lower in more vulnerable TA muscle than the EDL muscle (p=0.012). 
Since synaptic strength, as determined by ChAT activity (Buffelli et al., 2003), is 
known to influence NMJ morphology and efficacy, particularly during development, 
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it is possible that it has lasting implications for innervation in the muscles of 
mSOD1 mice. These findings indicate a potential role for synaptic strength in NMJ 
vulnerability in ALS. Whereby the strongest nerve terminals with high levels of 
ChAT activity are less vulnerable to mSOD1 pathology. 
 
3.4.3 Arimoclomol reduces mSOD1-mediated muscle pathology 
Treatment with Arimoclomol significantly reduced the level of denervation in the 
muscles of mSOD1 mice, at 45 days of age, and maintained the level of 
innervation until 120 days-of-age. It also increased the level of sprouting and PNI in 
EDL and soleus muscles after disease onset. These effects were greatest in the 
more vulnerable fast-twitch EDL muscle. Arimoclomol also increased endplate size 
and prevented the change in the oxidative profile of the fast-twitch TA and EDL 
muscles in mSOD1 mice and Arimoclomol also moderately increased ChAT and 
AChE activity in the more vulnerable fast-twitch muscles.  
 
 
 
 
 
 
 
Figure 3.9: The ratio of ChAT:AChE in the TA, EDL and soleus muscle of WT 
mice 
The above bar chart shows the Amount of ChAT per unit of AChE in the TA, EDL and 
soleus muscle of WT mice.  
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These findings suggest that treatment with Arimoclomol may effect synaptic 
plasticity, a mediating factor for NMJ vulnerability (Santos and Caroni, 2003), 
preferentially rescuing the more vulnerable NMJs. As Arimoclomol is a co-inducer 
of the HSR and hsps are the primary modulators of the HSR. It is likely that at least 
one mechanism by which Arimoclomol exerts these effects is mSOD1 muscle is via 
the HSR within muscle. In addition to its established ability to increase this 
cytoprotective mechanism within the CNS (Kieran et al 2004), this suggests that 
the endogenous effect HSR is normally insufficient to deal with mSOD1-induced 
toxicity within muscle. 
 
3.4.4 Conclusions 
In conclusion, the results presented in this Chapter demonstrate that denervation 
occurs first in fast-twitch muscles, and before motoneuron death. Furthermore, 
treatment with Arimoclomol delays the rate of denervation and promotes 
compensatory mechanisms such as sprouting, resulting in an increase in PNI at 
the NMJ of mSOD1 muscles. This study also highlights the differential decrease in 
functional markers of cholinergic transmission and endplate size, which treatment 
with Arimoclomol also increases. These results therefore indicate that Arimoclomol 
acts both centrally on motoneurons (Kieran et al, 2004; Kalmar et al., 2008) but 
also has a significant beneficial effect on muscle pathology. This is likely to be due 
to an additional peripheral effect and not just a consequence of increased 
motoneuron survival, as Arimoclomols beneficial effect was present at 45 days in 
the fast EDL muscle, and resulted in a reduction in denervation, when motoneuron 
loss has yet to begin.  
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Chapter 4 : The effect of Arimoclomol on the HSR in the 
muscle of mSOD1 mice 
 108 
4.1   Introduction 
The precise role of muscle in ALS and mSOD1-mediated pathology remains 
controversial. While there is evidence demonstrating significant and differential 
pathology in ALS muscle, its role as a primary target in the disease is still debated. 
Results presented in Chapter three, confirmed previously reported evidence 
supporting a differential NMJ and muscle pathology in mSOD1 mice. These results 
also revealed that treatment with Arimoclomol reduces pathology at the NMJ and 
within the muscle. As Arimoclomol’s action is reported to be mediated by hsps, it 
was concluded that manipulation of the HSR might be beneficial to mSOD1 
muscle.  
 
Hsps are known to promote motoneuron survival and muscle function in a number 
of neurodegenerative diseases (Adachi et al., 2003, Kieran et al., 2004, Howarth et 
al., 2007). They are also known to play a role in combating muscle stress (Broome 
et al., 2006). However, very little is known about hsp expression in the periphery in 
ALS. Therefore, this Chapter examines whether mSOD1 muscle has an intrinsic 
HSR and whether treatment with Arimoclomol alters this HSR. Furthermore, owing 
to the previously established preferential vulnerability of fast-twitch muscle to 
disease, the HSR in a fast and slow-twitch muscle is examined over the course of 
the disease. 
 
4.1.1 The HSR in skeletal muscle 
The HSR is a well-conserved, rapid and robust defence mechanism against a 
variety of damaging events in a cell. This ‘defence’ is orchestrated by a family of 
proteins called heat shock proteins (hsps). While every cell is capable of 
upregulating hsps and thus mounting a HSR, evidence indicates that different cell 
types and tissues vary in hsp expression (Oishi et al., 2002). In addition, hsp 
expression in the same tissues or cell type can vary with gender and age. Within 
skeletal muscle, hsp expression varies with muscle-type (Oishi et al., 2002, Voss et 
al., 2003, Kayani et al., 2008). For example, hsp72 is expressed more readily in the 
slow-twitch soleus muscle than fast-twitch muscles like the TA and EDL; while, 
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hsp60 and hsp25 are expressed at greater levels in fast-twitch muscles such as 
the Plantaris, TA and EDL (Oishi et al., 2002, Huey et al., 2007). This is most 
apparent following stress, when hsp60 is upregulated faster in the fast-twitch 
Plantaris muscle and hsp25 is more readily phosphorylated in fast-twitch muscles 
such as the Plantaris and EDL muscle (Huey et al., 2004).  
 
4.1.2 The role of hsp90 in muscle: implications for neuromuscular disease 
Hsp90 has been shown to promote AChR aggregation (Luo et al., 2008) and is 
implicated in the formation of muscle, notably myofibril organization (Du et al., 
2007). During myofibril organisation hsp90α, an hsp90 isoform is strongly 
expressed for a short duration prior to MyoD expression in slow-twitch muscle 
progenitor cells. As hsp90α levels decline in slow-twitch muscle progenitor cells, 
levels increase in fast-twitch muscle progenitor cells (Sass et al., 1999). 
 
Hsp90 is implicated in muscle pathology in both myopathies and neuromuscular 
diseases. In inclusion body myostitis (IBM), hsp90’s role is unclear. Muscle 
biopsies from IBM patients show increased hsp90 expression in regenerating 
fibres, suggesting a cytoprotective role (De Paepe et al., 2009). However, there is 
also evidence demonstrating high hsp90 levels in iNOS positive macrophages 
found which necrotic muscle fibres in IBM models. This co-expression of iNOS and 
hsp90 implies a possible role for hsp90 in inflammation. In Spinal bulbar muscular 
atrophy (SBMA), a neuromuscular disease, hsp90 has been found in intranuclear 
aggregates of skeletal muscle, and this may indicate a role for muscle-derived 
hsp90 within the disease (Thomas et al., 2006). Such findings precipitated 
research examining the manipulation of hsp90 as a therapeutic target.  
 
There are a number of neuromuscular degenerative diseases in which the 
targeting of hsp90 has resulted in a reduction of motoneuron death and muscle 
atrophy for example, in SBMA (Sobue, 2003). Most of these hsp90 therapies inhibit 
hsp90 function, which leads to the prolonged activation of HSF-1 and the 
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consequent upregulation of hsps (Tokui et al., 2009). These events ultimately 
increase protein refolding and degradation, significantly reducing the level of 
denatured proteins present in the cell (Bruijn et al., 2004). 
 
4.1.3 The role of hsp72 in muscle: implications for neuromuscular disease 
Hsp72 has been shown to be upregulated in skeletal muscle following heat shock, 
ischemia-reperfusion injury, following exercise and muscle overload (Yamashita et 
al., 1997, Oishi et al., 2005). Furthermore, hsp72 has been shown to protect 
muscle following damage, via interactions with myofibrils (Paulsen et al., 2007) and 
is also thought to regulate Ca2+ handling capacity in skeletal muscle via the 
sarcoplasmic reticulum (SR) of skeletal muscle (Tupling et al., 2008).   
 
Hsp72 is also known to play a role in muscle pathology in some myopathies and 
neuromuscular diseases and is reported to have strong cytoprotective capabilities 
in the muscle. Indeed, hsp72 has been found in inclusions within the muscle from 
IBM patients (Fratta et al., 2005). It also has increased expression in the muscle of 
DMD patients (Bornman et al., 1995), where it enhances muscle cell survival 
(Bouchentouf et al., 2004). However, hsp72’s role in muscle in neuromuscular 
disease is limited.  
 
As Duchenne muscular dystrophy (DMD), IBM, and mSOD1 muscle share a 
number of pathologies, such as oxidative and SR stress (Baker and Austin, 1989, 
Nogalska et al., 2007, Nguyen et al., 2009), they may also share a role for hsp72 in 
the protection of muscle from pathology. 
 
4.1.4 The role of hsp60 in muscle: implications for neuromuscular disease 
The majority of hsp60 resides in the mitochondrial matrix, facilitating the import of 
nascent proteins into the mitochondria (Carrier et al., 2000). Another of its reported 
actions roles is the rescue of proteins that have undergone spontaneous 
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denaturation within mitochondria (McArdle et al., 2001). This role is particularly 
important in muscles, which have a high protein turnover and contain the high 
concentrations of mitochondria necessary to respond rapidly to changes in energy 
demand (Locke, 1997).  
 
Interestingly, hsp60 has been implicated in neurodegenerative disease, with hsp60 
mutations resulting in spastic paraplegia (Hansen et al., 2002, Magen et al., 2008). 
Although very little is known about the role of hsp60 in skeletal muscle pathology, 
hsp60 has been shown to increase the presence of cytoprotective proteins like 
IGF-1 stimulated receptor (Shan et al., 2003). Furthermore, as the administration of 
IGF-1 has been shown to increase muscle function and motoneuron survival in 
mSOD1 mice (Dobrowolny et al., 2005), increased hsp60 expression may also be 
beneficial to mSOD1 muscle. Furthermore, as skeletal muscle is a tissue rich in 
mitochondria and since mitochondrial damage is present in mSOD1 muscle, it is 
likely that a robust hsp60 response is required to maintain normal mitochondrial 
function.  
 
4.1.5 The role of hsp25 in muscle: implications for neuromuscular disease 
Hsp25 expression is essential for the development of contractile machinery within 
the cell during embryogenesis (Gernold et al., 1993). Under conditions of oxidative 
stress, it is more prone to phosphorylation in fast-twitch muscles compared to slow-
twitch muscles (Huey et al., 2007). This differential response to stress in fast and 
slow-twitch muscles may indicate a lower threshold for a stress response in fast-
twitch muscles. 
 
Interestingly, in disease, it is well acknowledged that mutations in hsp27 (the hsp25 
human homologue) result in Charcot Marie tooth disease, a neuromuscular 
disease (Brown et al., 2007). It is also known that hsp25 levels are increased in 
muscles that are more resistant to DMD pathology (Lewis and Ohlendieck, 2010). 
These muscles tend to be predominantly slow-twitch muscles (Carnwath and 
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Shotton, 1987). These findings suggest that hsp25 in mSOD1 muscle may help 
protect muscle from mSOD1-mediated pathology. 
 
4.1.6 Hsps promote muscle innervation 
Results from Chapter 3revealed that sprouting at mSOD1 NMJs is limited and that 
the extent of nerve terminal sprouting was increased by treatment with 
Arimoclomol. As Arimoclomol’s primary action is the upregulation of hsps and in 
view of its established neuroprotective effect in the CNS, it is possible that its 
neuroprotective actions facilitate the maintenance of innervation and sprouting in 
the PNS via increased hsp expression. 
It is known that hsp90 expression can promote neurite outgrowth in vitro, during 
development of the NMJ. Indeed, Ishimoto et al. (1998) discovered that hsp90 from 
chick muscle increased neurite outgrowth in spinal neurons in vitro. Hsp25 has 
also been implicated in the muscle’s response to denervation (Huey et al., 2004) 
and it too is reported to increase neurite outgrowth during development, with the 
overexpression of hsp25 increasing neurite length and branching in dorsal root 
ganglion neurons (Read and Gorman, 2009). 
 
As events at the NMJ have been shown to recapitulate some of the events that 
occur during development and evidence is available for the role of hsp90 and 
hsp25 in promoting neurite growth, it is possible that both hsp90 and hsp25 
promote the sprouting of mature, injured motor axons. If so, they may be beneficial 
to the reinnervation of denervated endplates in the muscle of mSOD1 mice. 
 
4.1.7 Manipulation of the HSR in mSOD1 mice 
Every cell has an intrinsic HSR. However, during continued cell stress this HSR 
can become overwhelmed, and may benefit from augmentation. Upregulation of 
the HSR in mSOD1 mice has proven an effective therapeutic strategy. Both 
pharmacological and genetic approaches have been used to upregulate the HSR 
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in mSOD1 models (Bruijn et al., 2004). Genetic approaches have revealed limited 
beneficial effects, with the overexpression of hsp70 and hsp40 conferring little 
benefit in vivo (Liu et al., 2005). The delivery of exogenous hsp70 increased 
motoneuron survival (Gifondorwa et al., 2007). However, only pharmacological 
manipulation has yielded significant and consistent results. Indeed, the use of 
pharmacological agents to augment the HSR in mSOD1 mice has been shown to 
increase motoneuron survival, muscle function and lifespan (Gifondorwa et al. 
2007, Kalmar et al., 2008, Kieran et al., 2004, Kiaei et al., 2005).  
 
4.1.8 Induction and the Co-induction of the HSR in disease 
A small number of pharmacological agents can induce the HSR. Celastrol, a 
quinone methide triterpene derivative, is such a drug. It also possesses some anti-
inflammatory properties, as well as inhibiting NO production in the CNS. Celastrol’s 
neuroprotective abilities have been demonstrated in various models of ALS (Kiaei 
et al., 2005), Parkinson’s disease (Cleren et al., 2005), and Huntington’s disease 
(Wang et al., 2005). However, its applicability as a therapy for neurodegenerative 
disease has been questioned, as it induces of the HSR. Kalmar et al. (2009) 
recently demonstrated that treatment with Celastrol induces the HSR in normally 
unstressed cells, an effect that is toxic in motoneurons (Kalmar et al., 2009).  
 
An alternative approach is to co-induce the HSR. This results in the upregulation of 
hsps in a targeted fashion, so that only stressed cells are affected. Arimoclomol is 
such a drug. It only augments the HSR in cells that have already activated the 
HSR. It is neuroprotective in models of ALS, diabetes, and nerve trauma (Kalmar 
et al., 2002, Kurthy et al., 2002, Kieran et al., 2004, Kalmar and Greensmith, 2009) 
and currently, it is in Phase II clinical trials for ALS patients in the USA. In both in 
vitro and in vivo models of ALS, Arimoclomol has been shown to co-induce a 
number of hsps including, hsp60, hsp70 and hsp90 in both motoneurons and 
astroglia (Kieran and Greensmith, 2004, Kalmar et al., 2008). In vivo, the systemic 
delivery of Arimoclomol to mSOD1 mice increases motoneuron survival, muscle 
function and lifespan (Kieran et al., 2004). Currently, it is known to have strong 
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cytoprotective actions in the CNS, but its actions in the PNS have yet to be 
examined. However, given the effect of Arimoclomol observed in Chapter three, it 
is possible that some of Arimoclomol’s beneficial effects arise from its ability to 
manipulate the HSR in the periphery. 
 
4.1.9 Aim 
In view of the results from Chapter three, in this Chapter, the HSR response in 
skeletal muscle in mSOD1 mice is examined, over the course of disease. 
Specifically, the expression of stress response proteins in the fast-twitch TA 
muscle and slow-twitch soleus muscle of WT, wtSOD1 and mSOD1 mice is 
investigated and the effect of treatment with Arimoclomol on the HSR examined in 
these muscles. 
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4.2   Methods 
4.2.1 Animals 
Animals were housed, genotyped and maintained until various stages of disease, 
as detailed in Chapter 2,Section 2.1.1, 2.1.2 and 2.1.3. 
 
4.2.2 Muscle Dissection and homogenisation 
Muscles were dissected as detailed in Chapter 2,Section 2.2.2. Snap frozen 
muscles were homogenised and then processed (Chapter 2,Section 2.2.8). 
 
4.2.3 Western blotting 
Following muscle homogenisation, a western blot was performed as described in 
Chapter 2,Section 2.2.9. Hsp line densities were normalised against β-actin line 
densities, and then all values were expressed as a percentage of WT, which was 
given the value 100%. Statistical analysis was carried out between wtSOD1 values 
and mSOD1 values, in order to assess whether the overexpression of SOD1 
resulted in a change in hsp expression. Levels of protein expression did not vary 
with age in WT and wtSOD1 mice, so data from each respective group was pooled 
and subsequently referred to as WT and wtSOD1. 
 
4.2.4 Immunohistochemistry and Microscopy 
Muscle was taken from WT, wtSOD1 and mSOD1 mice as described in Chapter 
2,Section 2.2.3. The muscles were then cryosectioned transversely at 12µm and 
stained with a variety of antibodies listed in Table 2.1 and Table 2.2. Unless 
otherwise stated, these sections were examined by light microscopy. 
 
4.2.5 Statistical analysis 
Statistical significance was assessed using a one-way ANOVA test. Post hoc, all 
pair-wise multiple comparisons were done using a student’s T-test, unless 
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otherwise stated.  Values are assessed as mean ± standard error of the mean 
(SEM). Significance was set at p≤ 0.05. 
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4.3   Results 
As examination of the TA and EDL muscle yielded similar results in Chapter 3, only 
the TA muscle was examined as a sample of fast muscle, as it bulk facilitates ease 
of analysis from this chapter onwards. 
 
In untreated and Arimoclomol treated mSOD1 mice, the expression of hsp90, 
hsp72, hsp60 and hsp25 was examined in WT, wtSOD1 and mSOD1 mice at 
various ages using western blotting and IHC. In order to allow for comparison 
between different western blots, all hsp line densities were normalised against the 
line densities for β-actin loading controls, and were then expressed as a 
percentage of the corresponding WT sample. The WT value was given the value 
100%.  
 
4.3.1 Hsp90 expression in mSOD1 TA muscle 
Examination of hsp90 expression in the TA and soleus muscles of WT, wtSOD1 
and mSOD1 mice revealed two hsp90 isoforms. These two bands were identified 
as the larger inducible alpha isoform and a smaller hsp90 beta isoform. This was 
present in all samples investigated (see Fig.4.1). When measuring the line 
densities of hsp90 western blots, the line densities of these two bands were 
combined. Examination of hsp90 expression in the fast-twitch TA and slow-twitch 
soleus muscle in WT mice revealed no difference between the two muscles under 
normal conditions (Fig.4.1). 
 
In Fig.4.1, it can be seen that hsp90 expression in wtSOD1 TA muscle was 108.3% 
(±2.53 SEM; n=4) of WT TA.  Examination of mSOD1 TA revealed that at 45 days 
of age, hsp90 expression was 136.7% (±7.72 SEM; n=4) of WT TA muscle, which 
was significantly greater than wtSOD1 (p=0.043). At 75 days of age, hsp90 
expression remained stable and was 137.4% (±3.63 SEM; n=4) of WT TA levels. 
This was still significantly greater than wtSOD1 (p=0.050). By 100 days, hsp90 
expression had fallen slightly, so that it was 117.3% (±7.52 SEM; n=4) of WT TA 
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levels, and was no longer significantly greater than wtSOD1 (p=0.795). By 120 
days hsp90 expression had fallen even further so that is was 78.3% (±4.84 SEM; 
n=4) of WT TA muscle, significantly less than wtSOD1 (p=0.0495), and was only 
half of the amount of hsp90 found in 45-day-old mSOD1 TA muscle (p=0.0007). 
 
The pattern of hsp90 expression in TA muscle was assessed using 
immunohistochemistry. Hsp90 immunoreactivity was very low in the TA muscle 
from wtSOD1 mice (Fig.4.1). In mSOD1 TA muscle, at 45 days, low levels of hsp90 
were found in the sarcoplasm (Fig.4.1f, see, ‘*’). By 75 days of age, in the mSOD1 
TA muscle, hsp90 expression had increased and was localised to the sarcoplasm 
and sarcolemma of the muscle fibres (Fig.4.1g, see ‘*’). At 100 days of age, hsp90 
expression was greatly reduced in the TA muscle of mSOD1 mice. By 120 days, 
hsp90 immunoreactivity was not detected in muscle fibres but instead in the areas 
surrounding the muscle fibres, most likely connective tissue. Western blotting 
analysis revealed that treatment with Arimoclomol resulted in a clear increase in 
hsp90 levels that were 303.33% (±8.59 SEM; n=3) of WT. This was significantly 
more hsp90 than in untreated mSOD1 TA muscle (p=0.010). This upregulation was 
reflected in IHC, which showed increased sarcoplasmic hsp90 expression in 
Arimoclomol-treated muscle fibres compared to untreated mSOD1 TA muscle 
(Fig.4.1).  
 
Since hsp90 has been shown to promote neurite outgrowth and AChR aggregation 
in vitro, hsp90 expression at the NMJ in the TA muscle of Arimoclomol-treated 
mSOD1 mice was examined and was found to accumulate in close proximity to the 
post-synaptic junction in Arimoclomol-treated mSOD1 TA muscle (Fig.4.2b, see 
‘*’), but not untreated mSOD1 TA muscle.  
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Figure 4.1: Hsp90 expression in the TA muscle of WT, wtSOD1 and mSOD1 
mice  
(A) shows a representative western blot of TA and soleus muscle homogenate 
from WT mice. (B) shows a representative western blot of hsp90 levels in WT, 
wtSOD1 and untreated mSOD1 TA muscle at 45, 75, 90 and 120 days of age. (C) 
shows a representative western blot of TA muscle homogenate from WT, untreated 
mSOD1 and Arimoclomol-treated mice at 120 days of age. The bar chart (D) 
summarises the normalised line density measurements from blots like (B&C). This 
was carried out as described in Chapter 2,Section 2.2.8. The dashed line 
represents WT control values. (E) shows hsp90 expression in TA muscle of 
wtSOD1 mice. (F) demonstrates hsp90 expression in a mSOD1 TA muscle at 45 
days. Some hsp90 is present at the sarcoplasm (*). (G) shows hsp90 expression in 
the mSOD1 TA muscle at 75 days, with strong expression in the connective tissue 
surrounding muscle fibres (*). (H&I) provide an example of hsp90 expression in TA 
muscle at 100 and 120-day-old in mSOD1 mice. (J) shows hsp90 expression in the 
TA muscle from Arimoclomol-treated mSOD1 mice. 
 
Error bars = standard error of the mean; n=4; * = p≤0.05; ***=P≤0.001; Scale bar= 
50µm; green (hsp90), blue (DAPI) 
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Figure 4.2: hsp90 expression at the NMJ of the TA muscle of untreated and 
Arimoclomol-treated mice 
(A) shows a transverse section of TA muscle from untreated mSOD1 mice at 120-
days of age stained for hsp90 (green) and AChR (red). (B) shows the 
colocalisation of hsp90 with the α-bungarotoxin (red; see arrow). Accumulations of 
hsp90 are present beneath the endplate (green; *) in the TA muscle of 
Arimoclomol-treated mSOD1 mice.  
Scale bar = 50µm; n=4 
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4.3.2 Hsp90 expression in mSOD1 soleus muscle 
Hsp90 expression in the slow-twitch soleus muscle was also examined using 
western blotting and IHC. As can be seen in Fig.4.3, hsp90 levels in wtSOD1 
soleus muscle were 109.6% (±13.0 SEM; n=4) of WT (100%). 
 
 
Figure 4.3: Hsp90 expression in the soleus muscles of WT, wtSOD1 and 
mSOD1 mice 
(A) shows a representative western blot of hsp90 expression in soleus muscle from 
WT, wtSOD1 and untreated mSOD1 soleus muscle at 45, 75, 100 & 120 days of 
age. (B) shows a representative western blot of hsp90 expression in soleus muscle 
from WT, untreated mSOD1 and Arimoclomol-treated mSOD1 mice at 120 days of 
age. The bar chart (C) summarises the mean line densities of hsp90 expression. 
The dashed line at 100% represents hsp90 expression in WT soleus muscle. (D) 
shows an example of hsp90 expression in the soleus muscle of wtSOD1 mice. (E) 
displays an example of sarcoplasmic hsp90 expression (*) in the mSOD1 soleus 
muscle of 45-day-old mice. (F) shows an example of strong hsp90 expression (*) in 
75-day-old mSOD1 mice. (G&H) display an example hsp90 expression in soleus 
muscle of 100-day-old and 120-day-old mSOD1 mice respectively. (I) 
demonstrates hsp90 staining in the soleus muscle from 120-day-old mice.  
 
Error bars = standard error of the mean; n=4; * = p≤ 0.05; **=p≤0.01;  
Scale bar= 50µm 
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In mSOD1 mice, at 45 days of age, hsp90 expression was only 81.0% (±16.0 SEM; 
n=4) of WT soleus, which differed from wtSOD1 soleus (p=0.677; Fig.4.3). Hsp90 
levels peaked at 75 days in mSOD1 mice, so that levels were 170.0% (±14.7 SEM; 
n=4) of WT mice and significantly higher than in wtSOD1 soleus muscle (p=0.047). 
From 75 days of age onwards, hsp90 levels began to decline, albeit marginally, so 
that by 100 days hsp90 levels were 159.76% (±13.54 SEM; n=4) of WT mice, 
which was still significantly more than wtSOD1 soleus muscle (p=0.037). By 120 
days, hsp90 expression had further declined and was 132.2% (±17.6 SEM; n=4) of 
WT soleus, and was no longer differed significantly from wtSOD1 soleus muscle 
(p=0.836). 
 
Immunohistochemistry revealed low hsp90 immunoreactivity in wtSOD1 mice (see 
Fig.4.3), with a clear upregulation in mSOD1 soleus muscle. At 45 days of age, 
hsp90 was localised to the sarcolemma of soleus muscles (see Fig.4.3e). By 75 
days of age, hsp90 expression had increased, with intense staining found in the 
sarcoplasm throughout the muscle fibres and at the sarcolemma (Fig.4.3f, see ‘*’). 
By 100 days of age, hsp90 levels had declined (Fig.4.3g). At 120 days of age, 
hsp90 expression was restricted to the connective tissue of the soleus muscle, and 
hsp90 expression was particularly strong surrounding angular, atrophied muscle 
fibres (Fig.4.3h). 
 
Treatment with Arimoclomol increased hsp90 levels in mSOD1 soleus muscle so 
that at 120 days of age they were 180.95% (±42.35 SEM; n=3) of WT. However, 
this did not reach significance when compared to untreated mSOD1 muscle 
(p=0.96). IHC indicated that treatment with Arimoclomol resulted in a modest 
increase in hsp90 expression in the soleus muscle of mSOD1 mice (Fig.4.3i).  
 
4.3.3 Hsp72 expression in the TA muscle of mSOD1 mice 
The expression of hsp72, a key protein involved in the refolding of misfolded 
proteins, was next examined in the TA and soleus muscle of WT, wtSOD1, 
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untreated and Arimoclomol-treated mSOD1 mice over the course of the disease. 
As can be seen in Fig.4.4, hsp72 expression in wtSOD1 TA muscle was similar to 
that in WT TA and was 107.39% (±2.04 SEM; n=4) of WT levels.  
 
Hsp72 expression in untreated mSOD1 TA muscle was then examined, at 45, 75, 
100 and 120 days of age. In mSOD1 TA muscle, at 45 days of age, hsp72 
expression was similar to that observed in wtSOD1 TA muscle with hsp72 levels 
reaching 119.04% (±5.44 SEM; n=4) of WT TA muscle, which was significantly 
greater than wtSOD1 TA muscle (p=0.046). By 75 days of age, hsp72 levels in 
mSOD1 TA muscle had doubled to 224.15% (±9.06SEM; n=4) of WT, which was 
significantly above wtSOD1 TA muscle (p<0.001). As disease progressed, hsp72 
levels declined. At 100 days, the amount of hsp72 was still marginally elevated, 
and in mSOD1 TA muscle hsp72 levels were 142.81% (±12.48SEM; n=4) of WT 
TA muscle, which was significantly more than wtSOD1 TA muscle (p<0.01). At 120 
days, mSOD1 TA hsp72 levels were 115.5% (±11.17SEM; n=4) of WT, which was 
no longer significantly higher than hsp72 levels in TA muscle from wtSOD1 mice 
(p=0.078). 
 
Immunohistochemical staining revealed that hsp72 expression was below 
detection levels in wtSOD1 TA muscle (Fig.4.4f). However, there was a clear 
increase in hsp72 expression in mSOD1 TA muscle compared to wtSOD1 TA at all 
ages examined. At 45 days, staining was mainly sarcoplasmic in muscle fibres, 
with some immunoreactivity present in surrounding connective tissue (Fig.4.4g,‘*’). 
By 75 days, there was intense sarcoplasmic hsp72 staining in mSOD1 TA muscle 
fibres (Fig.4.4h,’*’). However, by 100 days, hsp72 expression had fallen a great 
deal in the TA muscle sarcoplasm (Fig.4.4i) and was greatly reduced by 120 days 
of age (Fig.4.4j). 
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Figure 4.4: Hsp72 expression in TA muscle of WT, wtSOD1 and mSOD1 mice 
(A) shows a representative hsp72 western blot of TA and soleus muscle 
homogenate from WT mice.  A representative blot displaying hsp72 levels in the 
TA muscle of WT, wtSOD1 and mSOD1 at various ages is seen in (B). (C) shows a 
representative blot of pre-absorbed soleus muscle homogenate from WT mice. 
This blot was stained for hsp72. A band at 70kDa was not present, indicating 
antibody specificity. (D) shows a representative blot for TA muscle homogenate 
from WT, untreated and Arimoclomol-treated mSOD1 mice. The bar chart (E) 
summarises the mean normalised line density from hsp72 blots (B&D). (F) shows 
an example of hsp72 immunoreactivity in wtSOD1 TA muscle. In 45-day-old 
mSOD1 mice (G), hsp72 is seen in mSOD1 TA muscle fibres as well as the 
connective tissue (*). In 75-day-old mSOD1 mice (H), very strong expression of 
hsp72 was found in the connective tissue surrounding the muscle fibres (*). (I) 
shows hsp72 expression in 100-day-old mSOD1 TA. In (J) preferential staining of 
some fibres in 120-day-old TA muscle from mSOD1 mice is visible (a, b). (K) 
shows an example of hsp72 expression in 120-day-old mSOD1 TA muscle 
following treatment with Arimoclomol. Nuclear staining is present (*), and there is a 
preferential upregulation of hsp72 expression in some muscle fibres compared to 
others (see a, b).  
 
Error bars = standard error of the mean; n=4; *=p≤ 0.05; **=p≤ 0.01; Scale 
bar=50µm 
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Figure 4.5: Hsp72 expression at the NMJ of TA and soleus muscles of 
untreated and Arimoclomol-treated mSOD1 mice.  
Sections of TA and soleus muscle from untreated and Arimoclomol treated mSDO1 
mice were stained with alpha bungarotoxin and immunostained for hsp72, (A) 
shows that hsp72 expression in the TA muscle of 120-day-old mSOD1 mice is 
present at the NMJ (see arrow). (B) shows an example of hsp72 expression in the 
TA muscle of mSOD1 mice treated with Arimoclomol. Hsp72 expression is present 
at the nucleus (*) and co-localises with some α-bungarotoxin but not all (see 
arrow). (C) shows hsp72 expression in the soleus muscle of 120-day-old mSOD1 
mice, hsp72 is co-localised to some extent with α-bungarotoxin, but not all alpha 
bungarotoxin positive areas (see arrow). (D) shows an example of hsp72 in the 
soleus muscle of mSOD1 mice treated with Arimoclomol. There is clear co-
localisation of hsp72 with α-bungarotoxin in the soleus (see arrow). 
Scale bar =50µm; n=4 
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Treatment with Arimoclomol significantly increased hsp72 expression in TA 
muscles of mSOD1 mice compared to untreated mSOD1 mice. In Arimoclomol-
treated TA muscle hsp72 levels were 173.02% (±20.33 SEM; n=3) of WT mice. 
This was significantly more than in untreated mSOD1 TA muscle (p=0.001). 
Examination of hsp72 expression using IHC revealed that treatment with 
Arimoclomol increased hsp72 expression within the sarcoplasm in some fibres, 
which also had centralised nuclei – a marker for muscle fibre regeneration 
(Fig.4.4i, see ‘a’). However, some muscle fibres expressed very little hsp72 in the 
sarcoplasm (Fig.4.4i, see ‘b’). Hsp72 expression was increased at nuclei within the 
muscle fibres (Fig.4.4i, see ‘*’). IHC also revealed that treatment with Arimoclomol 
resulted in a modest increase in hsp72 expression at the NMJ of TA muscle from 
mSOD1 mice (Fig.4.5b), compared to untreated TA muscle of mSOD1 mice. 
 
4.3.4 Hsp72 expression in mSOD1 soleus muscle 
Fig.4.6 shows that hsp72 expression in wtSOD1 soleus muscle was 86.8% (±9.0 
SEM; n=4) of WT.  
 
mSOD1 soleus muscle contained significantly more hsp72 than wtSOD1 soleus 
muscle, at all ages studied. At 45 days of age, hsp72 levels were already elevated 
to 144.6% (±10.4 SEM; n=4) of WT, which was not significantly elevated compared 
to wtSOD1 soleus muscle (p=0.229). Hsp72 levels continued to rise and by 75 
days, hsp72 levels in mSOD1 soleus were 222.6% (±36.8 SEM; n=4) of WT soleus 
muscle, which was significantly more than wtSOD1 (p=0.007). Thus, hsp72 levels 
had approximately doubled between 45-75 days in mSOD1 soleus muscle. By 100 
days of age, hsp72 increased further to 275.5% (±45.2 SEM; n=4) of WT soleus, 
which was also significant compared to wtSOD1 soleus muscle (p<0.001). By 120 
days of age, hsp72 levels began to decline so that they were 161.5% (±7.7 SEM; 
n=4) of WT soleus, which was no longer differed significantly from wtSOD1 soleus 
muscle (p=0.160). 
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Sections of soleus muscle from wtSOD1 and mSOD1 mice were also 
immunostained for hsp72. No difference in the pattern of staining or intensity was 
observed at any age in wtSOD1 soleus muscle (Fig.4.6). By contrast, in mSOD1 
soleus muscle, hsp72 immunoflourescence was more intense than that observed 
in wtSOD1 soleus muscle. At 45 days, hsp72 staining was restricted to the 
sarcoplasm of the muscle fibres (see Fig.4.6e). By 75 days (Fig.4.6f), some muscle 
fibres contained very large, dense accumulations of hsp72 (Fig.4.7g) within the 
sarcoplasm of the muscle fibres. As disease progressed, hsp72 immunoreactivity 
continued to increase in the connective tissue and by 120 days of age, hsp72 
immunoflourescence had declined in the sarcoplasm of most muscle fibres and 
was greatest in the tissue surrounding the muscle fibres. Following treatment of 
mSOD1 mice with Arimoclomol, hsp72 levels in mSOD1 mice were 122.70% 
(±3.88 SEM; n=3) of WT. However, this was not significantly different to untreated 
mSOD1 soleus muscle (p=0.619).  
 
IHC revealed that the amount of hsp72 was not significantly altered in 
Arimoclomol-treated mSOD1 soleus muscle. The pattern of staining within 
Arimoclomol-treated soleus muscle fibres was considerably different to that seen in 
untreated mSOD1 soleus muscle. Arimoclomol-treated mSOD1 soleus muscle 
displayed raised hsp72 levels in a sub-population of muscle fibres. Furthermore, 
hsp72 expression was also increased at the NMJ of some but not all endplates 
(Fig.4.5d, see arrow), as determined by double staining with the AChR marker, 
alpha bungarotoxin. 
 
4.3.5 Hsp60 expression in mSOD1 TA muscle.  
Next, hsp60 expression was examined and levels were found to be similar in TA 
and soleus muscles of WT mice. Fig.4.7 indicates that in wtSOD1 TA, hsp60 levels 
were not significantly different from those observed in WT TA muscle, with wtSOD1 
TA muscle displaying hsp60 levels that were 103.7% (±8.2SEM; n=4) of WT.  
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Figure 4.6: Hsp72 expression in the soleus muscle of WT, wtSOD1 and 
mSOD1 mice 
Image (A) shows a representative western blot of hsp72 in the soleus muscles of 
WT, wtSOD1 and mSOD1 mice at various ages. Image (B) shows a representative 
western blot of soleus muscle homogenate from WT, untreated mSOD1 and 
Arimoclomol-treated 120-day-old mSOD1 mice. The bar chart (C) summarises the 
normalised line density of hsp72 western blots. The dashed line represents the WT 
control line density (100%). Muscle sections were also stained for hsp72 
immunohistochemistry. (D-F) show an example of hsp72 expression using 
immunofluoresent histochemistry on wtSOD1 and mSOD1 at 45,75,90 and 120 
days of age, respectively. (H) shows hsp72 expression in the soleus muscle of 
mSOD1 mice following treatment with Arimoclomol. Hsp72 was preferentially 
expressed in nucleated muscle fibres ‘a’, indicating increased hsp72 expression in 
regenerating muscle fibres. While other fibres express very little ‘b’. 
 
n=4; error bars= standard error of the mean; *=p≤ 0.05; **=p≤ 0.01; ***=p≤ 0.001; 
Scale bar = 50µm 
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In mSOD1 TA muscle, at 45 days of age, hsp60 levels were 137.8% ±8.7 SEM; 
n=4) of WT. This was not significantly more than wtSOD1 (p=0.376). At 75 days, 
hsp60 levels were 130.3% (±7.4 SEM; n=4) of WT TA muscle, which was still not 
significantly greater than wtSOD1 mice (p=0.133). At 100 days, hsp60 levels were 
127.0% (±9.6 SEM; n=4) of WT TA muscle, which was similar to wtSOD1 
(p=0.231). At 120 days, hsp60 levels were 116.2% (±8.0 SEM; n=4) of WT, which 
was not significantly greater than wtSOD1 mice (p=0.807). Hsp60 expression was 
also examined using IHC. As shown in Fig.4.7, there was very little hsp60 detected 
in wtSOD1 TA muscles. In mSOD1 TA muscle, immunoreactivity for hsp60 
remained the same until 120 days. At 120 days, hsp60 immunoreactivity was 
higher at the periphery of muscle fibres (Fig.4.7j). 
 
Treatment with Arimoclomol increased hsp60 levels significantly. Levels were 
218.20% (±2.46SEM; n=3) of WT, which was significantly more than untreated 
mSOD1 TA muscle (p=0.002). IHC revealed that treatment with Arimoclomol 
increased hsp60 expression in the sarcoplasm of a sub-population of muscle fibres 
(Fig.4.7k, see ’a’), while other muscle fibres expressed far less hsp60 (Fig.4.7k, 
see ‘b’). 
 
4.3.6 Hsp60 expression in mSOD1 soleus muscle 
Hsp60 expression in the slow-twitch soleus muscle using western blotting and IHC 
was also examined. Overall, there was no significant change in hsp60 levels in the 
soleus muscle of mSOD1 at any age studied (n=4; p=0.353). As shown in Fig.4.8, 
IHC revealed that hsp60 expression in wtSOD1 soleus muscle was similar to 
mSOD1 soleus muscle. Additionally, hsp60 expression was similar in mSOD1 
soleus muscle at all ages examined. Treatment with Arimoclomol did not increase 
hsp60 expression in mSOD1 soleus muscle and in Arimoclomol-treated soleus 
muscle; hsp60 levels were 95.61% (±12.49SEM; n=3; p=0.977) of WT (Fig.4.8). 
IHC revealed that hsp60 expression was slightly increased in the connective tissue 
of the soleus muscle from Arimoclomol-treated mSOD1 mice. (Fig.4.8, *). 
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Figure 4.7: Hsp60 expression in the TA muscle of WT, wtSOD1 and mSOD1 
mice  
(A) shows a representative hsp60 western blot of TA and soleus muscle from WT 
mice. (B) shows a hsp60 western blot of TA muscle from WT, wtSOD1 and 
mSOD1 mice at 45, 75, 100 and 120 days of age. (C) shows an example of a pre-
absorbed hsp60 western blot. The band at 60kDa was not present, indicating 
antibody specificity. (D) shows an example of a hsp60 western blot of TA muscle 
from WT, untreated and Arimoclomol-treated 120-day-old mSOD1 mice. The bar 
chart (E) summarises normalised line density measurements from hsp60 western 
blots. Muscle sections were also processed for hsp60 using 
immunohistochemistry. (F) shows an example of hsp60 expression in TA muscle of 
wtSOD1 mice. (G) shows an example of hsp60 expression in the TA muscle of 
mSOD1 mice at 45 days of age. (H-J) shows hsp60 expression in the TA muscle of 
mSOD1 mice at 75, 100 and 120 days, respectively. (K) shows an example of 
hsp60 expression in 120-day-old following treatment with Arimoclomol, while ‘a’ 
highlights a muscle fibre with very little hsp60 immunoreactivity while ‘b’ conversely 
show a muscle fibre with high hsp60 immunoreactivity where immunoreactivity is 
localised to myofibrils within the muscle fibre.  
 
Error bars = standard error of the mean; *=p≤ 0.05; **=p≤ 0.01; ***=p≤ 0.001; Scale 
bar=50µm; n=4 
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4.3.7 Hsp25 expression in the TA muscle of mSOD1 mice 
Hsp25 is a key protein involved in counteracting the deleterious effects of oxidative 
stress within cells (Bryantsev et al., 2002). It is upregulated in skeletal muscle 
following oxidative stress and exercise (Koh, 2002). Hsp25 expression in TA and 
soleus muscles in WT, wtSOD1 and mSOD1 mice was examined at various stages 
of disease. Hsp25 levels were determined by western blotting as detailed in 
Chapter 2, Section 2.2.9 at the pattern of hsp25 expression examined with 
immunohistochemistry. 
 
Examination of hsp25 expression in the fast-twitch TA and slow-twitch soleus 
muscle of WT mice was carried out in order to establish whether differential hsp25 
expression took place in the absence of cell stress. Western blotting revealed 
similar levels of hsp25 expression in the TA and soleus muscles. Following this, 
hsp25 expression in wtSOD1 and mSOD1 mice was assessed. Fig.4.9 shows that 
hsp25 levels in wtSOD1 TA were 78.1% (±24.1 SEM; n=4) of WT. hsp25 
expression in mSOD1 mice was then assessed. In presymptomatic mSOD1 TA 
muscle, and hsp25 levels were similar to wtSOD1 TA muscle, so that at 45 days of 
age, hsp25 levels in the TA muscle were 93.2% (±8.0 SEM; n=4) of WT, did not 
differ significantly from wtSOD1 (p=0.983). 
 
However, by 75 days, hsp25 levels had more than doubled and were 223.7% 
(±SEM; n=4) of WT, which was significantly more than in wtSOD1 (p<0.001). By 
100 days of age, levels had begun to decline and hsp25 levels were 139.3% (±13.1 
SEM; n=4) of WT and no longer significantly greater than wtSOD1 (p=0.124). By 
120 days of age, hsp25 levels had fallen to 127.7% (±26.7 SEM; n=4) of WT, which 
was not significantly more than wtSOD1 (p=0.845).  
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Figure 4.8: Hsp60 expression in mSOD1 soleus muscle  
(A) shows a representative hsp60 western blot of TA muscle from WT, wtSOD1 
and mSOD1 soleus muscle at various ages. (B) shows a representative hsp60 
western blot of TA muscle from 120-day-old WT, untreated and Arimoclomol-
treated mSOD1 mice. The bar chart (C) summarises the normalised line density 
measurements from hsp60 western blots. Muscle sections were also processed for 
hsp60 using immunohistochemistry. (D) shows the pattern of hsp60 expression in 
soleus muscle wtSOD1 mice. (E&F) illustrates the pattern of hsp60 expression in 
mSOD1 soleus muscle, at 45 and 75 days of age. (G&H) are examples of hsp60 
expression in the soleus muscle at 100 and 120 days of age, respectively. (I) 
shows hsp60 expression in the soleus muscle of 120-day-old mSOD1 mice 
following treatment with Arimoclomol.  
 
Error bars = Standard error of the mean; *=p<0.05; Scale bar=50µm; n=4 
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The pattern of hsp25 expression in TA muscle was also examined using IHC (see 
Fig.4.9). In the TA muscle of wtSOD1 mice, hsp25 expression was negligible 
(Fig.4.9). Hsp25 expression was similar in mSOD1 TA muscle; in 45-day-old 
mSOD1 TA muscle, hsp25 expression was still low (Fig.4.9f). At 75, 100 and 120 
days of age, hsp25 expression remained the same (Fig.4.9g-i), with no clear 
upregulation of any specific fibres at any stage of disease examined. 
 
Treatment of mSOD1 mice with Arimoclomol increased hsp25 expression in TA 
muscle, so that levels were 250.05% (±9.0SEM; n=4) of WT, which was 
significantly more than untreated mSOD1 TA muscle (p<0.0001). However, this 
increase was not detected with IHC (Fig.4.10j), which showed no clear difference 
in the pattern or intensity of hsp25 expression in Arimoclomol treated TA muscle.  
 
4.3.8 Hsp25 expression in mSOD1 soleus muscle 
As can be seen in Fig.4.10, the level of hsp25 in wtSOD1 soleus muscle was 
150.93% (±10.11 SEM; n=4) of WT. In mSOD1 soleus muscle, hsp25 levels 
changed significantly over the course of disease. At 45 days of age, hsp25 levels in 
mSOD1 soleus were 198.4% (±56.6 SEM; n=4) of WT, which was greater than 
wtSOD1, but did not reach significance (p=0.378). By 75 days of age, there was 
significantly more hsp25 in mSOD1 soleus (p<0.001): levels were 1324.28% 
(±197.65 SEM; n=4) of WT. From this stage onwards, hsp25 levels began to 
decline and by 100 days, levels were 853.58% (±95.81 SEM; n=4) of WT, which 
was still significantly more wtSOD1 (p<0.001). At 120 days, levels were 485.82% 
(±56.71 SEM; n=4) of WT, which was again significantly more than wtSOD1 
(p=0.001).  
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Figure 4.9: Hsp25 expression in mSOD1 TA muscle 
(A) shows a representative hsp25 western blot of TA and soleus muscle from WT 
mice. (B) shows a representative hsp25 western blot of TA muscle from WT, 
wtSOD1 and mSOD1 mice at 45, 75, 100 and 120 days of age. (C) shows a 
representative blot for hsp25 on TA muscle homogenate from WT, untreated and 
Arimoclomol-treated mSOD1 mice at 120 days of age. The bar chart (D) 
summarises the normalised line density measurements from hsp25 western blots. 
The dashed line at 100% represents WT control line density values. Muscle 
sections were also processed for hsp60 using immunohistochemistry. (E) shows 
hsp25 expression in the TA muscle of wtSOD1 mice. (F) shows TA muscle from 
45-day-old mSOD1 mice. (G-I) shows hsp25 expression in TA muscle from 75-day-
old, 100-day-old and 120-day-old mSOD1 mice. (J) shows an example of hsp25 
expression in the TA muscle of 120-day-old mSOD1 mice following treatment with 
Arimoclomol. 
 
Error bars = standard error of the mean; **= p≤ 0.01; ***=p≤ 0.001; Scale bar = 
50µm; n= 4 
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Immunohistochemical staining for hsp25 in soleus muscle sections revealed that 
hsp25 was present in the majority of wtSOD1 soleus muscle fibres (Fig.4.10d). At 
all ages studied, hsp25 immunoreactivity in mSOD1 soleus did not change 
significantly in the sarcoplasm of the mSOD1 soleus muscle. In mSOD1 soleus 
muscle, hsp25 was expressed in the majority of muscle fibres and did not change 
with age. From 45-120 days of age, there was also some sarcolemmal and 
sarcoplasmic hsp25 expression (Fig.4.10e-h). 
 
Western blotting revealed that the treatment with Arimoclomol resulted in increased 
hsp25 levels, which were 1402.42% (±20.0SEM; n=4) of WT compared to 
untreated mSOD1 levels (p=0.003; Fig.4.10b). However, changes revealed by 
western blotting were not detected with IHC (Fig.4.10i).  
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Figure 4.10: Hsp25 expression in soleus muscle  
(A) shows a representative hsp25 western blot of soleus muscle from WT, wtSOD1 
and mSOD1 mice at 45, 75, 90 and 120 days of age. (B) shows a representative 
blot for hsp25 on soleus muscle homogenate from WT, untreated mSOD1 and 
Arimoclomol-treated mSOD1 mice at 120 days of age. The bar chart (C) 
summarises the normalised line density measurements from hsp25 western blots. 
The dashed line at 100% represents WT control line density. Muscle sections were 
also processed for hsp60 using immunohistochemistry. (D) represents hsp25 
expression in the soleus of wtSOD1 mice. (E-H) represents hsp25 expression in 
the soleus muscle of mSOD1 mice at 45, 75, 90 and 120 days of age respectively. 
(I) shows hsp72 expression in the soleus muscle of 120-day-old mSOD1 mice 
following treatment with Arimoclomol. 
 
Error bars = standard error of the mean; *** p≤0.001; **=p≤0.01; *=p≤0.05; Scale 
bar = 50µm; n= 4 
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4.4  Discussion 
In this Chapter, I undertook a systematic assessment of hsp levels in the fast-
twitch TA and slow-twitch soleus muscle in mSOD1 mice over the course of the 
disease. The expression of hsp90, hsp72, hsp60 and hsp25 was examined in 
mSOD1 mice at a presymptomatic stage (45 days of age), symptomatic onset (75 
days of age), and early stage of disease (100 days of age) and a late stage of 
disease (120 days of age). The role that these hsps play in muscle pathology in the 
disease was examined using western blotting and IHC, in order to ascertain how 
hsp levels are regulated throughout the disease. In addition, I investigated the 
effect of treatment with an inducer of the HSR, Arimoclomol, on the expression of 
these hsps in a fast-twitch and slow-twitch muscle in mSOD1 mice. 
 
The results show that all hsps examined, except hsp60, were strongly upregulated 
in the hindlimb muscles of mSOD1, particularly between 45-75 days of age. After 
this point, hsp levels declined, which was accompanied by the worsening of 
symptoms. In addition, hsp90 and hsp25 levels were greater in the slow-twitch 
soleus, but upon the onset of disease, a similar ‘fold’ increase was seen in the fast-
twitch TA and slow-twitch soleus muscle. Despite a similar fold increase in general, 
hsp90 and hsp25 was upregulated for a longer period in the soleus muscle than 
the more vulnerable TA muscle. Hsp72 levels were also greater in the slow-twitch 
soleus before disease onset.  
 
Furthermore, this Chapter revealed that treatment with Arimoclomol increased 
significantly the expression of hsp90, hsp72, hsp60 and hsp25 in both TA and 
soleus muscles of mSOD1 mice.  
 
4.4.1 Hsp expression in muscle may influence innervation in mSOD1 mice 
A strong increase in hsp90, hsp72 and hsp25 expression was found between 45 
and 75 days of age in both muscles; however, by 120 days (a late symptomatic 
stage) hsp levels in mSOD1 TA are similar to WT. Interestingly, the peak in hsp 
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levels coincided with the sprouting in both muscles. As hsp90 and hsp25 have also 
been shown to promote neurite outgrowth in vitro and are implicated in the 
denervation response, by suppressing muscle atrophy induced by atrogin-1 
expression in muscle, it is possible that an increase in hsp expression in the 
muscle influences innervation at the NMJ (Ishimoto et al., 1998, Read and 
Gorman, 2009). Huey et al. (2005) and Abuzzo (2010) previously found a strong 
but short-lived increase in hsp25 following the denervation of muscle in rodents. 
These findings support the hypothesis that the upregulation hsp90 and hsp25 seen 
in mSOD1 muscle contributes to the simultaneous increase in sprouting (Chapter 
three). Interestingly, as hsp90 levels declined, sprouting also declined and the level 
of denervation increased. Therefore, it is possible that that hsp90 and hsp25 
expression within muscle may augment the ‘compensatory mechanisms’ in muscle, 
helping to maintain innervation in the muscle of mSOD1 mice.   
 
4.4.2 There is a differential HSR in fast and slow-twitch muscle 
There was a clear hsp72 response in both the TA and soleus muscle. However, 
the magnitude of the upregulation of hsp72 expression differed between the two 
muscles considerably. In the mSOD1 TA muscle, hsp72 expression remained at 
WT and wtSOD1 levels until symptomatic onset, when there was a sharp 
approximately 2-fold increase in hsp72. However, this increase was short-lived and 
fell again to WT levels. In contrast to the TA muscle, a very strong, 3-fold increase 
in hsp72 expression occurred in the soleus muscle. This was initiated before 
symptomatic onset and in the mSOD1 soleus muscle, hsp72 levels continued to 
rise until 100 days (an early stage of the disease).  
 
As both hsp72 and hsp25 have strong anti-oxidative actions and oxidative stress is 
a noted characteristic of mSOD1 pathology in muscle (Oishi et al., 2005, Gupte et 
al., 2009), the differential expression of hsp72 and hsp25 may also contribute to 
the established differential vulnerability between the two muscles to disease. 
Indeed, a less robust and weaker hsp72 response is likely to leave the TA muscle 
more vulnerable to oxidative stress, SR stress and subsequent mitochondrial 
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damage. Ultimately, this would render it more vulnerable to mSOD1-mediated 
pathology and less capable of dealing with neuromuscular pathology, such as 
denervation, and possibly reduced the effectiveness of compensatory mechanisms 
such as nerve terminal sprouting, which results in the reinnervation of denervated 
fibres. 
 
4.4.3 Hsp levels are high at points of vascularisation 
Furthermore, immnohistochemical analysis of hsp90 70, 60 and 25 expression 
revealed a general increase in the level of hsp expression outside of the muscle 
fibres at high points of vasculature. Thus, it is possible that hsps are not only 
released by the muscle but are also present within the blood. However, the 
examination of hsp content in the serum of mSOD1 mice, was outside of the 
parameters of this study. 
 
4.4.4 Treatment with Arimoclomol increases hsp expression  
Treatment with Arimoclomol resulted in a significant increase in the level of hsp90, 
hsp72, hsp60 and hsp25 in both the TA and the soleus muscles of mSOD1 mice. 
Kieran et al. (2004) and Kalmar et al. (2009) have previously shown the beneficial 
effects of increased hsp expression in the CNS of mSOD1 mice, induced by 
treatment with Arimoclomol. However, whether Arimoclomol also had a systemic 
effect in the periphery, which may contribute to its disease modifying effects in 
mSOD1 mice, has not yet been investigated. It is known that the upregulation of 
hsps can be beneficial to muscles under stress. For example, increased hsp60, a 
mitochondrial protein, can be beneficial to mitochondria, which are known to 
undergo significant pathology in the muscle of mSOD1 mice (Dupuis et al., 2004). 
In fact, its overexpression has been shown to confer strong cytoprotection to 
cardiac myocytes in vitro, reducing cell death following ischemia (Lin, Lin et al. 
2001). Likewise, hsp72 and hsp25 are known to have strong cytoprotective actions 
in muscle. Their anti-oxidative capabilities act to counter contractile damage 
following exercise (Preville et al., 1998, Vasilaki et al., 2006). Thus, increased 
levels of hsp72 and hsp25 are likely to prove beneficial to ROS metabolism in 
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mSOD1 muscle, reducing oxidative stress. Furthermore, as excessive ROS has 
been shown to destabilise the NMJ, and promote denervation (Dupuis and Loeffler, 
2009), Arimoclomol’s action at the NMJ may indeed work to lower ROS, and 
increase sprouting (via hsp90 and hsp25 mediated pathways), ultimately 
increasing innervation via a number of hsp pathways within muscle. 
 
This study also revealed that treatment with Arimoclomol increased the 
accumulation of hsp90 around the NMJ in the TA muscle, but not soleus muscle of 
mSOD1 mice. As hsp90 is known to regulate key proteins that mediate AChR 
aggregation (Luo et al., 2008) as well as neurite outgrowth (Ishimoto et al., 1998), it 
is likely to be cytoprotective to the preferentially vulnerable NMJs of the mSOD1 
TA muscle.  
 
4.4.5 Conclusion 
In conclusion, the data presented in the Chapter show that there is a strong but 
short-lived HSR in both the fast-twitch TA and the slow-twitch soleus muscle of 
mSOD1 mice, which is initiated between 45 and 75 days of age. This upregulation 
in hsp expression coincides with the period during which mechanisms that attempt 
to compensate for the loss of innervation are most active. This is when sprouting 
becomes significant (Chapter 3). As disease progresses, hsp levels and the level 
of sprouting declined. Since hsp90 and hsp25 have been shown to promote neurite 
outgrowth, it is possible that they are involved in the sprouting response in the 
periphery in mSOD1 mice, following the denervation of endplates. Hsp levels were 
generally greater in the slow-twitch soleus muscle, and as hsps have strong 
cytoprotective actions, it is possible that this elevated level of hsps contributes to 
the comparative resilience of the soleus to disease. In addition, elevated hsp72 
and hsp25 levels persisted in the more resilient soleus muscle. Hsp72 and hsp25 
are potent anti-oxidative proteins, and they may therefore contribute to the 
differential vulnerability of fast and slow-twitch muscles to disease.  
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Although the level of Arimoclomol present in the TA and soleus muscles was not 
examined, I was able show that treatment with Arimoclomol elevated hsp90, 
hsp72, hsp60 and hsp25 expression in both TA and soleus muscle in mSOD1 
mice. As hsp90 and hsp25 have been shown to increase neurite outgrowth, it is 
possible that they promote sprouting and thus the reinnervation of denervated 
endplates. Treatment also increased the expression of hsp72 and hsp90 at the 
NMJ, which is likely to be cytoprotective to both mSOD1 motoneurons and muscle. 
This was more apparent in the more vulnerable TA muscle. Together, these 
findings suggest that increased hsp expression is responsible, at least in part, for 
the beneficial effects of Arimoclomol in mSOD1 mice previously established in our 
group (Kieran et al., 2004). 
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Chapter 5 :  The effect of treatment with Arimoclomol on 
Nitric oxide synthase expression in mSOD1 mice 
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5.1 Introduction 
As neuromuscular disease and myopathies have a number of shared pathological 
characteristics, I was interested in examining the expression of proteins known to 
influence muscle in myopathies. One recurrent feature of muscle pathology across 
several pathological characters is the preferential vulnerability of fast-twitch 
muscles to pathology, which is also a feature of mSOD1 induced muscle 
pathology. For example, fast-twitch muscle is also preferentially vulnerable to 
disease in Duchene muscular dystrophy (DMD) (Grozdanovic and Baumgarten, 
1999). One protein that has been implicated in such pathologies is neuronal nitric 
oxide synthase (nNOS), which has also been implicated in the muscle response to 
denervation (Ribera et al., 1998) and recently discovered to be implicated in ALS 
(Suzuki et al., 2010). Likewise, inducible nitric oxide synthase (iNOS) has a key 
role in the pathogenesis of inflammatory myopathy, Inclusion Body Myostitis (IBM) 
(Baron et al., 2000). Neuroinflammation is also significant in the CNS of ALS 
patients and mSOD1 mice (Chen et al., 2009). Thus, the expression of these two 
proteins was examined in fast and slow-twitch muscles of mSOD1 mice, in order to 
investigate whether nNOS and iNOS played may play a role in pathology in the 
muscles of mSOD1 mice.  
 
5.1.1 Neuronal nitric oxide synthase 
nNOS, a calcium-camodulin dependent enzyme, is expressed throughout the 
nervous system, however, it is most abundant in skeletal muscle, where it is found 
anchored to the sarcolemma via the dystrophin-glycoprotein complex (Stamler and 
Meissner, 2001) (See Fig.5.1). Furthermore, nNOS is expressed to a greater 
degree in fast-twitch muscle fibres (Stamler and Meissner, 2001). In addition, to its 
presence at the sarcolemma, accumulates at the NMJ, and within the presynaptic 
nerve terminal (Pereira et al., 2001), where it produces low levels of nitric oxide 
(NO) that act as a chemical messenger (Reid, 1998). NO produced by nNOS is 
involved in a number of pathways that are necessary for normal muscle function 
(Stamler and Meissner, 2001), such as the modulation of muscle contraction, NMJ 
stability, vasodilation and glucose uptake within skeletal muscle (Stamler and 
Meissner, 2001).   
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Figure 5.1: nNOS expression at the sarcolemma of skeletal muscle 
This schematic representation illustrates the presence of nNOS in the DGC 
complex. It is anchored at the membrane by caveolin and is also associated with α-
syntrophin, which is bound to dystrophin, which in turn is bound to actin (Sweeney 
and Barton, 2000).  
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nNOS is known to interact with hsp90 (Peng et al., 2009), which regulates its 
activity and turnover. Hsp90 is essential for the normal function of nNOS (Bender 
et al., 2004), stabilising it and promoting nNOS activity by preventing its binding to 
hsp70 and the subsequent degradation of nNOS (Peng et al., 2009). Increased 
hsp90/nNOS interactions are thought to increase vasodilation and alter cell 
metabolism (Pratt et al., 2008). 
 
5.1.2 nNOS expression following denervation 
nNOS expression alters significantly following denervation, with nNOS 
translocating from the sarcolemma to the sarcoplasm (see Fig.5.2). This results in 
the generation of reactive nitrogen species (RNS) and the upregulation of the 
transcription factor FOXO. FOXO plays an important role in the initiation of muscle 
atrophy (Senf et al., 2010), initiating the transcription of the ubiquitin ligase and  
atrogin-1 genes. This increases the ubiquitination of proteins and the ensuing 
increase in protein degradation by the proteosome, and thus muscle atrophy. 
Indeed, the importance of nNOS to denervation-induced muscle atrophy was 
successfully demonstrated by Suzuki et al. (2007) who used nNOS-deficient 
(nNOS-/-) mice to show that in the absence of sarcoplasmic nNOS denervation 
does not result in the activation of the FOXO pathway, and thus nNOS-/- mice 
exhibit significantly less denervation-dependent muscle atrophy than WT mice 
(Suzuki et al., 2007).   
 
Following muscle denervation, nNOS decreases within the presynaptic terminal 
(Suzuki et al., 2010). However, nNOS expression becomes apparent in terminal 
Schwann cells (tSChs), where it is thought to facilitate sprouting via tSCh 
projections (Keilhoff et al., 2002). In fact, Keilhoff et al. (2002) demonstrated using 
nerve injury in nNOS knockout mice that nNOS expression was necessary for 
normal Wallerian degeneration, the pruning of uncontrolled sprouts and even 
remyelination. They proposed suggested that nNOS was implicated in the 
remyelination of the proximal axon, the formation of new neuromuscular endplates,  
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Figure 5.2: A model of the role of nNOS following denervation 
Under normal conditions, nNOS is associated with the DGC at the sarcolemma. 
Following denervation nNOS dissociates from α1-syntrophin (Syn) and 
translocates to the sarcoplasm, where it continues to produce NO and regulates 
transcription factors such as FOXO. This results in increased muscle-specific 
ubiquitin ligase, MuRF-1 and atrogin-1, prompting muscle protein degradation via 
the proteosome (Diagram taken from Suzuki et al., 2007). 
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and the elongation of tSCh processes. 
 
Marques et al. (2006) also found that in the absence of nNOS, tSCh processes do 
not occur. As this phenomenon promotes the reinnervation of denervated 
endplates, the manipulation of nNOS at the NMJ may be beneficial to mSOD1 
mice (Marques et al., 2006). Although the precise role that tSChs play in the 
maintenance of NMJ integrity following insult is not fully understood, it has been 
consistently demonstrated that nNOS in tSChs plays a pivotal role in the 
reinnervation of denervated endplates in nNOS-/- mice (Ribera et al., 1998, Percival 
et al., 2008). 
 
5.1.3 Neuronal nitric oxide synthase in neuromuscular disease 
nNOS expression has been well-characterised in myopathies such as DMD 
(Pereira et al., 2001). In patients with DMD, nNOS is often absent from the 
sarcolemma and instead is distributed at reduced levels in the sarcoplasm. This 
pathology is more often observed in fast-twitch muscles (Webster et al., 1988, 
Grozdanovic and Baumgarten, 1999).  
 
Although our understanding of nNOS in ALS is less extensive than DMD, nNOS 
expression is known to be altered in skeletal muscle of ALS patients and mouse 
models of the disease (Chao et al., 1996, Soraru et al., 2007). In addition to 
instigating denervation-induced muscle atrophy (Suzuki et al., 2007), it has been 
proposed that the loss of nNOS from the sarcolemma and its translocation to the 
sarcoplasm may effect the modulation of protein nitrosylation (Jaffrey et al., 2001), 
muscle contraction (Percival et al., 2010), as well as cell metabolism (Mulvey et al., 
2005), NMJ stability (Auld and Robitaille, 2003) and vasodilation (Hare and 
Stamler, 1999). Therefore, it is possible that the disruption of nNOS expression in 
muscle in ALS may contribute to aspects of mSOD1-mediated pathology such as 
muscle atrophy, altered muscle contraction and cell metabolism and reinnervation. 
Furthermore, as fast and slow-twitch muscles are differentially effected by a 
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number of these pathological characteristics, it is possible that nNOS is also 
differentially expressed. 
 
Manipulation of nNOS has been shown to benefit muscle in patients suffering from 
Becker’s and Duchenne’s muscular dystrophy, where the severity of the disease 
can be correlated to the presence of sarcoplasmic nNOS (Bredt, 1998). In a mouse 
model of DMD, the overexpression of nNOS in muscle has been shown to increase 
sarcolemmal nNOS and alleviate some defects at the NMJ and improve muscle 
function (Shiao et al., 2004). To date, a number of treatments inhibiting systemic 
NO production have been tried, but few have yielded significant results. The 
upregulation of nNOS in mSOD1 mice, particularly in the muscle, has not been 
extensively examined.  
 
5.1.4 Inducible nitric oxide synthase in neuromuscular disease 
While nNOS operates at a physiological level, NO synthesised by iNOS is 
commonly associated with pathological events within the cell, namely inflammation 
(Stamler and Meissner, 2001). In the muscle, iNOS is highly expressed in patients 
with chronic heart failure, autoimmune diseases and inflammatory myopathies 
such as IBM (Stamler and Meissner, 2001).  
 
In addition, neuroinflammation is a pathological hallmark in the CNS of mSOD1 
mice and contributes to motoneuron death (Hensley et al., 2006). Following 
symptomatic onset, iNOS is expressed at high levels in astrocytes and microglia 
within the spinal cord where it has been implicated in glial activation (Lee et al., 
2009). However, the role of inflammation in the muscle in ALS remains unclear. In 
myopathies, muscle atrophy redundant can result from continued denervation, loss 
of activity, inflammation or metabolic dysregulation (Agusti et al., 2004, Atkin et al., 
2005, Suzuki et al., 2007, Dupuis et al., 2009). All of these pathologies feature in 
ALS muscle to varying degrees and are present in the mSOD1 mouse model of 
ALS. More knowledge about iNOS’s actions in the periphery, where symptomatic 
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onset first occurs, may provide further insight into the mechanisms underlying 
muscle atrophy, as well as suggesting effective therapeutic strategies to combat 
the disease. 
 
Aim 
In view of nNOS’s role in DMD, denervation, and iNOS’s role in IBM and 
neuroinflammation in the CNS in ALS, iNOS and nNOS expression in the fast-
twitch TA and slow-twitch soleus muscle of mSOD1 mice will be examined over the 
course of disease. The effect of Arimoclomol, a known co-inducer of the HSR, on 
iNOS and nNOS expression in the TA and soleus muscles of mSOD1 mice will 
also be investigated. 
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5.2 Methods 
5.2.1 Animals 
Animals were housed, genotyped and maintained until various stages of disease, 
as detailed in Chapter 2, Section 2.1.1, 2.1.2 and 2.1.3. 
 
5.2.2 Muscle Dissection and Muscle homogenisation 
Muscles were dissected as detailed in Chapter 2, Section 2.2.2. Muscle 
homogenisation was carried out as detailed in Chapter 2, Section 2.2.8. 
 
5.2.3 Western blotting 
NNOS and iNOS western blots were undertaken as detailed in Chapter 2, Section 
2.2.9. For each blot, a loading control was also run using β-actin and nNOS, and 
iNOS line densities from the experiments were normalised against line densities of 
β-actin bands using ImageQuant software (Amersham). For ease of presentation, 
data was then expressed as a percentage of the corresponding WT. Statistical 
analysis was carried out between the transgenic wtSOD1 and mSOD1 mice, in 
order to eliminate the effects of protein overexpression of SOD1 in the mSOD1 
model when examining untreated samples. In experiments examining the effect of 
Arimoclomol, statistical analysis was carried out between untreated and 
Arimoclomol-treated hyphenate mSOD1 samples. 
 
5.2.4 Immunohistochemistry and microscopy 
Immunohistochemical stains for nNOS, AChR and hsp90 were carried out as 
described in Chapter 2, Section 2.2.3 using the antibodies detailed in Table 2.3 
and 2.4. 
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5.2.5 Mouse-on-mouse Immunohistochemistry 
For iNOS staining, a polyclonal mouse antibody was used. Consequently, 
immunohistochemical detection of iNOS in muscle sections required the use of a 
mouse-on-mouse (MOM) immunodetection kit (Vector Labs.). The protocol for 
MOM IHC can be found in Chapter 2, Section 2.2.4. 
 
5.2.6 Statistical analysis 
Statistical significance between the mean values was assessed using a one-way 
ANOVA test. Post hoc, all pairwise multiple comparisons were done using the T-
test unless otherwise mentioned.  Values are assessed as mean ± standard error 
of the mean (SEM). Significance was set at p≤ 0.05. 
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5.3 Results  
nNOS expression was examined in TA and soleus muscles of WT, wtSOD1 and 
mSOD1 mice by Western blot and IHC. For Western blot data, the expression 
levels in the muscles of mSOD1 mice were expressed as a percentage of WT 
levels and then compared to those of wtSOD1 mice in order to take the effect of 
overexpression of the SOD1 protein into account. 
 
5.3.1 nNOS expression in the TA muscle of mSOD1 mice 
As shown in Fig.5.3, nNOS expression in wtSOD1 TA muscle was 148.1% (±7.2 
SEM; n=4) of WT (100%).  In mSOD1 TA muscle, nNOS levels changed 
significantly during disease progression. At 45 days of age, nNOS levels were 
148.9% (±30.6 SEM; n=4) of WT. This was similar to that observed in wtSOD1 TA 
muscle (p=0.981). However, by 75 days, the level of nNOS present in mSOD1 TA 
muscle had increased dramatically, so that levels were 262.7% (±20.9 SEM; n=4) 
of WT, and this was significantly more than wtSOD1 TA muscle (p<0.001). As 
disease progressed, nNOS levels declined in mSOD1 TA muscle and by 100 days 
of age, nNOS levels were 114.7% (±9.1 SEM; n=4) of WT levels. However, this 
was not significantly less than wtSOD1 TA muscle (p=0.076). By 120 days of age, 
the level of nNOS had declined even further and was only 68.7% (±4.8 SEM; n=4) 
of WT; this level was significantly less than wtSOD1 TA muscle (p=0.0008).  
 
Immunostaining for nNOS on TA muscle sections revealed that nNOS was 
expressed at the sarcolemma of wtSOD1 TA muscle (Fig.5.3). However, nNOS 
expression in mSOD1 TA muscle was considerably altered. Even at 45 days, 
immunoreactivity for nNOS was reduced at the sarcolemma (Fig.5.3c, see arrow). 
By 75 days of age, nNOS immunoreactivity had largely relocated to the 
sarcoplasm. By 120 days, nNOS immunoreactivity the majority muscle fibres is 
vastly reduced, with the little nNOS present limited to the sarcoplasm (Fig.5.3). 
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Figure 5.3: Neuronal nitric oxide synthase expression in mSOD1 TA muscle  
Western blots for nNOS are shown (A-C) on TA muscle homogenate. (A) shows a 
pre-absorbed blot for nNOS run on a sample from wtSOD1 TA muscle. (B) shows 
a typical example of a nNOS western blot of TA muscle from WT, wtSOD1 and 45, 
75, 100 & 120 day old mSOD1 mice. (C) shows a representative nNOS western 
blot of TA muscle from WT and 120-day-old untreated and Arimoclomol-treated 
mSOD1 mice. The bar chart (D) summarises the line densities. Examples of typical 
immunohistochemical staining for nNOS in wtSOD1 TA muscle are shown in (E). 
The pattern of nNOS expression in mSOD1 TA muscles is shown at (F) 45 days, 
(G) 75 days (H) 100 days (I) 120 days and (J) Arimoclomol-treated 120-day-old TA 
muscles from mSOD1 mice. 
 
n=4; error bars= ± SEM; * = p<0.05; **= p≤0.01; ***= p≤0.001; Green= nNOS; 
scale bar =50µm 
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Next, the effect of treatment with Arimoclomol was examined. The blots showed 
that nNOS in mSOD1 TA muscles was significantly greater in TA muscles from 
Arimoclomol-treated 120-day-old mSOD1 mice, so that they were 194.1% (±14.0 
SEM; n=4) of WT. This was significantly more than seen in wtSOD1 (p=0.008). 
 
nNOS expression at the NMJ of the TA muscle was also examined in longitudinal 
sections of muscle from 120-day-old WT and mSOD1 mice (Fig.5.4). The structure 
of the NMJ was represented clearly on these sections. In WT muscle, nNOS was 
closely associated with α-bungarotoxin. However, a large proportion of the NMJs 
on mSOD1 TA muscle displayed disrupted AChR clustering and nNOS expression 
was reduced or absent (Fig.5.4c,d, see arrow).  
 
nNOS expression in mSOD1 TA at the NMJ was also examined using transverse 
sections of WT, wtSOD1 and untreated and Arimoclomol-treated 120-day-old 
mSOD1 TA muscle were co-stained with alpha bungarotoxin, DAPI and an 
antibody for nNOS. nNOS was closely associated with the NMJ and muscle. 
Transverse sections revealed that nNOS expression at the NMJ was greatly 
increased in wtSOD1 TA muscle fibres (Fig.5.4f, see arrow). In mSOD1 TA muscle 
there was a very different pattern of nNOS expression at the NMJ. In mSOD1 TA 
muscle, some NMJs did not colocalise with nNOS (Fig.5.4g, see white arrow). 
Treatment with Arimoclomol, however, increased nNOS expression at the NMJ of 
mSOD1 TA muscle (Fig.5.4h, see arrow).  
 
Hsp90 is known to elevate nNOS expression in muscle fibres by binding with 
nNOS, thus preventing its degradation (Song et al, 2001; Brennan et al., 2008; 
Pratt et al., 2008). As the increased translocation nNOS is likely to exacerbate 
aberrant nNOS signalling, the pattern of hsp90 and nNOS staining was examined 
in mSOD1 muscle.  
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Figure 5.4: nNOS expression at the NMJ in TA muscle of mSOD1 mice 
(A) shows an example of a longitudinal section of the WT TA muscle stained for 
nNOS (green) and (B) a merged representation of WT TA muscle stained for 
nNOS (green), α-bungarotoxin (red) and DAPI (blue). (C) a longitudinal section of 
mSOD1 TA muscle stained for nNOS (green) and (D) co-stained for nNOS (green), 
AChRs with α-bungarotoxin (red) and nuclei with DAPI (blue). (E-H) shows 
examples of nNOS expression in a transverse section of TA muscle stained for 
nNOS (green), α-bungarotoxin (red) and DAPI (blue), from WT (E), wtSOD1 (F), 
untreated mSOD1 (G) and Arimoclomol-treated (H) mSOD1 mice. 
 
n=4; nNOS (green), α-bungarotoxin (red) and DAPI (blue); scale bar =50µm 
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The results showed that nNOS/hsp90 colocalisation differed between wtSOD1 and 
mSOD1 TA muscle (Fig.5.5). TA muscle from 100-day-old wtSOD1 and mSOD1 
mice was stained with antibodies for nNOS, hsp90 and DAPI. The results revealed 
that there was very little colocalisation of nNOS with hsp90 in wtSOD1 TA muscle 
(Fig.5.5a), while there was a considerable level of colocalisation of nNOS and 
hsp90 expression at the sarcolemma and sarcoplasm of mSOD1 TA muscle 
(Fig.5.5c). Hsp90 colocalisation with sarcoplasmic nNOS was greatest [greater] in 
smaller, angulated muscle fibres (Fig.5.5b) than in the larger fibres (Fig.5.5c). 
 
Having established that Arimoclomol is sufficient to increase nNOS levels, I 
examined whether treatment would alter nNOS/hsp90 interaction in the TA muscle 
of mSOD1 mice. As can be seen in Fig.5.5e, treatment with Arimoclomol greatly 
reduced nNOS/hsp90 colocalisation within the sarcoplasm, leaving some 
nNOS/hsp90 colocalisation at the sarcolemma of muscle fibres.  
 
5.3.2 nNOS expression in the soleus muscle of mSOD1 mice  
nNOS expression was also examined in the slow-twitch soleus muscle of WT, 
wtSOD1 and mSOD1 mice at 45, 70, 100 and 120 days of age. As can be seen in 
Fig.5.6, western blotting revealed that nNOS levels in wtSOD1 soleus were higher 
than in WT soleus muscle, and were found to be 190.7% (±4.2 SEM; n=4) of WT. 
Next, nNOS levels in the soleus muscle of mSOD1 mice were examined, and did 
not change significantly over the course of the disease. Thus, at 45 days, nNOS 
levels were 184.6% (±21.8 SEM; n=4) of WT, which was similar to wtSOD1 
(p=0.82), and 214.3% (±88.0 SEM; n=4) of WT at 75 days, which was not 
significantly more than wtSOD1 (p=0.30). After this point nNOS levels began to 
decline, so that by 100 and 120 days of age, nNOS levels in mSOD1 soleus 
muscle were 124.4% (±40.9 SEM; n=4) and 95.2% (±62.8 SEM; n=4) of WT.  
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Figure 5.5: nNOS and hsp90 expression in TA and soleus muscle of mSOD1 
mice 
TA (A) and soleus (B) muscles of wtSOD1 mice at 100 days of age were stained 
for nNOS (red) and hsp90 (green).  An example of hsp90 (green) and nNOS (red) 
co-staining in mSOD1 mice can be seen in the TA (C) and (D) soleus muscles. A 
representative stain of hsp90 and nNOS colocalisation in Arimoclomol-treated 120-
day-old mSOD1 TA (E) and soleus (F) muscle can also be seen. 
 
n=4; Green= hsp90; Red=nNOS; Blue= nuclei; scale bar =50µm 
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Figure 5.6: nNOS expression in the soleus muscle of mSOD1 mice 
(A) shows a typical nNOS western blot of soleus muscle from WT, wtSOD1 
mSOD1 mice at 45, 75, 100 and 120 days of age. (B) shows a typical nNOS 
western blot of soleus muscle from WT, untreated and Arimoclomol-treated 
mSOD1 mice at 120 days of age. The bar chart (C) summarises the line densities 
from (A&B). (D-I) shows an example of soleus muscles immunostained for nNOS. 
Examples of nNOS (green) staining in wtSOD1 mice are summarised in (D). An 
example of nNOS staining in the soleus muscle of mSOD1 mice at 45 days of age 
can be seen in (E). An example of nNOS expression in the soleus muscle of 
mSOD1 mice at 75 (F), 100 (G) and 120 (H) is also shown. (I) shows an example 
of nNOS (green) and DAPI (blue) expression in the soleus muscle of 120 day old 
Arimoclomol-treated mSOD1 mice.  
 
n=4; error bars= ± SEM; * = p<0.05; scale bar =50µm 
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Although these levels were reduced, they were not significantly less than wtSOD1: 
(p=0.40) and (p=0.87) respectively. Treatment with Arimoclomol increased nNOS 
expression, so that levels were 436.41% (±136.76 SEM; n=4) of WT. This is 
significantly more than untreated mSOD1 soleus muscle (p=0.0132).  
 
The pattern of nNOS expression in WT, wtSOD1 and mSOD1 skeletal muscle was 
also examined using IHC. Immunostaining revealed that nNOS was present at the 
sarcolemma of muscle fibres of wtSOD1 soleus muscle (Fig.5.6) and nNOS 
immunoreactivity did not significantly differ in mSOD1 mice from that observed in 
wtSOD1 mice (Fig.5.6).  
 
Examination of nNOS expression at the NMJ of soleus muscle from WT, wtSOD1 
and mSOD1 mice showed that nNOS was present at the NMJ of WT soleus but 
was considerably increased at the NMJ of wtSOD1 soleus muscle. In 120-day-old 
mSOD1 soleus muscle, nNOS was also detected at the NMJs of WT soleus 
muscle, although this intensity was less (Fig.5.7). Staining of longitudinal mSOD1 
muscle sections revealed that nNOS was present in nucleated structures 
surrounding the endplate and nerve terminal. These were likely to be terminal 
Schwann cells (Fig.5.7).  
 
Evaluation of hsp90 and nNOS colocalisation using IHC revealed that hsp90 and 
nNOS colocalisation in mSOD1 soleus muscle was far less pronounced than in 
mSOD1 TA. Treatment with Arimoclomol removed the majority of nNOS/hsp90 
colocalisation at the sarcolemma (Fig.5.5f) and reduced the presence of 
sarcoplasmic nNOS/hsp90 colocalisation. 
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Figure 5.7: nNOS expression at the NMJ of soleus muscle from mSOD1 mice 
Transverse sections of soleus muscle (A) WT, (B) wtSOD1 (C) 120-day-old 
mSOD1 mice were stained with nNOS (green), DAPI (blue) and α-bungarotoxin 
(red). Longitudinal sections from the soleus of mSOD1 mice (D&E) were also 
stained for nNOS, which was co-localised around AChRs in soleus muscles of 120-
day-old mSOD1 mice. A merged image showing nNOS, AChR and nuclei is shown 
(E). 
n=4; scale bar =50µm 
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5.3.3 iNOS expression in the TA muscle of mSOD1 mice 
iNOS is an important enzyme that plays a role in the initiation of the inflammatory 
response in cells (Seago et al., 1995). Unlike nNOS, which is physiologically 
relevant to the normal function of muscle, iNOS is associated with pathological 
events in the muscle (Zhao and Qiu, 2004) and is found to be upregulated in a 
number of myopathies such as DMD and IBM (Yang et al., 1998, Louboutin et al., 
2001).  
 
Western blot analysis revealed that the level of iNOS in TA muscle of WT and 
wtSOD1 mice was very low (Fig.5.8). The level of iNOS in the TA muscle of 
wtSOD1 mice was 90.0% (±3.3 SEM; n=4) of WT (100%). iNOS levels remained 
low in the TA muscle of mSOD1 mice and in 45-day-old mSOD1 mice, levels were 
98.9% (±4.3 SEM; n=4) of WT TA muscle, which was similar to wtSOD1 (p=0.626). 
But by 75 days, iNOS levels had more than doubled, so that levels were 244.0% 
(±10.5 SEM; n=4) of WT. This was significantly more than wtSOD1 (p<0.001). 
Levels remained elevated at 100 days of age, when they were 245.0% (±30.8 
SEM; n=4) of WT, which was significantly more than wtSOD1 (p<0.001). By 120 
days, iNOS had fallen to 167.0% (±3.6 SEM; n=4) of WT, which was significantly 
more than wtSOD1 (p=0.003).  
 
Immunohistochemistry was used to examine the pattern of iNOS expression in 
wtSOD1 and mSOD1 TA muscle. As can be seen in Figure 5.8, iNOS 
immunoreactivity was low in wtSOD1 TA muscle as well as in the TA muscles of 
mSOD1 mice at all stages examined. Treatment with Arimoclomol increased iNOS 
levels in mSOD1 TA muscles so that they were 224.2% (±34.2 SEM; n=3) of WT 
levels. This was significantly more than untreated mSOD1 TA muscle (p=0.002). 
However, analysis of iNOS expression using IHC revealed that iNOS 
immunoreactivity was still low in Arimoclomol-treated mSOD1 TA muscle.    
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Figure 5.8: iNOS expression in mSOD1 TA muscle  
(A) shows an example of a iNOS western blot of TA muscle from WT, wtSOD1 and 
mSOD1 mice at 45, 75, 100 and 120 days of age. (B) shows a representative iNOS 
blot of TA muscle from WT, untreated and Arimoclomol-treated mSOD1 mice at 
120 days of age. The bar chart (C) summarises the optical line densities. (D) 
shows an example of iNOS (green) immunostaining in wtSOD1 TA muscle. iNOS 
expression in TA muscle from mSOD1 mice at 45 days (E), 75 days (F), 100 days 
(G) and 120 days (H) can also be seen, respectively. (I) shows iNOS expression in 
TA muscle from 120-day-old Arimoclomol-treated mSOD1 mice. 
 
n=4; error bars= ± SEM; * = p<0.05; scale bar =50µm 
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5.3.4 iNOS expression in mSOD1 soleus muscle  
As can be seen in Figure 5.9, iNOS levels were similar in wtSOD1 soleus muscle 
to that in WT soleus: 133.5% (±9.6 SEM; n=4). However, iNOS levels in mSOD1 
soleus changed significantly during disease progression. At 45 days of age, they 
were 146.9% (±26.3 SEM; n=4) of WT soleus muscle, which was not significantly 
more than wtSOD1 (p=0.063). By 75 days of age, this had increased to 174.9% 
(±32.6 SEM; n=4) of WT, which was significantly more than wtSOD1 soleus muscle 
(p=0.032). INOS levels continued to increase in mSOD1 soleus muscle, so that by 
100 days of age iNOS levels were 232.3% (±21.7 SEM; n=4) of WT. This was 
significantly more than in wtSOD1 soleus muscle (p=0.018). Levels remained 
raised, so that at 120 days of age they were 180.8% (±7.2 SEM; n=4) of WT, and 
this was significantly more than wtSOD1 soleus muscle (p=0.0313).  
 
Treatment with Arimoclomol decreased iNOS levels, so that at 120 days of age, 
they were 125.4% (±17.45 SEM; n=3) of WT. This was significantly less than in 
untreated mSOD1 soleus muscle (p=0.05). Immunohistochemistry revealed that 
there was very little iNOS in wtSOD1 soleus muscle (Fig.5.9), which was the case 
with mSOD1 soleus muscle. Treatment with Arimoclomol did not alter the pattern 
of staining in the mSOD1 soleus muscle.  
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Figure 5.9: iNOS expression in the soleus muscle of mSOD1 mice 
(A) shows an example of a iNOS western blot of soleus muscle from WT, wtSOD1 
as well as 45, 75, 100 and 120 mSOD1 mice. (B) shows an example of a iNOS 
western blot of soleus muscle from WT, untreated and Arimoclomol-treated 
mSOD1 mice at 120 days. The bar chart (C) summarises the line densities. (D) 
shows an example of iNOS (green) immunostaining in wtSOD1 soleus muscle. An 
example of iNOS expression in soleus muscle from mSOD1 mice at (E) 45 days 
(F) 75 days (G) 100 days and (H) 120 days can be seen. (G) shows an example of 
iNOS expression in the soleus muscle of Arimoclomol-treated mSOD1 mice, and 
the section is co-stained with DAPI (blue).  
 
n=4; error bars= ± SEM; * = p<0.05; scale bar =50µm 
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5.4 Discussion 
This Chapter examined NOS expression in the fast-twitch TA and slow-twitch 
soleus muscle and the results revealed that nNOS and iNOS expression was 
significantly altered in muscles of mSOD1 mice. Furthermore, the results show that 
treatment with Arimoclomol, a co-inducer of the HSR, significantly alters mSOD1-
mediated changes in nNOS and iNOS expression in muscle of mSOD1 mice. 
 
5.4.1 Nitric Oxide synthase levels are altered in wtSOD1 TA muscle 
The results presented in this Chapter show that nNOS expression is significantly 
raised in wtSOD1 TA muscle. While this has never been reported in mSOD1 
muscle, it is of interest to note that nNOS overexpression has been shown to alter 
SOD1 expression in murine muscle (Baldelli et al., 2008), although the underlying 
mechanism is not fully understood. It is known that NO, produced by NOS, can 
react spontaneously with SOD1 and can generate protein tyrosine nitration 
(Ferrante et al., 1997). Furthermore, in motoneurons, after zinc depletion in 
mSOD1, superoxide anions lead to the generation of RNS; thus, it is possible that 
O2 levels influence nNOS expression. In addition, in cardiac muscle, superoxide 
and nNOS have been shown to work in opposing pathways in order to promote 
effective excitation-contraction coupling (ECC). Since a similar mechanism for ECC 
is present in skeletal muscle, it is possible that a similar nNOS/SOD1 relationship 
may also be present (Eu et al., 2000). This ECC pathway is illustrated in Fig.5.10. 
 
5.4.2 Neuronal Nitric Oxide synthase expression is altered in mSOD1 muscle 
To date, nNOS expression in muscles of ALS patients and mSOD1 mice has only 
been examined in a small number of studies and only at a late symptomatic stage 
when denervation is already extensive. In this study, nNOS was examined in the 
muscle of mSOD1 mice before symptomatic onset and was monitored over the 
course of the disease. This study demonstrated that in the TA muscle of mSOD1 
mice there is a significant, but transient increase in nNOS expression at 
symptomatic onset, which is coupled with the translocation of nNOS to the 
sarcoplasm where it is likely to promote FOXO activation and muscle atrophy. 
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Figure 5.10: Possible mechanism for increased nNOS expression in wtSOD1 
muscle 
In cardiac muscle, the enzymes nNOS and xanthine oxidoreductase (XOR) are 
expressed in close proximity to the SR, promoting effective excitation-contraction 
coupling. These enzymes are similarly located in skeletal muscle. nNOS catalyses 
the production of NO, which can then S-nitrosylate a specific cysteine on the RyR1 
SR calcium channel. This increases the probability of the channel opening and 
thus promotes calcium release during excitation–contraction coupling. XOR utilises 
O2 (produced by SOD1) in order to produce superoxide, which can diffuse out of 
the SR and inhibit calcium responsiveness of contractile machinery, thus inhibiting 
contraction. In addition to activating calcium release through the RyR1, NO can 
increase contractility by impeding the release of superoxide from the SR by direct 
reaction (solid red arrow). This results in the spontaneous formation of 
peroxytnitrite. Additionally, superoxide may be able to inhibit contractility by 
inhibiting NO-mediated activation of the RyR1, via the spontaneous formation of 
peroxytnitrite (Cleveland and Rothstein, 2001) (dashed blue line). In wtSOD1 mice, 
excess SOD1 activity may result in increase H2O2 and O2, which in turn may 
enable the production of O-2 by XOR. This results in an increase in O-2, which can 
then diffuse out of the SR and decrease the responsiveness of contractile 
machinery. Increased nNOS expression results in an increase in NO, which can 
counteract the effects of O-2. This results in normal muscle contraction (Image 
adapted from (Bonaventura and Gow, 2004).  
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After this stage, nNOS levels fall dramatically and by a late stage of disease, nNOS 
levels are significantly lower than wtSOD1 levels (Soraru et al., 2007; Suzuki et 
al.,2010). The translocation of nNOS from the sarcolemma to the sarcoplasm 
following denervation has been documented in ALS patients (Soraru et al., 2007) 
and mSOD1 mouse models (Suzuki et al., 2010). The results presented in this 
Chapter show that nNOS is initially upregulated at a time when sprouting becomes 
present, but then is quickly down-regulated as nNOS begins to translocate to the 
sarcoplasm. As the disease progresses in mSOD1 mice, increased levels of nNOS 
are found at the sarcoplasm and nNOS staining at the sarcolemma becomes 
discontinuous. This change is likely to result in muscle pathology via the FOXO 
pathway, as NO is known to activate the transcription factor FOXO (Suzuki et al., 
2007). FOXO accumulates in the nucleus of muscle cells, and its actions 
consequently promote the degradation of muscle proteins via the proteosome 
(Senf et al., 2010).  
 
5.4.3 Neuronal Nitric Oxide synthase is differentially expressed in fast and 
slow-twitch muscle in mSOD1 mice 
Examination of nNOS expression in the fast-twitch TA and slow-twitch soleus 
muscle of mSOD1 mice also revealed a differential pattern of nNOS expression in 
the two muscle types. In the soleus muscle of mSOD1 mice, nNOS levels did not 
alter significantly over the course of the disease, while levels changed dramatically 
in the TA muscle of mSOD1 mice. NNOS was also found more readily at the 
sarcolemma in the TA muscle. Notably, the soleus muscle does not undergo 
significant muscle atrophy until a late stage of disease, while atrophy in the TA 
occurs at a far earlier stage (Kalmar et al. 2009). Furthermore, the fact that nNOS-
/- mice display decreased muscle atrophy suggests that the differential expression 
of nNOS may underlie, at least in part, the preferential vulnerability of the TA 
muscle.  
 
The results presented in this Chapter show that hsp90 colocalises strongly with 
nNOS in skeletal muscle from mSOD1 mice, but to a lesser extent in wtSOD1 
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mice. Furthermore, that hsp90/nNOS colocalisation is greatest in the sarcoplasm of 
the TA muscle of mSOD1 mice. Evidence indicates that hsp90’s binding to nNOS 
inhibits the binding of hsp72, thus preventing its degradation via the proteosome 
(Peng et al., 2009). If so, higher levels of NO may be produced in more vulnerable 
fast-twitch muscles such as the TA muscle, and NO produced by the displaced 
nNOS may facilitate muscle atrophy via the FOXO pathway (Suzuki et al., 2007). 
 
5.4.4 Neuronal Nitric Oxide synthase expression is altered at the endplate of 
muscle from mSOD1 mice 
NNOS expression is essential for terminal Schwann cell activation, which promotes 
sprouting and reinnervation. Indeed, nNOS-deficient mice display no tSCh 
reactivity following denervation, and subsequently very little sprouting or 
reinnervation (Marques et al., 2006). Following denervation in nerve injury models, 
considerable sprouting ensures normal muscle function. This can result in up to a 
8-fold increase in motor unit size (Vrbova and Gordon, 1994). This does not occur 
in mSOD1 mice, and instead sprouting (as shown in Chapter 3) persists for a short 
duration and then declines. NNOS’ paramount role has been consistently 
demonstrated in reinnervation and has been implicated in Wallerian degeneration, 
sprouting and the general neuromuscular plasticity (Vrbova and Gordon, 1994). 
Thus, it is possible that the low level of sprouting in mSOD1 mice is due to, at least 
in part, an altered nNOS response. 
 
This Chapter examined nNOS expression at the NMJ in the fast-twitch TA muscle 
and the slow-twitch soleus muscle of mSOD1 mice and demonstrated that nNOS 
was only found at a few NMJs in the TA and soleus muscles of 100-day-old 
mSOD1 mice, when denervation is significant in the TA muscle (as shown in 
Chapter three). Indeed, nNOS immunoreactivity was low in areas where AChRs 
expression was sparse, indicative of denervated emptied endplates. Furthermore, 
there is a body of evidence to suggest that some NMJs are intrinsically more 
vulnerable to denervation. These endplates are often innervated by fast-fatigable 
motor units (Santos et al., 2003). It is possible that these NMJs are the earliest to 
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become denervated, and are subsequently unable to up-regulate nNOS expression 
in tSCh. In turn, this makes them less likely to be reinnervated by a sprout, and 
thereby leaves those muscles fibres even more vulnerable to denervation, induced 
muscle atrophy and other mSOD1 pathology.  
 
5.4.5 Inducible Nitric Oxide Synthase expression is altered in the muscle of 
mSOD1 mice 
INOS expression in the muscle of mSOD1 mice was different from nNOS 
expression. This study revealed increasing, progressive iNOS levels in both the TA 
and the soleus muscle, indicative of a slow but mounting inflammatory response. 
These changes were greatest at points of vascularisation and colocalised with 
CD11b expression, a marker of macrophages, (appendix two, Fig. 9.1b,d). 
Together these data suggest that the iNOS present was not released by muscle, 
but rather by macrophages present in the blood stream; furthermore, macrophages 
that were elicited by a significant systemic inflammation response, in contrast to a 
muscle-mediated inflammatory response. Indeed, the strong immunostaining of 
the, more resilient but more vascular, soleus muscle for CD11b indicates the 
possibility of autoimmune response present in the mSOD1 mice during the later 
stages of disease.  
 
It is interesting to note, that it has been established that ALS shares a number of 
pathological characteristics, such as oxidative stress and mitochondrial dysfunction 
with autoimmune neuropathies like multiple sclerosis (Staines, 2008) as well as 
autoimmune myopathies like IBM (see Table 1.2). Furthermore, it has been shown 
that Riluzole, an anti-glutamatergic drug and the only drug available for the 
treatment of ALS, can suppress autoimmune encephalitis (Gilgun-Sherki et al, 
2003). In addition, muscle from ALS patients has been found to possess calcium 
channel binding kinetics similar to that seen in autoimmune motoneuron diseases 
(Smith RG et al., 1995). Thus, it is possible that the CD11b (indicative of 
macrophages) present at point of vascularisation, in both fast and slow muscles 
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may be a marker for an additional inflammatory pathology, which may be 
independent of the glial cell-mediated neuroinflammation present within the CNS.  
 
5.4.6 Treatment with Arimoclomol alters nNOS & iNOS expression in mSOD1 
muscle 
The results in this Chapter showed that the systematic treatment of mSOD1 mice 
with Arimoclomol upregulated nNOS expression differentially in fast and slow-
twitch muscle of in mSOD1 mice. Immunostaining revealed that this upregulation 
was largely limited to the NMJ, which demonstrated a strong increase in nNOS 
reactivity. Arimoclomol also resulted in the reduction of hsp90/nNOS colocalisation 
at the sarcoplasm. This effect was greatest in the fast-twitch TA muscle. These 
findings suggest that treatment with Arimoclomol is sufficient to reduce 
sarcoplasmic nNOS, while increasing nNOS at the NMJ. It is of interest to note that 
reduced sarcoplasmic nNOS would result in a reduction in muscle atrophy via the 
down-regulation of the FOXO pathway. Meanwhile, increased nNOS at the NMJ 
could be indicative of nNOS expression in tSChs, which could promote sprouting. 
These effects may increase reinnervation of denervation endplates, maintaining 
muscle function for longer within mSOD1 muscle and may be responsible, at least 
in part, for the beneficial effects of Arimoclomol presented in Chapter 3. Treatment 
with Arimoclomol increased iNOS expression in the more vulnerable TA muscle; 
however, this increase was not reflected in an increase in iNOS immunoreactivity. 
Paradoxically, treatment with Arimoclomol decreased in iNOS expression within 
the more resilient soleus muscle. 
 
5.4.7 Conclusion 
In conclusion, although Arimoclomol increases nNOS expression in fast-twitch 
muscles of mSOD1 mice, it has little effect on nNOS levels in slow-twitch muscles 
like the soleus. In the fast-twitch TA muscle, this upregulation is restricted to the 
sarcolemma and around the endplate region, suggesting that Arimoclomol may 
influence both muscle atrophy (via the FOXO/Akt pathway) and sprouting via 
nNOS.
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Chapter 6 : The effect of mSOD1 expression in muscle 
cultures following cell stress
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6.1 Introduction 
ALS is known to be a non cell autonomous disease with non-neuronal cells in the 
CNS and spinal cord significantly contributing to motoneuron pathology (Ilieva et 
al., 2009). However, to date, the role of the primary target affected—muscle—
remains unclear.  
 
6.1.1 Muscle pathology in ALS 
Some studies suggest that muscle pathology is not a primary target in ALS, and 
that neuromuscular events are secondary to events occurring in the CNS and that 
muscle pathology does not therefore contribute to disease pathogenesis (Miller et 
al., 2006). For example, Miller et al. (2006) demonstrated that the viral delivery of 
transcription-mediated silencing RNA to mSOD1 mice, which suppressed mSOD1 
accumulation in muscle, was insufficient to alter disease onset or survival.  
 
However, the extent of mSOD1 silencing is difficult to determine. Furthermore, a 
number of additional studies indicate a role for muscle in mSOD1 pathology and 
ALS (Dobrowolny et al., 2008). For example, Dobrowolny et al. (2008) showed, 
using transgenic mice that expressed mSOD1 selectively in skeletal muscle, that 
expression was sufficient to cause progressive muscle atrophy, significant muscle 
weakness, and increased ROS as well as contractile and mitochondrial 
dysfunction. Likewise, Wong and Martin (2010) showed that the selective 
transgenic expression of mSOD1 in skeletal muscle could cause significant 
motoneuron pathology in the spinal cord accompanied by distal axonopathy, 
inclusion formation and motoneuron degeneration via an apoptotic-like capsase-3 
pathway (Dobrowolny et al., 2008, Wong and Martin, 2010). 
 
A growing body of evidence demonstrates significant underlying pathology within 
the muscle of ALS patients (Dupuis et al., 2003, Pradat et al., 2007, Halter et al., 
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2010). For example, prior to symptomatic onset and motoneuron death, there is 
significant denervation at the NMJ (Fischer et al., 2004) and mitochondrial 
pathology within muscle, resulting in increased mitochondrial uncoupling protein 
and the subsequent dismantling of the NMJ (Dupuis and Loeffler, 2009). 
 
Nevertheless, evidence shows a clear differential vulnerability between fast and 
slow-twitch muscle fibres to ALS pathology (Frey et al., 2000). Indeed, it has been 
shown that NMJs on fast-twitch muscles from mSOD1 mice undergo earlier 
denervation than slow-twitch muscles (Frey et al., 2000). Furthermore, there is 
evidence demonstrating an intrinsic vulnerability of fast-twitch fibres to injury and 
general cell insult (Lowrie and Vrbova, 1984). 
 
In previous Chapters, the results demonstrate a differential vulnerability of fast and 
slow-twitch muscles to mSOD1-mediated pathology. I have also highlighted 
pathways that are likely to contribute to this differential vulnerability. In agreement 
with other findings (Frey et al., 2000), the results in Chapter 3 revealed that 
mSOD1 fast-twitch muscle is more vulnerable to mSOD1 pathology than slow-
twitch muscle. Furthermore, that denervation occurred before symptomatic onset, 
much earlier than in the slow-twitch soleus and proved more extensive than in the 
slow-twitch soleus over the course of disease. Furthermore, the results in Chapter 
4 showed that fast-twitch muscle, such as the TA muscle, was less capable of 
mounting and maintaining a HSR over the course of the disease. In Chapter 5, the 
data showed a greater susceptibility for the dislocation of nNOS to the sarcoplasm, 
which is an event likely to promote denervation-induced muscle atrophy. 
 
In addition, a number of myopathies, like IBM and DMD, which also display 
preferential vulnerability in fast-twitch muscle. Thus, it is possible that fast-twitch 
muscle is intrinsically more vulnerable to disease and cell insult than slow-twitch 
muscles like the soleus muscle. If so, it is likely that fast-twitch muscle is less 
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capable of dealing with non-pathological cell stress, such as glucose deprivation or 
a contractile/oxidative stress. It is also possible that the expression of mSOD1 
renders muscle cells even more vulnerable to these stresses. 
 
6.1.2 Cell stress in muscle cells 
6.1.2.1 Muscle contraction 
One vital component of muscle contraction is excitation contraction coupling 
(ECC). It is process by which a chemical or electrical signal at the sarcolemma is 
coupled to the release of calcium from the sarcoplasmic reticulum (SR) and muscle 
contraction (Dulhunty et al., 2002).  The process begins with the activation of the 
AChR’s at the endplate of the NMJ and is followed by the depolarisation of the 
sarcolemma, which propagates through the sarcolemma down to transverse 
tubules (T-tubules) activating the ‘voltage sensor’ dihydropyridine receptors 
(DHPR). The DHPRs are associated with the voltage-gated L-type Ca2+ receptors 
found in the T-tubules and lie next to the ryanodine receptors (RyR). Activation of 
this channel results in the opening of the RyR channel, resulting in a Ca2+ transient 
in the sarcoplasm. This initial Ca2+ transient is further amplified by Ca2+ induced 
Ca2+ release from the SR, resulting in an increase in cytoplasmic calcium, which 
binds to Troponin-C and allows the formation of cross-bridges. This enables the 
actin filaments to slide along the fibre towards the Z line, causing muscle 
contraction (Dulhunty et al., 2002). 
 
Principally, there are two intracellular channels that are responsible for the release 
of Ca2+ from internal stores: the RyR and the inositol 1,4 5-triphosphate receptors 
(IP3Rs) (Berridge, 1997). The RyR channel mediates the fast release of Ca2+ and 
is associated with muscle contraction, while the other type of receptor, the IP3Rs, 
mediate Ca2+ release that regulate the transcription of muscle activity-dependent 
genes (Powell et al., 2001).  
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It has been well documented that caffeine is a strong modulator of RyR1 receptor, 
which helps mediate muscle contraction. The RyRy1 receptor, approximately 
565kDa in weight, is responsible for the release of Ca2+ from the SR. It is activated 
in a dose-dependent manner by low caffeine concentrations (0.5-5mM). Mutations 
in RyR receptors are thought to play a role in other neurodegenerative diseases, 
like Alzheimer’s disease (Stutzmann, 2005).  
 
6.1.2.2 Glucose deprivation in muscle 
Energy deprivation in skeletal muscle can arise from prolonged exercise or fasting 
and poses a considerable stress in muscle (de Lange et al., 2007). However, 
muscle has a number of adaptive mechanisms in order to minimise damage and 
ensure normal muscle function. In general, glucose serves as the primary fuel for 
skeletal muscle (Rose and Richter, 2005). In times of glucose deprivation, the 
metabolism of fatty acids ensures normal function (Zenimaru et al., 2008). This 
requires the rapid activation of a number of tightly regulated transcription, 
translation, and phosphorylation pathways. One such pathway is the AMPK/IGF-1 
pathway (Murphy, 2000). The activation of AMP-activated protein kinase (AMPK) 
results in the recruitment of factors such as peroxisome proliferator-activated 
receptor gamma, coactivator-1alpha, peroxisome proliferator-activated receptor 
delta, and their target genes (de Lange et al., 2007). These factors are involved in 
the formation of oxidative muscle fibres, mitochondrial biogenesis, oxidative 
phosphorylation, and fatty acid oxidation (de Lange et al., 2007). A muscle’s ability 
to metabolise glucose may alter several aspects of muscle function, from its 
oxidative profile to mitochondrial biogenesis, and therefore may have lasting 
implications for energy metabolism.  
 
6.1.3 Metabolic dysfunction in ALS muscle 
There is a growing body of evidence indicating a role for metabolic dysfunction in 
muscle pathology in mSOD1 mice and ALS patients, who are sometimes 
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hypermetabolic (Funalot et al., 2009). Anomalies in energy metabolism have been 
found in ALS mice, which have been shown to benefit from high-energy diets 
(Dupuis et al., 2004). The mSOD1 mice, also display depleted ATP levels as well 
as increased glycogen content, a phenomenon also seen in diabetes (Derave et 
al., 2003) and impaired lipid peroxidation (Dupuis et al., 2008). Additionally, 
mitochondrial pathology in muscle is well-established and associated with the 
destruction of the NMJ in mSOD1 mice (Dupuis and Loeffler, 2009). As muscle has 
a high-energy demand, it is possible that changes within this pathway have serious 
consequences for muscle, NMJ and motoneuron health.  
 
Not all muscles have the same energy demands (Shin'ichi, 1991), nor are all 
muscles equipped with the same metabolic apparatus for glucose and lipid uptake 
(Rose and Richter, 2005), or glucose and lipid metabolism (Villa Moruzzi et al., 
1981, Samec et al., 2002). As a result, metabolic dysfunction may affect various 
muscles to different degrees. Indeed, it is well-known that fast and slow-twitch 
muscles have different metabolic demands (Villa Moruzzi et al., 1981) and so it is 
possible that intrinsic differences in their ability to cope with metabolic stress may 
effect mSOD1 muscles. 
 
6.1.4 Exercise and mSOD1 muscle 
The role of effect of exercise in ALS and models of the disease is controversial. 
Bohannon first noted the beneficial effect of exercise in ALS patients in 1983 
(Bohannon, 1983). The study revealed that the application of resistance exercise to 
the upper extremities of an ALS patient resulted in improved static strength in a 
number of muscle groups. More recently, it has been suggested that moderate 
exercise delays the onset of symptoms by over a week, while high levels of 
exercise facilitate the onset of symptomatic onset (Carreras et al., 2009).  
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Furthermore, Carreras et al. (2009) showed that moderate exercise results in 
higher motor neuron density in the ventral horn of the lumbar spinal cord in 
mSOD1 mice. Equally, Deforges et al. (2009) showed that exercise promoting the 
relative maintenance of the fast phenotype in fast-twitch muscles in mSOD1 mice, 
as well as preserving large motoneuron, astrocyte and oligodendrocyte populations 
within the CNS and increasing life span by 25 days (Deforges et al., 2009). 
 
Examination of the effect of exercise in human has also been carried out. While 
human studies did not yield as impressive results, moderate exercise was still 
sufficient to result in a moderate effect in patients with early-stage ALS (Lui & Byl, 
2009). 
 
6.1.5 Aim 
One contributing factor to the controversy surrounding muscles role in ALS is the 
difficulty in separating effect of changes originating from motoneuron and those 
originating from the muscle. However, one possible method is to examine muscle 
pathology in aneural, muscle cultures. Thus, in this Chapter I aim to: 
 
 Whether aneural muscle cultures derived from presymptomatic mSOD1 
neonates display any intrinsic vulnerabilities to various stresses. 
 Whether there is a fundamental difference in the vulnerability of aneural 
fast-twitch and slow-twitch muscles to various stresses. 
 If so, whether mSOD1-mediated pathology is sufficient to exacerbate any 
existing differential vulnerabilities. 
 Whether mSOD1 muscle may release factors detrimental to the neuron.  
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6.2 Methods 
6.2.1 Cell cultures 
6.2.1.1 Mixed hindlimb muscle cultures and Fast and slow-twitch muscle 
cultures 
Mixed hindlimb muscle cultures from a modified protocol from Bryla et al. (2004) 
were prepared as described in Chapter 2, Section 2.1.3. A minimum of four 
animals were used for each culture. Cells were plated at 100,000/cm2. Fast and 
slow-twitch muscle cultures were also prepared as described in Chapter 2, Section 
2.3.4. A minimum of six animals were used for each culture and cells were plated 
at 100,000/cm2. The myogenicity of the cultures and their pattern of differentiation 
was also monitored and graphs summarising this can be found in appendix 3. 
 
6.2.2 SH-SY5Y cultures 
SH-SY5Y cultures were also grown as detailed in Chapter 2, Section 2.3.9. The 
SH-SY5Y cell line was chosen, as they are a well characterised cell line, without 
any of the natural variation that would be present in primary motoneuron culture. 
Thus, making a sensible choice for a preliminary study. 
 
6.2.3 The glucose deprivation (metabolic) stress 
The glucose deprivation stress was carried out on mixed as well as fast and slow-
twitch muscle cultures, as detailed in Chapter 2, Section 2.3.5. 
 
6.2.4 The contractile stress (caffeine) stress 
The contractile stress was carried out on mixed as well as fast and slow-twitch 
muscle cultures, as detailed in Chapter 2, Section 2.3.6 or a combination of the 
two, as detailed in Chapter 2, Section 2.3.7. 
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6.2.5 Muscle-conditioned medium preparation 
The preparation of muscle-conditioned medium was carried out as detailed in 
Chapter 2, Section 2.3.8. 
 
6.2.6 Cytotoxicity assay 
The assay to measure LDH release (an indicator of cell viability) was carried out as 
detailed in Chapter 2, Section 2.3.10. 
 
To obtain the minimum value for LDH release, I assayed 6 wells containing only 
media, which should contain no cells and therefore produce the lowest LDH 
release. This was taken as 0%, and the maximum LDH value for each culture was 
obtained by exposing cells from another six wells to 2% Triton X-100. This resulted 
in total cell lysis and thus the LDH release, while this value was taken as 100%. All 
LDH values reported were expressed as a percentage of the maximal LDH 
response obtained. 
 
6.2.7 Statistical analysis 
Statistical significance between the mean values was assessed using a student’s t-
test. Significance was set at p≤0.05. 
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6.3 Results 
This Chapter examines the effect of mSOD1 expression on the on the myogenicity 
of muscle cultures. It subsequently examines the vulnerability of mSOD1 muscle 
cultures to cell stress. In addition, the viability of fast and slow-twitch muscle fibres 
following cell stress is examined in WT, wtSOD1 and mSOD1 muscle. In order to 
examine the intrinsic vulnerability of muscle cells, neonatal mouse muscle cells 
were exposed to cellular stresses that mimic some of the characteristic 
physiological stresses that may act on muscle in vivo. To examine the effect of 
inducing a stress mimicking contractile stress and the subsequent oxidative stress, 
muscle cells were treated with caffeine (a ryanodine receptor agonist). Measuring 
LDH release from the cultures assessed the effect of these cell stressors, in both 
mixed hindlimb muscle and fast and slow-twitch muscle cultures. In addition cell 
viability was examined in neuronal cells exposed to muscle-conditioned media from 
WT, wtSOD1 and mSOD1 mice. 
 
Initially, the level of spontaneous differentiation was assessed and then a measure 
of the prevalence of myosin heavy chain I (MyHCI) and myosin heavy chain II 
(MyHCII) in the various muscle cultures was examined (Appendix 3) in the various 
genotypes examined.  For each genotype a minimum of 3 wells for each ‘n’ 
number was counted and recorded as a percentage of the entire population. This 
revealed that there is a small increase in percentage of myotubes in the mSOD1 
population, however, this did not reach significance. Likewise, examination of the 
MyHCI and MyHCII expression in WT, wtSOD1 and mSOD1 mice revealed a 
general increase in fibres that expressed MYHCII (Appendix 3, Fig. 10.2). While 
analysis of MyHCI and MyHCII expression in fast and slow WT and mSOD1 
muscle cultures revealed that there was a general increase in the percentage of 
myogenic cells that expressed MyHCII in cultures originating from the fast muscle 
compared to cultures from the slow muscle (Appendix 3, Fig. 10.3).  
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6.3.1 The effect of mSOD1 expression on the vulnerability of muscle cultures 
to cell stress 
By measuring LDH release, the effect of mSOD1 expression on muscle cell 
viability under basal and stress conditions was examined in primary muscle 
cultures. For each condition, LDH release (absorbance) was normalised against 
protein levels and then expressed as a percentage of the maximum LDH release, 
which was established by incubation with 2% Triton X-100. In all experiments, 
wtSOD1 values are compared to WT in order to establish whether SOD1 
overexpression altered cell viability. mSOD1 data was compared to wtSOD1 data 
in order to examine the effect of mSOD1 expression. 
 
6.3.2 Cell viability in WT, wtSOD1 and mSOD1 muscle cultures under basal 
conditions 
As can be seen in Fig.6.1, in WT cultures LDH release was 2.7% (±0.2 SEM; n=6) 
of the maximal response. Compared to WT, LDH release in wtSOD1 muscle 
cultures was 2.8% (±0.2 SEM; n=6; p=0.67) of the maximal response. In mSOD1 
cultures, LDH release was 3.4% (±0.5 SEM; n=6; p=0.284) compared to wtSOD1 
mice. Thus, there is no significant difference in cell viability in mixed muscle 
cultures of any genotype under basal conditions. 
 
6.3.3 Cell viability in WT, wtSOD1 and mSOD1 muscle cultures under 
conditions of metabolic stress 
Next, the effect of a metabolic stress induced by glucose deprivation on cell 
survival in mixed muscle cultures from WT, wtSOD1 and mSOD1 mice was 
examined (see Fig.6.2). Glucose deprivation in WT cultures resulted in LDH levels 
that were 2.6% (±0.3 SEM; n=6) of the maximal response. Glucose deprivation 
resulted in higher LDH levels in wtSOD1 mixed muscle cultures, so that they were 
4.3% (±0.4 SEM; n=6) of the maximal response. However, this was not significantly 
different from treated WT (p=0.062). In mSOD1 muscle cultures, glucose 
deprivation resulted in LDH levels that 5.6% (±0.3 SEM; n=6) of the maximal 
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Figure 6.1: Cell viability in mixed hindlimb muscle cultures, under basal 
conditions, from wtSOD1 and mSOD1 neonate mice  
WT, wtSOD1 and mSOD1 muscle cultures were incubated in muscle media for 24 
hours. The media was then collected and the level of LDH in the media was 
determined and recorded as a percentage of the maximal LDH release calibrated 
using positive and negative controls. The results were then represented as a 
percentage of the maximal LDH release, which was taken as 100%.  
 
*=p<0.05; n=6; error bars = ± standard error of the mean 
 
 
0.0 
0.5 
1.0 
1.5 
2.0 
2.5 
3.0 
3.5 
4.0 
4.5 
WT wtSOD1 mSOD1 
%
 L
D
H
 re
le
as
e 
197 
 
response, which was significantly higher than in glucose-deprived in wtSOD1 
cultures (p=0.046). 
 
6.3.4 Cell viability in WT, wtSOD1 and mSOD1 muscle cultures under 
conditions of contractile stress 
Cell survival following exposure to caffeine 1mM and 5mM, over 24hrs, was 
examined in WT mixed hindlimb muscle cultures in order to establish the most 
stressful concentration of caffeine. The results shown in Fig.6.3 revealed a dose-
dependent significant increase in LDH release in WT muscle cultures that had 
been treated with caffeine. At 1mM, LDH release was 3.3% (±0.2 SEM; n=6) of the 
maximal response. At 5mM, LDH levels were significantly higher at 4.7% (±0.1 
SEM; n=6) of the maximal response. This was significantly more than seen at 1mM 
(p=0.001).  
 
As shown in Fig.6.3b, exposing wtSOD1 cultures to 1mM of caffeine for 24 hours 
resulted in LDH levels that were 3.6% (±0.1 SEM; n=6) of the maximal response. 
Incubation with 5mM of caffeine resulted in LDH levels that were 3.2% (±0.2 SEM; 
n=6) of the maximal response. As this was not significantly different compared to 
WT (p=0.221). Thus, there was no dose-dependent increase in LDH release in 
wtSOD1 muscle cultures treated with 1mM to 5mM caffeine.  
 
In mSOD1 cultures, incubation with 1mM of caffeine resulted in elevated levels of 
LDH release so that they were 4.8% (±1.1 SEM; n=6) of WT controls. However, 
this was not significantly higher than wtSOD1 (p=0.302). Incubation with 5mM of 
caffeine increased LDH release further, so that levels were 7.2% (±1.1 SEM; n=6) 
of WT. This was significantly more than wtSOD1 (p=0.005). 
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Figure 6.2: Cell viability in WT, wtSOD1 and mSOD1 mixed hindlimb muscle 
cultures following glucose deprivation 
The effect of glucose deprivation on cell viability was examined in WT, wtSOD1 
and mSOD1 mixed hindlimb muscle cultures. The results from all groups were 
represented as a percentage of the maximal LDH response, which was taken as 
100%.  
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Figure 6.3: Cell death in WT hindlimb muscle culture following incubation 
with Caffeine  
The bar chart (A) shows LDH release following incubation with 1mM and 5mM in 
WT mixed muscle cultures. The bar chart (B) shows LDH release in wtSOD1 and 
mSOD1 mixed cultures following incubation with 1mM and 5mM caffeine, for 24 
hours. All data was expressed as a percentage of the maximal LDH response, 
which was given the value 100%. 
 
*=p≤0.05; n=6; error bars= ± standard error of the mean 
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6.3.5 Muscle cell survival following a metabolic and contractile stress. 
The effect of exposure to glucose deprivation coupled with caffeine was examined 
next. The results are summarised in Fig.6.4. In WT muscle cultures, LDH release 
was measured following exposure to 1mM and 5mM caffeine in the absence of 
glucose. This resulted in LDH levels that were 5.4% (±0.2 SEM; n=6), 4.4% (±1.8 
SEM; n=6) of the maximal response, respectively (see Fig.6.4).  
 
Cell viability following exposure to a combined stress was next examined in 
wtSOD1 and mSOD1 muscle cultures. In wtSOD1 cultures, following glucose 
deprivation and treatment with 1mM of caffeine, the extent of cell death was not 
significantly different from that observed in WT muscles, so that LDH levels were 
3.9% (±2.1 SEM; n=6; p=0.616) of the maximal response. At 5mM of caffeine, 
wtSOD1 muscle cultures produced 2.1% (±0.25 SEM; n=6) of the maximal 
response, which was not significantly different from the LDH values from WT 
cultures (p=0.234).  
 
Comparing mSOD1 cultures to wtSOD1 after glucose deprivation and exposure to 
1mM caffeine, LDH levels were 5.5% (±0.2 SEM; n=4; p=0.477) of the maximal 
response. However, there was a significant increase in cell death following glucose 
deprivation and incubation with 5mM caffeine over 24 hours, so that mixed mSOD1 
muscle cultures released five times as much LDH compared to wtSOD1, or 10.5% 
(±2.2 SEM; n=4; p=0.009) of the maximal response. These results show that mixed 
hindlimb mSOD1 muscle cultures were more vulnerable to glucose deprivation and 
a combined oxidative/metabolic stress than WT or wtSOD1 muscle cultures. 
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Figure 6.4: Cell death following a caffeine exposure and glucose deprivation 
in mixed muscle cultures  
The bar chart (A) shows LDH release following incubation with 1mM and 5mM 
combined with glucose deprivation for 24 hours, in WT mixed hindlimb muscle 
cultures from neonate mice. The bar chart (B) shows LDH release in wtSOD1 and 
mSOD1 mixed hindlimb muscle cultures from neonate mice following exposure to 
1mM and 5mM caffeine, in the absence of glucose over 24 hours. WT, wtSOD1 
and mSOD1 values were recorded as a percentage of the maximal LDH release, 
which was taken as 100%.  
 
***= p≤0.001; n=4; error bars = ± standard error of the mean 
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6.3.6 Cell viability of fast and slow-twitch muscle cultures 
These next set of experiments investigated whether muscle cultures originating 
from fast and slow-twitch muscles displayed differential vulnerability to these 
stresses. Therefore, these experiments compared the LDH release from fast and 
slow-twitch WT, wtSOD1 and mSOD1 muscle cultures under basal conditions, as 
well as under conditions of cellular stress induced by glucose deprivation. 
  
6.3.6.1 Cell viability of fast and slow-twitch muscle cultures under basal 
conditions 
Initially, the experiments established whether there was an innate difference in cell 
viability between muscle cells derived from fast and slow-twitch muscles under 
basal conditions. As can be seen Fig.6.5, in WT cultures from slow-twitch muscle, 
LDH levels were 4.01% (±0.2 SEM; n=4) of the maximal response. LDH levels in 
fast-twitch muscle cultures were 8.4% (±2.3 SEM; n=4) of the maximal LDH 
response. However, this was not significantly more than slow-twitch WT muscle 
cultures (p=0.118). wtSOD1 slow-twitch muscle cultures under basal conditions 
were examined next. wtSOD1 slow-twitch muscle cultures released LDH levels that 
were 14.3% (±10.3 SEM; n=4) of the maximal response, while mSOD1 slow-twitch 
muscle cultures released LDH levels that were 10.0% (±3.1 SEM; n=4) of the 
maximal response. 
 
This was similar to wtSOD1 slow-twitch muscle cultures (p=0.703). However, cell 
viability in fast-twitch muscle cultures differed considerably. In fast-twitch wtSOD1 
muscle cultures, LDH levels were 9.2% (±2.8 SEM; n=4) of the maximal response, 
while in fast-twitch mSOD1 muscle cultures LDH levels were triple that of wtSOD1. 
That is, LDH levels in fast-twitch mSOD1 muscle cultures were 34.2% (±9.2 SEM; 
n=4; p=0.041) of the maximal response, compared to fast-twitch wtSOD1 muscle 
cultures. This was also 3 times the LDH release of mSOD1 slow-twitch muscle 
cultures and significantly more than mSOD1 slow-twitch muscle cultures. 
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Figure 6.5: Cell viability in WT, wtSOD1 and mSOD1 fast and slow-twitch 
muscle cultures under basal conditions and following cell stress induced by 
glucose deprivation 
The bar chart shows LDH release from slow and fast-twitch primary WT, wtSOD1 
and mSOD1 neonate mice muscles cultures under basal and glucose deprived 
conditions. LDH readings were taken after 24 hours incubation in glucose depleted 
media. The maximal and minimal LDH release from the muscle cultures was 
determined and taken as 100% and 0% respectively. The maximal LDH reading 
was achieved by applying muscle media that contained 2% Triton X-100 solution.  
 
**=p≤0.01; ***= p≤0.001; n=4; error bars = ± standard error of the mean 
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6.3.6.2 Cell viability in fast and slow-twitch muscle cultures following glucose 
deprivation 
The results presented in this Chapter, show that there is a modest increase in cell 
death following glucose deprivation in mSOD1 muscle cultures. It was 
subsequently investigated whether mSOD1 expression in slow and fast-twitch 
muscle cultures differentially effected survival following cell stress. wtSOD1 and 
mSOD1 slow and fast-twitch muscle cultures were exposed to glucose deprivation 
for 24 hours and then assessed for LDH release.  In slow-twitch muscle cultures 
from WT mice, glucose deprivation marginally increased cell death so that LDH 
levels were 15.7% (±4.2 SEM; n=4; p=0.062) of the maximal LDH response, 
compared to untreated slow-twitch WT cultures. Glucose-deprived WT fast-twitch 
muscle cultures released LDH levels that were 40.1% (±14.8 SEM; n=4; p=0.079) 
of the maximal LDH response, compared to untreated fast-twitch WT cultures. 
Thus, glucose-deprived fast-twitch cultures produced more than double the LDH 
seen in glucose deprived WT slow-twitch cultures (p=0.162). 
 
As shown in Fig.6.5, wtSOD1 slow-twitch muscle cultures that had been treated 
with glucose-free media released 34.8% (±13.4 SEM; n=4) of the maximal LDH 
response. This was not significantly more than in untreated wtSOD1 slow-twitch 
cultures (p=0.27). While in mSOD1 slow-twitch muscle cultures, glucose 
deprivation resulted in 21.2% (±5.4 SEM; n=4) of the maximal LDH response, 
which was not significantly more than untreated mSOD1 slow-twitch cultures 
(p=0.122) or treated slow-twitch wtSOD1 muscle cultures (p=0.383). A different 
trend was seen when examining wtSOD1 and mSOD1 fast-twitch muscle cultures 
(Fig.6.5). Glucose-deprived wtSOD1 fast-twitch muscle cultures released 33.9% 
(±5.9 SEM; n=4) of the maximal response. This was significantly more than 
untreated wtSOD1 fast-twitch muscle cultures (p=0.009), but not treated wtSOD1 
slow-twitch muscle cultures (p=0.899). Glucose-deprived mSOD1 fast-twitch 
muscle cultures released 81.8% LDH (±7.1 SEM; n=4) of the maximal response, 
which was significantly more than treated, wtSOD1 fast-twitch muscle cultures 
(p=0.003), as well as treated mSOD1 slow-twitch muscle cultures (p<0.001). 
207 
 
 
6.3.7  The effect of mSOD1 muscle-conditioned media on neuronal survival 
In order to examine whether mSOD1 muscle is able to support motoneuron health, 
the effect of muscle-conditioned media (MCM) from WT, wtSOD1 and mSOD1 
muscle cultures on the survival of neuronal cells was examined using SH-SY5Y 
cells. Prior to incubation with SH-SY5Y cells, LDH levels in the supernatant from 
WT, wtSOD1 and mSOD1 muscle cultures were examined. This indicated there 
was no significant difference in LDH release in the media from WT, wtSOD1 and 
mSOD1 muscle cultures under basal conditions (see Fig.6.1). LDH levels from SH-
SY5Y cultures that were exposed to WT, wtSOD1 and mSOD1 MCM were 
normalised against protein levels and then represented as a percentage of the 
maximum LDH release achievable, which was given the value 100% (Fig.6.6). 
Incubating SH-5YSY cells with MCM taken from WT muscle cultures resulted in the 
release of LDH levels that were 44.1% (±0.2 SEM; n=4) of maximal levels. SH-
5YSY cells incubated with MCM from wtSOD1 muscle cultures released slightly 
more LDH into the media (p<0.01), so that LDH levels were 51.46% LDH (±0.2 
SEM; n=4) of the maximal LDH response, compared to WT. SH-5YSY cells 
incubated with media from mSOD1 muscle cultures released even more LDH, and 
levels reached 88.9% LDH (±0.4 SEM; n=3; p<0.001) of the maximal response, 
compared to cultures exposed to wtSOD1 (see Fig.6.6). 
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Figure 6.6: SH-SY5Y cell viability in muscle-conditioned media 
The bar chart shows the percentage of LDH release from SH-SY5Y following 
incubation over 72 hours with muscle-conditioned media from WT, wtSOD1 and 
mSOD1 mixed hindlimb muscle cultures. All values were normalised against 
minimal values and then represented as a percentage of the maximal LDH reading, 
which was given the value 100%.  
 
**=p≤0.01; n=4; error bars= ± standard error of the mean 
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6.4 Discussion 
In this Chapter, I examined the effect of various cellular stresses on muscle cell 
survival in WT, wtSOD1 and mSOD1 primary muscle cultures. This study revealed 
that mSOD1 muscle cultures were more vulnerable to glucose deprivation than WT 
and wtSOD1 muscle cultures. Interestingly, exposure to 5mM but not 1mM caffeine 
increased cell death in mSOD1 cultures. Likewise, exposure to 5mM but not 1mM 
caffeine in a combined stress model was sufficient to significantly increase cell 
death. Examination of cytotoxicity in specific fast and slow-twitch primary muscle 
cultures revealed that fast-twitch muscle cultures were more vulnerable to cell 
stress than slow-twitch muscle, even in cultures derived from WT mice. 
Additionally, mSOD1 expression rendered fast-twitch muscle cultures even more 
vulnerable to glucose deprivation and caffeine stress.  Finally, treatment of 
neuronal cells with MCM from muscle cultures showed that factors released by 
myotubes that express mSOD1 are detrimental to neuronal survival, indicating the 
possible presence of a toxic factor in mSOD1 MCM. 
 
6.4.1 mSOD1 mixed muscle cultures are more vulnerable to cell death  
This Chapter investigated the effects of three physiologically relevant stresses had 
on cell survival in the primary muscle cultures. Glucose deprivation resulted in a 
modest level of cell death in WT and wtSOD1 muscle cultures, but mSOD1 
cultures were significantly more sensitive to glucose deprivation. WT, wtSOD1 and 
mSOD1 muscle cultures were highly resistant to low levels of caffeine stress, 
resulting in negligible levels of cell death. However, at higher caffeine 
concentrations, mSOD1 mixed muscle cultures showed significant level of cell 
death. 
 
A similar pattern of vulnerability was seen in cultures exposed to a combined 
stress, which caused even greater levels of cell death. mSOD1 muscle cultures 
exposed to the combined caffeine and glucose deprivation stress demonstrated a 
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modest increase in cell death (10%) compared to a caffeine stress (7%), and, this 
did not reach significance (p=0.228). 
 
Previous, studies aimed at examining the role of muscle in ALS have not 
extensively examined the effect of physiologically relevant stress. Moreover, those 
few studies that have investigated the role of physiological stress in ALS 
pathogenesis in muscle have examined innervated muscle in vivo where it is 
difficult to isolate the origin of dysfunction. Exercise, such as regular treadmill 
running, has been shown to be beneficial to survival in mSOD1 mice (Kirkinezos et 
al., 2003). However, the results presented here show that high levels of caffeine, 
indicative of greater contractile and oxidative stress, are selectively detrimental to 
mSOD1 muscle, although lower concentrations are not. This suggests that there is 
a trigger point at which contractile stress, and the associated oxidative stress, 
overwhelms the muscle and become deleterious.  
 
Furthermore, Dupuis et al. (2009) have shown that increased ROS, a marker for 
oxidative stress, can trigger the dismantling of the NMJ. It is therefore possible that 
low levels of contractile stress may be beneficial for muscle function, while high 
levels of contractile stress, which generate high levels of ROS, facilitates the 
compromise of the NMJ in mSOD1 muscle. 
 
The results presented in Chapter 3 and 4 have shown that fast and slow-twitch 
muscle such as the TA and the soleus muscles are differentially affected by 
mSOD1 pathology, with fast-twitch muscles displaying greater denervation, hsp 
expression and greater nNOS dysfunction. The results presented in Chapter have 
shown that mSOD1 muscle is intrinsically more vulnerable to glucose deprivation 
than WT muscle. Glucose homeostasis has been examined previously in ALS 
patients before (Pradat et al., 2009). The results showed that blood glucose in ALS 
patients was significantly higher than controls. Furthermore, the patients with 
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impaired glucose tolerance were more likely to have elevated free fatty acids, a 
marker of metabolic dysfunction. However, an examination of glucose metabolism 
in muscles of ALS patients or mSOD1 mice has not been previously undertaken. 
Thus, dysfunction in glucose homeostasis in muscle may possibly contribute to the 
general glucose homeostasis dysfunction that was demonstrated in ALS patients 
by Pradat et al. (2009).  
 
The results of this Chapter also show that mSOD1 fast-twitch muscle cultures are 
preferentially vulnerable to glucose deprivation compared to wtSOD1 fast-twitch 
muscle cultures. This finding directly supports Dupuis et al. (2004b), which 
demonstrated that skeletal muscle hypermetabolism is present in mSOD1 mice 
and that a highly energetic diet extended survival by 20% in these mice (Dupuis et 
al., 2004). This suggests that metabolic dysfunction may well be a strong 
contributing factor to neuromuscular dysfunction in mSOD1 mice. Furthermore, as 
fast-twitch muscle cultures were preferentially vulnerable to glucose deprivation in 
all genotypes, it is possible that fast-twitch muscle is fundamentally more 
vulnerable to metabolic dysfunction. In light of research from Dupuis et al. (2004) 
this vulnerability is likely to contribute to the preferential denervation of fast-twitch 
muscles in ALS.  
 
6.4.2 mSOD1 muscle-conditioned media induces cell death in neuronal cells 
In order to examine whether muscle may play a directly deleterious role in 
motoneuron function in ALS, in this Chapter I examined the effect of treatment of 
neuronal cells with media collected from primary muscle cultures established from 
wtSOD1 and mSOD1 mice. Previous findings using a similar approach have clearly 
demonstrated that incubation of motoneurons with media from primary mSOD1 
astrocytes has toxic effects on motoneurons (Nagai et al., 2007). Using SH-SY5Y 
neuronal cells in this Chapter I also found that factors released from mixed mSOD1 
muscle cultures were sufficient to induce significantly higher levels of cell death in 
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SH-5YSY cells compared to wtSOD1 and WT cultures. This is clear evidence of 
the deleterious effect that mSOD1 expression in muscle cells has on neuron 
survival, supporting the findings Dobrowolny et al. (2008) and Wong and Martin 
(2010) who demonstrated that the expression of mSOD1 in muscle was sufficient 
to reduce neuron survival and thus confer cell-to-cell toxicity.  
 
Although the muscle conditioned media did not undergo proteomic analysis, it is of 
interest to note that it has been shown that the release of mSOD1 from neuron like 
cells in vitro via exosomes, results in increase significant pathology, including 
cytoplasmic inclusions and protein insolubility that correlated with toxicity (Gomes 
et al., 2007). Similarly, in the CNS mSOD1 release from microglia has been found 
to induce the morphological and functional activation of microglia, via toll-like 
receptors (TLR) 2 and TLR4; thus, increasing their release of pro-inflammatory 
cytokines and free radicals (Henkel et al., 2009; Zhao et al., 2010). While mSOD1 
release from muscles and a similar inflammatory response has yet to be examined, 
it is possible that a similar pathway exists mediating this cell-to-cell toxicity. 
 
6.4.3 Conclusion 
ALS is understood to be a non-cell autonomous disease, with microglia and 
astroglia playing a pivotal role in the onset and progression of disease. However, 
whether muscle also contributes to mSOD1 pathology and ALS has been disputed. 
While Dobrowolny et al. (2008) and Wong and Martin (2010) suggest that muscle 
is a primary target of ALS. Miller et al. (2006) have suggested that muscle 
pathology is merely a consequence of motoneuron pathology. Results from this 
Chapter support the hypothesis, put forward by Dobrowolny et al. (2008) and Wong 
and Martin (2010), that muscle does play a role in mSOD1 pathology and ALS, 
with factors secreted by muscle cells in cultures causing cell death in neurons.  
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In addition, this Chapter showed that mSOD1 muscle cultures are intrinsically 
different to WT and wtSOD1 muscle cultures equally, that muscle cultures from fast 
muscles are also intrinsically different from muscle cultures from slow muscle 
cultures. Furthermore, these muscle specific differences in muscle cultures are 
independent of genotype. Thus, aneural fast-twitch muscle cultures, like innervated 
fast-twitch muscles, are intrinsically more vulnerable to stress than aneural slow-
twitch muscle cultures.  
 
Furthermore, mSOD1 expression, even at a presymptomatic stage, is sufficient to 
exacerbate this intrinsic vulnerability, with fast-twitch muscle more vulnerable to 
glucose deprivation and caffeine stress. In addition, this study showed that only 
high concentrations of caffeine (5mM), a contractile and oxidative stress, result in 
increased cell death in muscle.  
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Chapter 7 : General discussion 
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7.1  Introduction 
The overall aim of this Thesis has been to study muscle pathology in a mouse 
model of ALS by characterising the appearance and progression of ALS pathology 
in hindlimb muscles of the SOD1G93A mouse model of ALS. This characterisation 
was undertaken in muscles with either a predominantly fast or slow-twitch 
phenotype, since previous results have suggested that these different muscle 
types have a differential vulnerability to disease (Frey et al., 2000). Furthermore, I 
also tested whether the apparent greater vulnerability of fast-twitch muscles to 
stress observed in ALS was an intrinsic feature of this muscle fibre type that was 
not acquired as a result of aging or in disease and that if fast-twitch muscles have 
an intrinsically poor stress response to disease. In addition, I examined whether 
the pharmacological manipulation of the HSR, reduced muscle and NMJ pathology 
in mSOD1 mice. In doing so, I aimed to establish if the previously reported 
cytoprotective actions of Arimoclomol are limited to the CNS, or whether it may 
also act in skeletal muscles. 
 
7.2  Fast-twitch muscle in mSOD1 mice is preferentially vulnerable to 
changes in neuromuscular transmission and denervation. 
In Chapter 3, I established that in mSOD1 mice there is significant NMJ pathology, 
with evidence of denervation, sprouting and PNI in skeletal muscles, even during 
early stages of disease. Both denervation and sprouting occur prior to symptom 
onset in the more vulnerable EDL muscle and to a greater degree than in slow-
twitch soleus muscles. Indeed, denervation and sprouting only reached 
significance at a late stage of disease (120 days) in the slow-twitch soleus muscle.  
 
Compensatory nerve terminal sprouting in the fast-twitch EDL muscle peaked 75 
days but quickly declined thereafter. Likewise, the level of PNI, which was 
significant at 45 days and 75 days in EDL muscles of mSOD1 mice, declined 
rapidly  as disease progressed.  
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In the EDL muscle, denervation was accompanied by a significant decrease in 
endplate size, which took place before disease onset, but did not decrease with 
denervation. This was not the case in the soleus muscle. The mean endplate size 
in the soleus muscle from WT mice was similar to that seen in EDL muscle from 
WT mice. However, endplate size in the soleus of mSOD1 mice remained similar 
to wildtype throughout the course of disease, regardless of the level of denervation. 
This finding indicates that unlike in nerve injury models, endplate size in ALS is 
dependant on more factors than just denervation. 
 
ChAT activity is known to decrease with age (Tucek and Gutmann, 1973) and 
following denervation (Tucek, 1973). Examination of the activity of enzymes 
associated with neurotransmission revealed that in mSOD1 mice, ChAT activity 
falls by almost one third over the course of the disease, in all muscles examined. In 
contrast, AChE activity is differentially affected in fast and slow-twitch muscles in 
mSOD1 mice. In the fast-twitch TA and EDL muscles AChE levels fell by 20-30% 
over the course of the disease compared to WT, while in the slow-twitch soleus 
muscle, AChE levels fell by approximately 50% over the course of disease, 
compared to WT. This differential decline in AChE activity would result in a 
different ChAT: AChE activity ratio in fast and slow-twitch muscles, with a greater 
ChAT: AChE ratio in the slow-twitch soleus and thus a relative increase in ChAT 
production in the soleus muscle. While the direct implication of these changes is 
unknown, it is of interest to note that a similar phenomenon is seen in the 
neuromuscular disease myasthenia gravis, and is considered to be a 
compensatory mechanism that ensures sufficient neuromuscular transmission 
(Molenaar et al., 1981). Thus, it is possible that this relative increase in ChAT 
activity in the soleus is also compensatory action to strengthen the synapse and 
promote muscle function, which may in the long-term, contribute to its relative 
resistance to disease in ALS. 
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7.3 A Peak in muscle hsp expression coincides with disease onset in mSOD1 
mice. 
The results presented in Chapter 4 revealed that in mSOD1 mice, levels of hsp90, 
hsp72 and hsp25 peak at symptom onset in fast-twitch muscles. This is the stage 
when muscle atrophy, denervation and nerve-terminal sprouting are significant. 
From this stage onwards, hsp levels in fast-twitch muscles decline rapidly to basal 
levels.  
 
As hsp25 and hsp90 expression has been shown to promote neurite development 
in vitro, it is possible that increased hsp90 and hsp25 expression in the muscle 
during the period in which muscle fibres begin to loose their innervation may 
promote compensatory mechanism such as sprouting in mSOD1 fast-twitch 
muscle. Furthermore, hsp72 expression, which has been shown to increase 
synaptic efficacy, may increased help to maximise synaptic function in the 
particularly vulnerable fast-twitch muscles in mSOD1 mice at the time when 
synaptic connection become weak and vulnerable. 
 
7.4  Fast-twitch muscles in mSOD1 mice have a reduced HSR, which is 
upregulated by treatment with Arimoclomol. 
Although both fast and slow-twitch muscles mount a HSR in mSOD1 mice at 
symptom onset, the HSR in the TA muscle was relatively short-lived. In contrast, in 
slow-twitch muscles such as soleus, the increase in hsp expression was 
maintained throughout disease progression in mSOD1 mice. This finding suggests 
that fast-twitch muscles are intrinsically less able to respond to cellular stress by 
upregulation of cytoprotective proteins, such as hsps. This poor stress response 
may contribute to their greater vulnerability in ALS.  
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7.5  Fast-twitch muscles in mSOD1 mice display greater nNOS dysfunction 
than slow-twitch muscle. 
Examination of the NOS response in hindlimb muscles of mSOD1 mice at various 
stages of disease progression revealed that despite clear evidence of 
neuroinflammation in the CNS (Conti et al., 2007), iNOS levels were low in skeletal 
muscles of mSOD1 mice. Thus, it is unlikely that iNOS plays an important role in 
muscle pathology in mSOD1 mice.  
 
However, in mSOD1 mice, nNOS, a hsp90-mediated signalling protein (Peng et al., 
2009), was found to translocate from the sarcolemma to the sarcoplasm, a 
phenomenon associated with muscle atrophy (Suzuki et al., 2010). Within the 
sarcoplasm, nNOS expression was colocalised with hsp90, but only in fast-twitch 
muscle of mSOD1 mice. Recently, Peng et al. (2009) demonstrated a clear 
relationship between hsp90 and nNOS. nNOS requires calmodulin in order to 
catalyse the production of NO and this is enhanced by the presence of hsp90, 
which inhibits the CHIP-dependent ubiquitination of nNOS (Peng et al., 2009). As 
nNOS undergoes toxic damage, hsp90 is thought to be unable to bind, enabling 
hsp70 mediated nNOS degradation. In mSOD1 TA muscle, the increased 
hsp90/nNOS colocalisation in the sarcoplasm indicates that the quality control 
machinery may be dysfunctional. This would result in increased nNOS activity in 
the sarcoplasm, and greater muscle atrophy.  
 
7.6  Fast-twitch muscles in mSOD1 mice are intrinsically more vulnerable to 
cell stress than slow-twitch muscles.  
In Chapter 6, the effect of various cellular stressors on the response of mSOD1 
muscle cells in culture was examined. The results showed that mSOD1 muscle 
cultures were more vulnerable to 5mM caffeine than glucose deprivation. These 
results indicated that the contractile and oxidative stress were more cytotoxic to the 
mSOD1 muscle than 24hrs without media.  
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The effect of glucose deprivation was then examined in fast-twitch muscle cultures, 
which were shown to be more vulnerable to glucose deprivation than slow-twitch 
muscles. Indeed, slow-twitch muscle cultures were surprisingly resistant to glucose 
deprivation. However, as analysis of muscle from cultures has revealed an intrinsic 
difference in the level of differentiation in mSOD1 cultures it is possible that such 
factors may also be apparent in cultures from fast and slow muscle cultures 
(Appendix 3, Fig. 10.3). These results also suggest that there maybe an intrinsic 
differential energy metabolism in fast and slow-twitch muscles, which may 
influence the vulnerability of these muscles to disease in ALS.  
 
Fast and slow-twitch muscles have different metabolic demands. In general, slow-
twitch muscle tends to have a dense vascular network enabling the rapid delivery 
of nutrients and high glycogen levels. In comparison, fast-twitch muscles tend to 
have less dense vascularisation and a greater dependency on anaerobic 
respiration, metabolising fatty acids in preference to glycogen. Thus, it is therefore 
possible that mSOD1 fast-twitch muscle, which has a greater dependence on 
glycolytic pathways, is less able to respond and cope under conditions of metabolic 
stress than slow-twitch muscle. Interestingly, Dupuis et al. (2008) have found that 
ALS patients exhibit abnormal glucose tolerance, and that muscle from ALS 
patients demonstrates hypermetabolism (Gonzalez de Aguilar et al., 2005).  
 
Furthermore, these authors reported a causal link between a muscle-restricted 
metabolic defect and the ensuing oxidative stress and denervation (Dupuis et al., 
2009, Jang et al., 2010). Supporting these findings, the results presented in 
Chapter 4 suggest that this impaired energy metabolism may be selective to fast-
twitch muscles. It has been suggested that this metabolic dysfunction was 
sufficient to induce motoneuron death (Dupuis, 2009). In support of this possibility, 
the results penetrated in Chapter 6 shows that incubation in mSOD1 muscle-
conditioned medium can induce degeneration of neuronal cells, suggesting the 
presence of a toxic factor in muscle-conditioned media obtained from mSOD1 
muscles in culture this toxic factor may be the result of altered micro RNA (miRNA) 
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activity as it has been shown that, a skeletal muscle-specific miRNA (miRNA-206), 
is up-regulated on the onset of neurological symptoms in mSOD1 mice. 
Furthermore, it has been suggested that miR-206 is needed to form new NMJs 
ones after denervation. Equally, as exosomes may mediate muscle- motoneuron 
toxicity via mSOD1 secretion. It is also possible that other toxic factors are 
released via the exosome. 
 
The finding that incubation in mSOD1 muscle conditioned medium is sufficient to 
induce the death of neuronal cells adds further support to the hypothesis that 
mSOD1 pathology and ALS is a non-cell autonomous disease (Bruijn et al., 2004). 
Indeed, it is now widely accepted that glial cells in the CNS are not only involved in 
the normal maintenance and function of motoneurons (Clement et al., 2003), but 
under disease conditions glial cells play an important role in determining disease 
progression. Microglia have been shown to heavily influence disease onset (Bruijn 
et al., 2004) and astroglial reactivity influences disease duration (Bruijn et al., 
2004). Equally, it is possible that muscle cells release exosomes that have 
deleterious effects on motoneurons. However, whether muscle, which interacts 
with motoneurons in the periphery, also plays a role in ALS and mSOD1 pathology 
is remains controversial.  
 
Miller et al., (2006) found little evidence of a causal role for muscle using viral 
delivery of transcription-mediated siRNA to suppress mSOD1 expression in 
muscle. They found that the reduction of mSOD1 in muscle was not sufficient to 
alter a decline in grip strength, disease onset or duration. However, Dobrowolny et 
al. (2008) and Wong & Martin (2010) found that muscle-restricted transgenic 
expression of mSOD1 resulted in significant pathology in the muscle as well as 
motoneuron pathology and death. While these findings may appear contradictory it 
is possible that siRNA-mediated suppression of mSOD1 expression was not 
complete in the Miller et al. (2006) study. 
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Thus, one can conclude that the findings presented in this Thesis suggest that, as 
observed in the CNS, non-neuronal cells do play an important role in influencing 
disease progression in ALS, and that expression of mSOD1 in skeletal muscles in 
the periphery influences motoneuron function, which in turn is likely to influence 
motoneuron survival. 
 
7.6.1 Effects of treatment with Arimoclomol on muscle pathology in mSOD1 
mice.  
Treatment of mSOD1 mice with Arimoclomol results in a significant delay in 
denervation. This improvement in the level of innervation was observed from the 
time of symptom onset and the level of innervation was maintained throughout 
disease progression.  Arimoclomol also increased the level of sprouting in the fast-
twitch EDL muscle, contributing to the maintenance of innervation observed in 
these muscles; this beneficial effect reached significance at a late stage as 
sprouting began to fall in untreated mSOD1 mice.  
 
Treatment with Arimoclomol also increased sprouting in the slow-twitch soleus 
muscle, however, this increase was modest and did not reach significance. The 
levels of cellular stress and the necessity for compensatory sprouting are likely to 
be very low, may explain the relatively modest level of sprouting observed in 
soleus muscle, even following treatment with Arimoclomol. Arimoclomol had a 
limited effect on PNI in mSOD1 muscle, although the level of PNI did increase in 
the muscles of Arimoclomol treated mSOD1 mice, this only reached significance at 
a late stage of disease (120 days of age), when approximately 15% of endplates 
are innervated by more than one nerve terminal.  
 
This study revealed that Arimoclomol exerted a modest effect on ChAT and AChE 
activity in both fast and slow-twitch muscles. In the TA and EDL muscles from 
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treated mice, ChAT and AChE activity was significantly increased before and at 
symptom onset (75 days).  
 
Treatment with Arimoclomol resulted in a significant increase in hsp90, hsp72 and 
hsp25 expression in hindlimb muscles of mSOD1 mice. This was most apparent in 
the fast, comparatively vulnerable TA muscle, which otherwise mounted a limited 
HSR in untreated mSOD1 mice. Treatment with Arimoclomol was sufficient to 
reduce sarcoplasmic levels of nNOS in mSOD1 mice, with less hsp90/nNOS 
colocalisation in the sarcoplasm. This was most apparent in the more vulnerable 
fast-twitch TA muscle. As nNOS usually oscillates between hsp90 and hsp70 
associations (Peng et al., 2009), it is possible that this decline in hsp90/nNOS 
colocalisation is the result of increased hsp70-mediated ubiquitination and 
degradation of sarcoplasmic nNOS (Peng et al., 2009). This could potentially 
downregulate the FOXO/atrogin-1 pathway, thus subsequently reducing 
denervation induced muscle atrophy (Suzuki et al., 2007b, Suzuki et al., 2010). 
While atrogin-1 expression was not examined in this Thesis it would be interesting 
to examine atrogin-1 expression in future work. 
 
Although Arimoclomol decreased sarcoplasmic nNOS, it increased overall nNOS 
levels, notably at the NMJ. It had been previously reported, nNOS is essential for 
terminal Schwann Cell (tSCh) reactivity, which are required for various types of 
sprouting (Ribera et al., 1998, Pereira et al., 2001). Therefore, nNOS expression at 
the NMJ may be beneficial for compensatory sprouting and thus, the reinnervation 
of denervated endplates.  
 
It is of interest to note that Kieran et al (2004) reported that treatment with 
Arimoclomol reduced muscle atrophy, and in Chapter 3, I found that treatment with 
Arimoclomol increases sprouting in mSOD1 muscle. Together, these findings 
suggest that nNOS is likely to contribute to muscle pathology in mSOD1 mice. 
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Furthermore, as treatment with Arimoclomol is sufficient to alter nNOS expression 
it may contribute to Arimoclomol’s beneficial effects at the NMJ in mSOD1 mice. 
 
7.7  Conclusion 
The results presented in the Thesis demonstrate that skeletal muscles are affected 
early in disease in mSOD1 mice, before symptom onset and motoneuron death 
occurs. Furthermore, my results indicate that fast-twitch muscles are affected 
earlier and to a greater extent than slow-twitch muscles in mSOD1 mice and that 
this is due, at least in part, to an intrinsic difference in their ability to mount a stress 
response.  Thus, fast-twitch muscles, which are intrinsically more vulnerable to 
cellular stress and are particularly affected in ALS, have a reduced ability to mount 
a significant HSR as well as a greater susceptibility to nNOS signalling dysfunction 
and metabolic dysfunction than slow-twitch muscles. These factors are likely to 
result in increased oxidative stress in fast-twitch muscles, decreased oxidative 
tolerance and destabilisation of the NMJ (Dupuis, 2009).  
 
Together these results indicate that at least some of the previously reported 
beneficial effects of Arimoclomol (Kieran et al., 2004) are due, to Arimoclomol’s 
actions in the periphery. Furthermore, these findings suggest that targeting 
pathology in the muscle and CNS is likely to be a successful therapeutic approach. 
 
In conclusion, the data presented in this Thesis demonstrates that fast-twitch 
muscles are intrinsically more vulnerable to cell stress and this contributes to its 
increased vulnerability to cell stress such as denervation and oxidative stress in 
mSOD1 mice. Moreover, increasing the ability of muscles to respond to cellular 
stress by treatment of mSOD1 mice with Arimoclomol, results in a reduction in 
muscle pathology. Therefore, in mSOD1 mice, Arimoclomol clearly targets 
pathology both in the periphery in skeletal muscles, as well as centrally within glia 
and motoneurons, as previously shown (Kieran et al, 2004; Kalmar et al, 2009). 
Together with the data presented in this Thesis, these results support the proposal 
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that the targeting of pathological changes in skeletal muscles may be a successful 
approach to take, in combination with strategies that target pathology within the 
CNS, in ALS.  
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Figure 8.1 Innervation characteristics in the muscle of EDL and soleus 
muscle from wtSOD1 mice 
The extent of denervation (A) sprouting (B) and PNI (C) was examined in the EDL and 
soleus muscles of wtSOD1 mice by silver cholinesterase staining.  
n=4; error bars = SEM 
 
 250 
Appendix two 
 
Figure 9.1 Inducible Nitric oxide synthase and CD11b expression in the TA 
and soleus muscle of wtSOD1 and mSOD1 mice at 120 days of age.  
Immunohistochemical staining was carried out using an iNOS antibody (Invitrogen) 
and CD11b (Abcam, Hertfordshire) on transverse sections of muscle. (A) shows an 
example of iNOS (red) and CD11b (green) immoreactivity in wtSOD1 TA muscle. 
(B) shows an example of iNOS and CD11b staining in mSOD1 TA muscle where 
colocalisation of iNOS and CD11b expression is present at a point of 
vascularisation (arrow). (C) shows an example of wtSOD1 soleus muscle stained 
for iNOS and CD11b. (D) shows an example of iNOS and CD11b expression in 
120-day-old soleus muscle from mSOD1 mice. iNOS and CD11b colocalisation is 
strong at points of vascularisation (arrow). 
Scale bar = 50µm; n=5 
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Appendix three 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10.1 Myogenic differentiation in muscle cultures from the hindlimb of 
WT, wtSOD1 and mSOD1 neonate mice.  
The ratio of myoblasts, myocytes and myotubes in a 7-day-old culture were 
examined in WT, wtSOD1 and mSOD1 cultures. The cultures were immunostained 
for myosin and then the three structures counted. Myoblasts were taken to be 
spherical structures (red arrow), spindle-like myocytes (light blue arrow) and the 
elongated multi-nucleated structures myotubes (dark blue arrow). The Graph 
shows the percentage of myoblasts, myocytes and myotubes in WT, wtSOD1 and 
mSOD1 cultures.  
*=p<0.05; n=6; error bars = ± standard error of the mean 
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Figure 10.2 Myosin heavy chain slow and fast (MyHCII) expression in mixed 
muscle cultures from the hindlimb of WT, wtSOD1 and mSOD1 neonate mice. 
(A-C) WT, wtSOD1 and mSOD1 cultures were immunostained for MyHCI (red -
Novocastra) following 7DIV, respectively. They were subsequently costained for 
MyHC II (green- Novocastra) and DAPI (blue), and then the number of myogenic 
structures with either or both were counted. This data is summarised in chart (D). 
n=3; scale bar = 20µm 
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Figure 10.3 Myosin heavy chain slow and fast (MyHCII) expression in fast and 
slow muscle cultures from WT and mSOD1 neonate mice. 
Cultures that were immunostained for MyHCI (Novocastra) following 7DIV. They 
were subsequently costained for MyHC II (Novocastra), and then the number of 
myogenic structures with either or both were counted. 
n=4 
 
